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JOSHUA ANDREW SMITH.  Mechanisms of Mitochondrial Dysfunction in Sepsis-
Induced Acute Kidney Injury.  (Under the direction of RICK G. SCHNELLMANN). 
  
Mitochondrial dysfunction is a well-characterized pathophysiological feature of 
acute kidney injury (AKI).  Our laboratory has previously implicated suppression of 
mitochondrial biogenesis, the process by which cells generate new and functional 
mitochondria, as an important contributor to development of mitochondrial dysfunction 
in multiple experimental models of AKI.  However, relatively little is known about the 
molecular mechanisms responsible for disruption of biogenesis in renal cells.  The 
primary goals of this project were to define signaling pathways mediating acute 
suppression of renal cortical mitochondrial biogenesis and to characterize changes in 
glycolytic metabolism that might support both cellular and organ function following 
sepsis-induced AKI.  
Mitochondrial biogenesis is primarily regulated by peroxisome proliferator-
activated receptor γ coactivator-1α (PGC-1α), which has been termed the master 
regulator of this process.  In an endotoxin model of septic AKI in mice, we noted rapid 
suppression of both renal cortical PGC-1α mRNA and protein levels at 3 and 18 hours 
post-LPS, respectively.  Endotoxin-induced loss of PGC-1α led to reduced expression of 
downstream regulators of mitochondrial biogenesis and electron transport chain proteins 
along with a decrease in mitochondrial DNA content.  Using genetic and 
pharmacological approaches, we identified an essential role for TLR4-mediated 
activation of MEK/ERK signaling in acute (< 3 hr) disruption of PGC-1α expression and 




may facilitate development of novel therapeutic approaches to reverse mitochondrial 
dysfunction and enhance renal recovery after AKI.    
   We next examined changes in glycolytic metabolism that might serve as an 
adaptive mechanism to generate ATP and support renal function in sepsis-induced AKI.  
We observed a specific and rapid (< 3 hr) increase in activity of renal cortical hexokinase 
(HK), the first committed step of glycolysis, that was maintained up to 18 h after 
systemic LPS exposure.  LPS-mediated HK activation was not sufficient to increase 
glucose flux through the glycolytic pathway as indicated by reduced or unchanged 
pyruvate and lactate levels in the renal cortex.  Surprisingly, HK activation was closely 
associated with increased activity of glucose-6-phosphate dehydrogenase (G6PDH), the 
rate-limiting enzyme of the pentose phosphate pathway (PPP), suggesting that glucose is 
selectively utilized via this pathway following sepsis-induced AKI.  We also 
demonstrated that LPS-induced HK activation occurs in an EGFR/PI3K/Akt-dependent 
manner in this model.  Further work may lead to identification of increased glucose 
metabolism through the PPP as an adaptive mechanism to counteract oxidative stress in 
the septic kidney.   
 In our final study, we tested the efficacy of a potent and specific MEK/ERK 
inhibitor GSK1120212 in a clinically relevant model of sepsis induced by cecal ligation 
and puncture (CLP) in mice.  Pharmacological blockade of MEK/ERK signaling partially 
attenuated the systemic response to CLP as indicated by reduced levels of circulating pro-
inflammatory cytokines (TNF-α, IL-1β, IL-6, and GM-CSF) and restoration of core body 
temperature in GSK1120212-treated mice.  In the kidney, GSK1120212 post-treatment 




characterized markers of proximal tubular injury.  Despite these effects, MEK/ERK 
inhibition was not sufficient to prevent renal dysfunction as measured by BUN.  Taken 
together, these findings suggest that MEK/ERK inhibition represents a novel approach to 






Review of acute kidney injury, sepsis, mitochondrial biology, and renal 
proximal tubule cell metabolism 
ACUTE KIDNEY INJURY 
Definitions and Clinical Classification Systems  
 Acute kidney injury (AKI) is broadly defined as the rapid (hours to days) loss of 
renal function leading to subsequent disruptions in normal elimination of metabolic waste 
products, electrolyte and fluid balance, and/or urine output (1).  Abrupt and severe loss of 
renal function was previously referred to as acute renal failure (ARF).   However, AKI 
has largely replaced this terminology to better illustrate that even renal insults of lesser 
severity not resulting in overt organ failure may lead to clinically relevant changes in 
renal function.  Use of ARF is now predominantly restricted to patients who suffer 
kidney injury which requires renal replacement therapy (RRT) or dialysis.  Clinical 
diagnosis of AKI relies primarily on estimation of glomerular filtration rate (GFR) using 
serum creatinine (SCr) as well as changes in urine output.  Recent efforts have led to the 
development of consensus criteria to stratify AKI cases by severity using these diagnostic 
endpoints.  In particular, the RIFLE criteria (Risk, Injury, Failure, Loss of function, and 
End-stage kidney disease) developed by the Acute Dialysis Quality Initiative (ADQI) 
represents probably the most comprehensive clinical classification system for AKI (2).  
The RIFLE system allows for stratification of patients to the five categories listed above 
based on the following definitions: risk is defined as a ≥ 1.5-fold increase in SCr along 
with urine output < 0.5 mL/kg/h for at least 6 hours; injury is classified by a ≥ 2-fold 
increase in SCr and urine output < 0.5 mL/kg/h for 12 hours; failure may be defined as a 




combination with urine output < 0.3 mL/kg/h for 24 hours or anuria for 12 hours; Loss of 
function indicates the complete loss of renal function for > 4 weeks; and End-stage 
kidney disease is defined as sustained absence of renal function for > 3 months.  A 
similar classification system, referred to as AKIN staging, has also been developed by the 
Acute Kidney Injury Network (3).  An outline of criteria for both the RIFLE and AKIN 
classification systems is provided below (Figure 1-1).  It should be noted that a number of 
studies have validated the utility of both the RIFLE and AKIN classification systems in 
predicting outcomes and mortality following AKI (4, 5).  For example, a recent cohort 
study in the hospital setting demonstrated that patients with maximum RIFLE classes of 
risk, injury, and failure had mortality rates of 8.8%, 11.4%, and 26.3%, respectively (6).  
Thus, development of these standardized criteria has been a tremendous tool for both 














Figure 1-1: Comparison of RIFLE (Risk, Injury, Failure, Loss, and End-stage 
kidney disease) and AKIN (Acute Kidney Injury Network) criteria for the diagnosis 
and staging of AKI. sCrea = serum creatinine; RRT = renal replacement therapy.  












Epidemiology of AKI   
 Estimates of the incidence of AKI vary greatly depending on criteria used for 
diagnosis and characteristics of the populations studied.  A recent community-based 
study in the US following almost four million individuals estimated incidence of non-
dialysis-requiring AKI to be approximately 384 per 100,000 person-years, while 
incidence of dialysis-requiring AKI was 24.4 per 100,000 person-years (8).  AKI 
occurred more often in the elderly and in males in this study population.  However, this 
study used changes in SCr relative to baseline to define AKI rather than the standardized 
criteria (RIFLE, AKIN) discussed above.  The occurrence of AKI in the hospital and 
intensive care settings is even greater with incidence in hospitalized adults suffering from 
acute illness predicted to be approximately 25% using the AKIN staging system (9).  In 
addition, incidence rates as high as 65% have been reported for critically ill patients in 
the ICU setting (10).  
An alarming trend toward increased prevalence of AKI has been observed in 
multiple patient populations over the last several decades.  In the community-based study 
described above, striking increases in incidence of non-dialysis-requiring (~38%) and 
dialysis-requiring (~33%) AKI were reported from 1996 to 2003 (8).  Similar trends have 
also been reported in the hospital and ICU settings, indicating that AKI is an increasingly 
common disorder (11, 12).   
Morbidity and Mortality Associated with AKI   
 A strong association between development of AKI and mortality has been 
reported in a variety of clinical settings.  A recent systematic review of large cohort 




forms of AKI is ~24% in adults and ~14% in children (9).  Mortality rates in the intensive 
care unit are much higher, with estimates approaching 50% - 60% in critically ill patients 
requiring renal replacement therapy (13, 14).  As discussed above, risk of mortality is 
strongly correlated with injury severity and exponential increases in mortality rates are 
apparent when stratifying patients by change in SCr after AKI (6, 15).  Mortality 
resulting from the disease appears to be undergoing a modest downward shift, which may 
be partially attributed to development of better supportive care for AKI patients (16, 17).  
However, patients who survive an acute episode of AKI remain at higher risk of poor 
outcomes and long-term mortality as result of morbidity associated with the disease (18).  
In particular, AKI is an independent risk factor for development of chronic kidney 
disease (CKD) and further progression to end-stage renal disease (ESRD) leading to 
additional risk of mortality and poor quality of life measures (19-21). 
Financial Costs Associated with AKI  
 In addition to the high risk of morbidity and mortality, AKI is also associated with 
a significant burden on healthcare and financial resources.  Unfortunately, the majority of 
studies addressing overall financial impact only take into account costs associated with 
acute care and procedures during an episode of AKI.  Given the significant risk of long-
term morbidity and mortality discussed above, these calculations likely omit a significant 
portion of the total economic burden associated with AKI that can be attributed to long-
term care and lost productivity (22).  A recent study conducted in the US following 
approximately 20,000 new hospital admissions demonstrated that patients suffering from 
AKI (defined as an elevation in SCr ≥ 0.5 mg/dL) had a mean increase of 3.5 days in 




hospital costs when compared to patients not developing AKI after adjusting for age, 
gender, and diagnosis (15).  Based on extrapolation from these findings, the authors 
concluded that expenses directly attributable to AKI might account for as much as 5% of 
overall hospital costs and over $10 billion in healthcare expenses annually in the US (15). 
These costs are likely to be significantly higher when accounting for long-term care and 
lost productivity. 
 It is important to note here that even smaller changes in SCr (≥ 0.3 mg/dL) have 
been associated with increased risk of death (~70% increase) and substantially higher 
overall hospital costs (~$5000 after adjustment for age, gender, and diagnosis) (15).  This 
finding further highlights the utility of the term AKI in replacing ARF to better describe a 
spectrum of injury where less severe insults can lead to clinically significant deterioration 
of renal function without overt organ failure.  As with mortality, severity of injury is 
strongly correlated with increasing hospital costs.  The figures below demonstrate effects 
of AKI on mortality and overall healthcare costs when stratifying based on changes in 
SCr from baseline (Figure 1-2A,B).  Taken together, these data indicate that AKI leads to 
significant mortality and is associated with high financial costs.    
             







Figure 1-2A: Effects of increasing severity of AKI determined by changes in SCr on 
mortality after AKI.  Green bars represent unadjusted data, blue bars have been adjusted 
for age and gender, and grey bars are adjusted for age, gender, diagnosis-related group 
(DRG) weight, chronic kidney disease (CKD) status, and ICD-9-CM codes for 
respiratory, gastrointestinal, malignant, and infectious diseases; n = 1564, 885, 246, and 
105 SCr changes of 0.3 to 0.4, 0.5 to 0.9, 1.0 to 1.9, and ≥ 2.0 mg/dl, respectively.  
Adapted from (15).  
 
 
Figure 1-2B: Effects of increasing severity of AKI determined by changes in SCr on 
total hospital costs after AKI.  Green bars represent unadjusted data, blue bars have 
been adjusted for age and gender, and grey bars are adjusted for age, gender, diagnosis-
related group (DRG) weight, chronic kidney disease (CKD) status, and ICD-9-CM codes 
for respiratory, gastrointestinal, malignant, and infectious diseases; n = 1564, 885, 246, 
and 105 SCr changes of 0.3 to 0.4, 0.5 to 0.9, 1.0 to 1.9, and ≥ 2.0 mg/dl, respectively.  





Clinical Management and Pharmacological Treatment of AKI 
 Treatment for AKI remains largely restricted to the use of supportive measures 
aimed at eliminating the cause of injury and preventing progressive renal dysfunction.  In 
clinical cases where hemodynamic changes and volume depletion contribute to 
development of AKI, fluid resuscitation is often used in an effort to promote intravascular 
expansion (23). Debate remains regarding the ideal type of fluid (crystalloid or colloid) 
for volume replacement as well as the overall clinical utility of this approach (24). 
Aggressive resuscitation may lead to development of fluid overload, which is associated 
with poor outcomes and increased mortality after AKI (25, 26).  Vasopressors (e.g. 
vasopressin, dopamine, norepinephrine) are often used in conjunction with fluid 
resuscitation to reverse hypotensive vasodilation and subsequent renal hypoperfusion.  
However, there is a considerable lack of evidence to suggest that vasopressor agents have 
beneficial effects on mortality or need for dialysis in the setting of hemodynamic shock 
(23). 
 Use of selective renal vasodilators has also been suggested as a potential therapy 
to prevent organ dysfunction arising from hemodynamic insufficiency.  Low dose 
dopamine therapy promotes renal vasodilation and thus increases urine output.  However, 
a recent systematic review concluded that low dose dopamine has a negligible effect on 
restoration of kidney function and mortality in patients suffering from AKI (27). 
Fenoldopam, a selective agonist of the dopamine receptor D1, has been employed in 
selected populations at risk for development of AKI.  Studies to this point are largely 
inconclusive concerning therapeutic efficacy of fenoldopam (23). Atrial naturetic peptide 




of the afferent glomerular arteriole and vasoconstriction of the efferent arteriole leading 
to an increase in GFR.  Although a small, open label trial suggested that ANP greatly 
improves GFR and reduces need for renal replacement therapy in patients experiencing 
AKI, subsequent multicenter, randomized trials failed to reproduce these findings (28, 
29).   
 Laboratory evidence has also led to investigation of multiple classes of diuretics 
for AKI treatment.  Among these, loop diuretics (such as furosemide) have been 
extensively studied due to potential renoprotective effects revealed in earlier mechanistic 
studies including: inhibition of sodium reabsorption in the medullary thick ascending 
limb, thereby decreasing cellular energy demand; clearance of tubular casts leading to a 
reduction in tubular obstruction and associated complications; and dilution of renal toxins 
such as myoglobin and hemoglobin in the tubular fluid limiting cellular insult in the 
injured kidney (30, 31).  However, multiple randomized, placebo-controlled clinical trials 
indicate that furosemide is of little benefit in the treatment of AKI (30, 32).  Mannitol, an 
osmotic diuretic, may have limited utility in rhabdomyolysis-induced AKI and organ 
transplantation, but there is no conclusive evidence for positive effects of this drug in 
other forms of AKI (33).   
 The evidence presented above highlights the dismal outlook for clinical treatment 
of AKI.  Dialysis (or renal replacement therapy) remains the only FDA-approved 
intervention, further indicating the tremendous need for identification of novel 
therapeutic targets in this disease.  However, drug development in AKI presents a number 
of unique challenges. Standard laboratory tests for assessment of renal function (SCr, 




guide treatment decisions limits effective early intervention. The pathophysiology of AKI 
is also extremely complex, heavily dependent on the underlying cause(s), and remains 
incompletely understood.  However, recent studies have begun to address these 
deficiencies through identification of novel biomarkers and elucidation of the numerous 
mechanisms leading to organ dysfunction following renal injury, lending hope that new, 
effective therapies for AKI are on the horizon.   
Clinical Assessment of AKI: Standard Laboratory Tests and Novel Biomarkers 
Serum Creatinine  
 Serum creatinine (SCr) is the most commonly used laboratory test to measure 
renal function.  As discussed above, changes in serum creatinine are an important 
component of both clinical classification systems (RIFLE and AKIN) for diagnosis and 
staging of AKI.  Creatinine is formed via catabolism of creatine phosphate in skeletal 
muscle and is primarily removed from the circulation by way of glomerular filtration in 
the kidneys.  It is often used as a clinical indicator of changes in glomerular filtration rate 
(GFR) for this reason, but may overestimate true GFR since creatinine undergoes modest 
secretion by the renal proximal tubule.  
Blood Urea Nitrogen  
 Blood urea nitrogen (BUN) is another metabolic waste product that has been 
extensively used for diagnosis of AKI.  Urea is produced in the liver as a byproduct of 
protein synthesis.  Blood urea nitrogen is used as a general indicator of kidney function, 






Problems Associated with Standard Laboratory Tests 
SCr and BUN have been used extensively in detection of AKI primary due to ease 
of use, low cost, and the absence of better alternatives.  However, both may vary due to a 
number of factors not directly related to renal function including gender, age, nutritional 
status, steroid use, gastrointestinal bleeding, muscle mass, muscle injury, and 
intravascular volume status.  SCr and BUN are also poor indicators of early renal injury 
because greater than 50% loss of baseline glomerular filtration rate is required for 
detectable elevation (1, 34).  These factors have led to extensive efforts to identify novel 
biomarkers for AKI that are organ-specific and have a greater dynamic range.  Promising 
targets are discussed in further detail below.  
Kidney Injury Molecule-1  
 Kidney injury molecule-1 (KIM-1) is a type I transmembrane glycoprotein 
containing both an immunoglobulin-like domain and a mucin domain within its 
extracellular component (35).  Expression of KIM-1 has been reported in a variety of 
immune cells where it appears to play a role in Th2, Th1, and Th17 differentiation as well 
as activation of B cells, dendritic cells, and NK cells (36).  Although KIM-1 is expressed 
at very low levels in the kidney under basal conditions, it was identified as the most 
highly up-regulated gene following ischemia/reperfusion (I/R) injury in rats and humans 
(37).  Further investigation revealed that KIM-1 is shed into the urine after injury to the 
proximal tubule (38).  A number of pre-clinical and clinical studies have validated 
urinary KIM-1 as an early and specific marker of AKI arising from various causes 
including sepsis (39-41).  Based on this evidence, urinary KIM-1 was recently approved 




Neutrophil Gelatinase-Associated Lipocalin 
 Neutrophil gelatinase-associated lipocalin (NGAL) was originally identified as 
small protein (25 kDa) localized to gelatinase-containing granules in neutrophils.  NGAL 
appears to play an important role in innate immunity through binding and depletion of 
iron-carrying siderophores essential for bacterial growth (42).  Experimental evidence 
indicates that NGAL mRNA and protein expression is rapidly (less than 3 hours) and 
robustly (greater than 10-fold) increased in the renal proximal tubule after I/R injury in 
mice (43). NGAL protein also appeared in the urine as early as 2 hours after reperfusion 
in this model, long before a change in SCr was detected (24 hours post-I/R) (43).  Most 
interestingly, urinary NGAL was also elevated following milder ischemic injury in mice 
that was insufficient to produce an increase in SCr, indicating that urinary NGAL may 
have an expanded dynamic range (43).  Subsequent clinical studies have supported the 
notion that NGAL is a reliable biomarker of AKI, and changes in NGAL may have 
predictive value for determining patient outcomes in this disease (44).  
Cystatin C  
 While KIM-1 and NGAL have been identified as novel biomarkers of tubular 
injury, the search for a superior indicator of glomerular filtration rate (GFR) and thus 
renal function has led to the identification of cystatin C as a potential candidate.  Cystatin 
C is a low molecular weight (13 kDa) protein generated by virtually all nucleated cells.  
Because it circulates without binding to serum proteins, cystatin C is freely filtered at the 
glomerulus and undergoes partial reabsorption by the renal proximal tubule.  Thus, 
urinary cystatin C content depends on two parameters that may be disrupted in AKI: GFR 




have shown promise as early and sensitive makers of AKI in animal models and selected 
patient populations (46, 47).  Serum cystatin C may have other distinct advantages over 
creatinine because circulating levels of this protein appear to be independent of gender, 
age, and muscle mass / injury (48).   
Other Biomarkers for AKI  
 In addition to those discussed above, an incredible number of putative markers for 
AKI detection and outcome prediction are currently under investigation including 
interleukin-18 (IL-18), interleukin-6 (IL-6), liver-type fatty acid binding protein (L-
FABP), glutathione-S-transferase (GST) and C-reactive protein (CRP) (1).  Figure 1-3 
below illustrates potential utility of selected biomarkers throughout the evolution of a 









Figure 1-3: Uses of standard laboratory tests and novel biomarkers throughout the 
clinical course of AKI.  GFR = glomerular filtration rate; NGAL = neutrophil 
gelatinase-associated lipocalin; Cys C = cystatin C; IL-18 = interleukin-18; KIM-1 = 
kidney injury molecule-1; GST = glutathione-S-transferase; L-FABP = liver-type fatty 




Causes of AKI 
 AKI is often classified as pre-renal, intrinsic, or post-renal based on precipitating 
factors leading to deterioration of renal function as described below.   
Prerenal Causes of AKI  
 Prerenal AKI may result from any condition that leads to clinically significant 
reduction in renal blood flow (RBF) and subsequent organ hypoperfusion.  Common 
causes of prerenal AKI include sepsis, congestive heart failure, cardiac surgery, and 
cardiogenic shock (49).  Sepsis is widely recognized as the most common contributing 
factor to the development of AKI in critically ill patients (50, 51).  In addition, conditions 
that deplete intravascular volume (hypovolemia) such as excessive vomiting, diarrhea, 
inappropriate diuretic use, and poor fluid intake may also result in renal ischemia.  A 
number of drugs inducing local changes in the renal vasculature including angiontensin-
converting enzyme inhibitors, diuretics, non-steroidal anti-inflammatory drugs, and small 
vessel vasoconstrictors (e.g. cyclosporine, tacrolimus) may increase risk of prerenal AKI, 
especially in patients with pre-existing vascular disease (49).  Estimates indicate that all 
prerenal causes account for approximately 70% of community-acquired AKI and 40% of 
hospital-acquired AKI (52, 53).  
Intrinsic Causes of AKI 
 Intrinsic AKI describes direct damage to the kidney and may affect any portion of 
renal anatomy including the glomerulus, renal tubules, interstitium, and vessels.  Tubular 
injury most often results from development of acute tubular necrosis (ATN) following an 
ischemic insult (causes discussed above).  Therefore, pre-renal and intrinsic causes 




direct injury to renal tubules (49).  Nephrotoxicants are also an important cause of tubular 
injury in intrinsic AKI.  A number of medications have toxic effects on the tubules 
including aminoglycoside antibiotics, radiocontrast agents, and chemotherapeutic agents 
(e.g. cisplatin).  Although much less common, acute interstitial nephritis (AIN) is another 
important contributor to cases of intrinsic AKI.  Interstitial nephritis may develop 
secondary to use of a variety of pharmacological agents including certain antibiotics 
(such as penicillins and cephalosporins) and non-steroidal anti-inflammatory drugs 
(NSAIDs).  In addition, patients with autoimmune disorders are at risk for interstitial 
nephritis and glomerulonephritis, both of which may lead to intrinsic renal injury. 
Intrinsic causes are thought to account for approximately 30% of hospital-acquired AKI 
(11). 
Postrenal Causes of AKI 
   Although relatively uncommon, obstruction of the urinary tract and urine flow 
from the kidneys may also lead to AKI.  Urinary tract obstruction contributes to renal 
failure by increasing intratubular hydrostatic pressure, leading to subsequent reductions 
in GFR and renal blood flow.  The most common causes of postrenal AKI include benign 
prostatic hyperplasia, malignancy of the urinary tract or surrounding anatomical 
structures, and renal calculi (49). 
 The incredible number of potential causes of AKI contributes greatly to the 
complexity of this disorder and to challenges associated with developing effective 
therapeutics.  Since the studies presented herein will address sepsis-induced AKI, this 
review will now focus on sepsis as a clinical entity with a particular emphasis on septic 





Definitions and Clinical Staging of Sepsis  
 Sepsis is an extremely complex disease that manifests by a variety of signs and 
symptoms depending on the etiology of infection.  Recent efforts to generate a consensus 
definition of sepsis have described this disease as the systemic inflammatory response to 
known or suspected infection (54).  In order to meet clinical criteria for diagnosis of 
sepsis, patients must display two or more signs of the systemic inflammatory response 
syndrome (SIRS) including: 1) body temperature > 38.3°C or < 36°C; 2) heart rate > 90 
beats per minute; 3) respiratory rate > 20 breaths per minute or PaCO2 < 32 mmHg; and 
4) white blood cell count > 12,000 cells per mm3, < 4,000 cells per mm3, or >10% 
immature band forms (54).  The systemic inflammatory response syndrome may occur in 
response to a variety of conditions, but sepsis is distinguished from other causes by the 
presence of infection.  Additional terms including “severe sepsis,” “septic shock,” and 
“multiple organ dysfunction syndrome” have also been developed to better describe 
different stages of sepsis based on disease severity.  Severe sepsis refers to sepsis along 
with organ dysfunction, hypotension, and/or hypoperfusion (54).  Clinical signs of organ 
dysfunction and hypoperfusion may include lactic acidosis (> 1 mmol / L), reduced urine 
output (< 0.5 mL/kg/hr), and/or altered mental status (55).  Septic shock is defined as 
persistent sepsis-associated hypotension (systolic blood pressure < 90 mmHg or a 
decrease in systolic blood pressure > 40 mmHg from baseline) despite appropriate fluid 
replacement (54).  Finally, multiple organ dysfunction syndrome denotes abnormal organ 
function in a critically ill patient such that normal homeostasis cannot be preserved 




predicting clinical outcomes, as more severe stages are correlated with increased 
mortality (56).  The figures provided below outline the terminology used to describe 
different stages of sepsis (Figure 1-4A) and expanded diagnostic criteria for this disease 
(Figure 1-4B).           
           















Epidemiology of Sepsis 
 Much of the epidemiological data to date concerning incidence of sepsis in the 
general population is derived from a large observational study tracking all hospital 
discharges from seven US states in 1995.  Of the nearly 6.7 million hospitalizations 
recorded in these regions throughout the calendar year, approximately 193,000 cases met 
the diagnostic criteria described above for severe sepsis (sepsis + organ dysfunction, 
hypotension, and/or hypoperfusion) (57).  Using this data, the authors extrapolated a 
nationwide incidence of 751,000 cases of severe sepsis annually or approximately 3 cases 
per 1000 individuals in the general population (57).  As expected, incidence of sepsis (as 
described above) appears to be even higher than that of severe sepsis.  A study conducted 
in 8 academic medical centers reported 19.9 and 10.1 cases per 100 ICU admissions for 
sepsis and severe sepsis, respectively (58).  Sepsis is also extremely common in the 
developing world, and current data suggests that there may be upwards of 19 million 
cases of sepsis and severe sepsis worldwide each year (59).  Unfortunately, incidence of 
sepsis appears to be trending upward (60, 61).    
Outcomes Associated with Sepsis 
 Sepsis is as associated with significant mortality that closely correlates with 
disease severity.  In an earlier prospective cohort study following approximately 3,700 
patients, 28-day mortality rates of 7%, 16%, 20%, and 46% were observed for patients 
with systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock, 
respectively, using the consensus definitions described above (62).  Similar findings have 




sepsis and septic shock combined ranging from 30-35% at 28 days (58).  Sepsis is often 
listed as a top 10 cause of death in the United States (63).  
In addition to early mortality, evidence indicates that survivors of an acute 
episode of sepsis have poorer long-term outcomes.  Risk of long-term death remains 
elevated for at least 5 years after initial diagnosis of sepsis (64, 65). Severe sepsis is also 
independently associated with development of significant, persistent cognitive and 
functional deficits in elderly survivors (66).  
Economic Impact of Sepsis 
 Sepsis places an enormous burden on healthcare and financial resources.  When 
comparing adult sepsis admissions (1,028) to all other adult admissions (248,761) in a 
multi-center, academic care setting, Bates et al. reported that average length of hospital 
stay was approximately 2 – 3 weeks longer in septic patients (67).  Nosocomial (hospital-
acquired) sepsis was associated with a significantly higher mean length of stay (26.2 days 
adjusted for age, gender, and other factors) versus community-acquired cases (18.2 days 
adjusted).  More importantly, total adjusted hospital charges for an acute episode of 
sepsis ($90,710 for nosocomial cases, $61,440 for community-acquired cases) were 
$44,000 - $73,000 higher than all other reasons for admission, indicating that septic 
patients account for substantial medical resource utilization (67).  In total, healthcare 
costs associated with severe sepsis were estimated to be nearly $17 billion annually in the 
US in 2001 and are likely to be even higher today (57).  
Sepsis Management and Treatment  
 Much like clinical management of AKI, sepsis care is largely limited to 




demonstrated that early, goal-directed therapy aimed at optimizing hemodynamic 
parameters and tissue perfusion decreased mortality in patients with severe sepsis or 
septic shock (68).  Based on these findings, a committee of experts in critical care 
developed the Surviving Sepsis Campaign to standardize early interventions in septic 
patients (69).  The Surviving Sepsis Campaign provides two “bundles” of appropriate 
monitoring and treatment measures to facilitate resuscitation, as well as additional 
treatment recommendations graded based on the strength of available clinical evidence 
(Figure 1-5 below).  Early administration of broad-spectrum antibiotics with activity 
against all likely causative pathogens is suggested based on studies demonstrating a clear 
positive association between delay in antimicrobial therapy and mortality (70).  A 
combination of intravenous fluids (specifically crystalloids), vasopressors 
(norepinephrine, epinephrine, vasopressin), positive inotropes (dobutamine), and low 
dose corticosteroids (hydrocortisone) are recommended as possible measures to correct 
hypovolemia / hypotension and improve survival (68, 69, 71).  In addition, mechanical 
ventilation and renal replacement therapy may be necessary in patients who develop 
acute respiratory distress syndrome (ARDS) and AKI, respectively (69, 72).  Successful 
compliance with the Surviving Sepsis Campaign guidelines in 165 medical centers 
throughout the United States, Europe, and South America resulted in a significant 
reduction in unadjusted mortality rates from ~37% to ~31% during a two year study 
period (73).  Although successful implementation of these supportive measures has 
provided modest benefits, it is important to note that attempts to improve outcomes by 
directly targeting the inflammatory response have been largely unsuccessful (74).  



















Figure 1-5: The Surviving Sepsis Campaign care bundles.  The Surviving Sepsis 
Campaign provides two distinct bundles of monitoring and treatment measures to 
promote resuscitation in septic patients.  The bundles are to be completed within 3 and 6 





 Causes of Sepsis 
 An incredible variety of infectious agents may cause sepsis including bacteria, 
fungi, and viruses.  Gram-negative bacteria including Escherichia coli, Klebsiella 
pneumoniae, Pseudomonas aeruginosa, and Enterobacter species were traditionally 
thought to be the most likely causative organisms (75).  However, data indicate a recent 
shift in the identity of microbes responsible for sepsis.  Gram-positive bacteria now 
account for the majority of sepsis diagnoses, with Staphylococcus aureus, Enterococcus 
species, coagulase-negative Staphylococci, and Streptococcus pneumoniae being the most 
often observed (61, 76).  In addition, fungi (especially members of the Candida genus) 
are thought to contribute to approximately 6% of cases (75, 76).  The lungs, urinary tract, 
and peritoneal cavity are common sources of these organisms in septic patients, and the 
site of infection often dictates the most likely causative agent (75, 76).  
Animal Models of Sepsis and Septic AKI  
 Much of our understanding of the pathophysiology of sepsis and sepsis-induced 
AKI is derived from experimental models.  Animal models of sepsis are classified into 
three categories based on the technique used to induce a systemic inflammatory response: 
1) administration of an exogenous microbial toxin; 2) administration of live pathogens; or 
3) modification of the host’s protective barriers.   
Administration of Exogenous Microbial Toxins  
 The most commonly used experimental model in this category is intravenous or 
intraperitoneal administration of lipopolysaccharide (LPS, also known as endotoxin), a 
component of the outer membrane of Gram-negative bacteria, in rodents.  LPS elicits a 




production of pro-inflammatory cytokines such TNF-α and IL-1β (77).  There are several 
distinct advantages to using the LPS model in rodents including ease of the experimental 
technique and highly reproducible effects (77, 78).  The early systemic inflammatory 
response to LPS also closely mimics many of the characteristics of sepsis in the clinic 
(78).  LPS has also been shown to induce renal injury in a dose-dependent manner in 
rodents.  In particular, administration of high doses of endotoxin results in decreased 
glomerular filtration rate (GFR), increased blood urea nitrogen (BUN), and elevated 
urinary markers of tubular injury including KIM-1 and NGAL (79).  Despite the noted 
advantages, there are also a number of differences when comparing this model to human 
sepsis cases.  The most important limitation of endotoxin administration is that the 
increase in systemic pro-inflammatory cytokines is rapid, transient, and several orders of 
magnitude higher when compared to the slower, more protracted, and lower grade 
responses in septic patients (80).  In addition, high doses of LPS lead to very early 
development of a hypodynamic cardiovascular condition in rodents whereas humans 
often display an initial hyperdynamic state (77).  These fundamental differences likely 
explain why a number of targeted anti-inflammatory agents developed based on the LPS 
model in rodents and primates (e.g. anti-TNF-α and IL-1) have largely failed to show 
efficacy in clinical trials (74).  A number of other bacterial toxins and TLR agonists 
including synthetic lipopeptides, CpG DNA, and zymosan have also been used to model 
sepsis in rodents (81).  
LPS Signaling  
 As discussed briefly above, LPS signals primarily through activation of TLR4 




neutrophils, B lymphocytes) and non-immune cells such as endothelial cells and 
epithelial cells (including proximal tubular epithelial cells) (82).  A number of accessory 
proteins are also involved in initiation of LPS signaling through TLR4.  In its native form 
in vivo, LPS exists as an oligomeric micelle that is not biologically active.  A soluble, 
circulating protein known as LPS binding protein (LBP) is required to convert endotoxin 
into a monomeric form that can bind its receptor (83).  Monomeric LPS is then delivered 
to the co-receptor CD14 that is expressed in both soluble (sCD14) and 
glycophosphatidylinositol-anchored membrane (mCD14) forms (84).  CD14 then 
transfers LPS to the MD-2 (also known as lymphocyte antigen 96)/TLR4 receptor 
complex on the plasma membrane of target cells.   Binding of LPS to the MD-2/TLR4 
complex induces conformational changes that promote TLR4 homodimerization and 
subsequent activation (85).  TLR4 utilizes intracellular Toll/IL-1 receptor (TIR) domains 
to recruit a variety of adaptor proteins that initiate signaling. TLR4 signaling is typically 
grouped into two broad classes based on the adaptor proteins involved: an acute MyD88 
(myeloid differentiation factor 88)-dependent pathway and a delayed MyD88-
independent pathway (86). 
MyD88 interacts with TLR4 and another essential adaptor known as TIRAP (toll-
interleukin 1 receptor (TIR) domain containing adaptor protein) via a TIR domain located 
near its carboxyl terminal. MyD88 also contains an N-terminal death domain (DD) that 
recruits other signaling proteins to the TLR4 complex.  In particular, MyD88 interacts 
with and activates specific IL-1 receptor-associated kinases including IRAK-1 and 
IRAK-4.  Association of active IRAK-1 with TNF receptor-associated factor 6 (TRAF6) 




1 (TAK1), a member of the mitogen-activated protein kinase kinase kinase (MAP3K) 
family.  TAK1 is then responsible for initiating downstream signaling by the nuclear 
factor κB (NFκB) and mitogen-activated protein kinase (MAPK) pathways (86).  TAK1-
mediated phosphorylation of the IκB kinase (IKK) complex leads to degradation of IκB 
and subsequent nuclear translocation of NFκB, which then promotes transcription of a 
wide variety of cytokines, chemokines, cellular adhesion molecules, and other 
components of the innate immune response (87).  The functional IKK complex also 
activates another MAP3K known as TPL-2 (tumor progression locus-2, also known as 
MAP3K8) leading to signaling through the MEK/ERK cascade (88).  In addition, TAK1 
phosphorylates MAP kinase kinases 7 (MKK7) and 3 (MKK3) to induce c-Jun N-
terminal kinases (JNKs) and p38 MAPKs, respectively (86).   Overall, the net effect of 
MyD88-dependent activation of NFκB and MAPK signaling pathways is a rapid pro-
inflammatory response at both the transcriptional and translational levels (87, 89).   
 Recent evidence indicates that macrophages lacking MyD88 still respond to LPS 
stimulation as measured by delayed activation of NFκB and IFN-β production, 
suggesting that TLR4 may also signal through MyD88-independent mechanisms (90, 91). 
The MyD88-independent cascade was subsequently identified and begins with the 
interaction of active TLR4 with two adaptors known as TIR-containing adaptor molecule 
(TRIF) and TRIF-related adaptor molecule (TRAM) via TIR domains contained in each 
of these proteins.  TRIF binds to and activates non-canonical IKKs including IKKε and 
TANK-binding kinase-1 (TBK-1).  Both IKKε and TBK-1 phosphorylate the 
transcription factor known as interferon regulatory factor-3 (IRF-3), allowing for its 




of interferon-β (IFN-β). IFN-β in turn binds the interferon α/β receptor (IFNAR) and 
activates the Janus kinase (JAK)-Signal Transducer and Activator of Transcription 
(STAT) signaling pathway (87).  In addition, TRIF possesses TRAF6-binding domains, 
allowing it to bind TRAF6 and initiate a delayed NFκB signaling response (93).  
However, it should be noted that MyD88 knockout mice are protected from endotoxin-
induced elevation of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and lethality, 
suggesting that MyD88-independent pathways play only a minor role in in vivo responses 
to LPS (90).  Recent work has also defined TLR4-independent actions of intracellular 
LPS including activation of the non-canonical inflammasome and caspases-1 and -11, 
although the overall contributions of these mechanisms to Gram-negative bacterial sepsis 
remain unclear (94, 95).  TLR4-dependent LPS signaling and known negative regulators 






Figure 1-6A: TLR4-dependent LPS signaling. Binding of LPS to LBP and CD14 
facilitates loading of endotoxin onto LPS receptor complex, which is composed of 
dimerized TLR4 receptors and two molecules of the extracellular adapter MD-2.  LPS 
signaling leads to the early activation of NF-κB and MAPK kinase pathways mediated by 
the adapters MyD88 and TIRAP (Mal). As a later response to LPS, TLR4 gives rise to 
the activation of TRAF6 and TBK1, an event mediated by the adapters TRIF and TRAM. 
ST2, SIGIRR, MyD88s, IRAK-M, Tollip, IRAK2c and IRAK2d are negative regulators. 
IFN = interferon; ΙΚΚ = ΙκB kinase; IRAK = interleukin-1 receptor-associated kinase; 
IRF = interferon regulatory factor; ISRE = interferon-sensitive response element; LPS = 
lipopolysaccharide; LBP = LPS-binding protein; Mal = MyD88 adapter like (also known 
as TIRAP); MAPK = mitogen-activated protein kinase; MKK = mitogen-activated 
protein kinase kinase; MyD88 = myeloid differentiation factor 88; NF-κB = nuclear 
factor-κB; RIP = receptor interacting protein; SIGIRR = single immunoglobulin 
interleukin-1 receptor-related molecule; TBK = TANK-binding kinase; TLR = Toll-like 
receptor; ΤRΑF6 = tumor necrosis factor receptor-associated factor; TRIF = TIR-
containing adapter molecule; TRAM = TRIF-related adapter molecule; Tollip = TAB, 
TAK-1 binding protein; TAK = transforming growth factor-β-activated kinase. Uev1a = 
ubiquitin-conjugating enzyme variant 1a; Ubc13 = ubiquitin-conjugating enzyme.  



























Figure 1-6B: TLR4-dependent activation of TPL-2/MEK/ERK signaling by LPS.  
Stimulation of TLR4 by LPS activates the IKK complex, which phosphorylates Ser927 
and Ser932 of p105 large precursor of NF-κB1. This triggers p105 ubiquitination and 
subsequent degradation, liberating TPL-2. In the absence of p105, TPL-2 phosphorylates 
and activates MEK, which in turn phosphorylates and activates ERK. In unstimulated 
cells, TPL-2 and p105 form a ternary complex with ABIN-2. ABIN-2 is released from 
p105 after LPS stimulation, but its function is currently unknown. IKK-induced p105 
proteolysis also liberates the associated mature p50 NF-κB1 subunit to translocate into 
the nucleus and modulate target gene expression.  LPS = lipopolysaccharide; TLR4 = 
Toll-like receptor 4; IKK = IκB kinase complex; ABIN-2 = A20-binding inhibitor of 
nuclear factor-κB (NF-κB)-2; TPL-2 = tumor progression locus-2; MEK = mitogen-
activated protein kinase kinase; ERK = extracellular signal-regulated kinase; TNF-α = 




Administration of Live Pathogens 
  Administration of live bacteria has been employed in both rodents and other 
larger animals (pigs, sheep, primates) as an alterative means to study sepsis.  This method 
is particularly useful for studying unique systemic responses to a particular pathogen.  
However, models in this category are not well standardized across different laboratories.  
There is considerable variability in the route of administration (intravenous, 
intraperitoneal, subcutaneous, lung inoculation), bacterial species, and bacterial load (81).  
All of these factors may have important effects on the host response to pathogens.  For 
example, intravenous administration of Escherichia coli in mice led to a profound 
increase in serum levels of the cytokines TNF-α, IL-1, and IL-6 whereas intraperitoneal 
injection of the same bacterial load resulted in only local increases in these pro-
inflammatory markers (97).  It has also been established that large bacterial loads 
commonly used in these models undergo rapid lysis via the complement cascade and are 
therefore unable to colonize and replicate in the host organism (98).  For this reason, 
administration of live bacteria may better represent a model of toxicosis instead of true 
bacterial infection (77). Administration of live bacteria can lead to development of AKI 
in experimental animals depending on the experimental parameters described above. 
These models have been particularly useful in studying changes in renal hemodynamics 
in larger animals such as pigs and sheep (99, 100).    
Modification of the Host’s Protective Barriers 
 Models in this category employ a variety of techniques to alter normal protective 
barriers that act to exclude potential pathogens from sterile compartments.  The most 




(CLP) or colon ascendens stent peritonitis in rodents (77).  CLP is currently considered 
the “gold standard” of sepsis models.  The CLP procedure involves midline incision, 
isolation of the cecum, ligation of a portion of the cecum proximal to the ileocecal valve, 
and perforation of the ligated cecum using a needle.  This allows for expression of fecal 
contents into the periotoneal cavity and subsequent development of polymicrobial sepsis 
(101).  The severity of disease can be finely tuned based on the length of cecum ligated, 
number of cecal punctures, and the size of the needle used (102).  Unlike the models 
described above (LPS or bacterial administration), the systemic pro-inflammatory 
cytokine response following CLP is somewhat delayed, more protracted, and several 
orders of magnitude lower (80).  CLP is also associated with an apparent 
immunosuppressive phase marked by lymphocyte apoptosis at later time points (103, 
104).  Based on these findings, CLP is thought to better mimic both the systemic 
inflammatory response and the compensatory anti-inflammatory syndromes (CARS) 
characteristic of human cases of sepsis (77, 105).  CLP studies have also successfully 
reproduced failure of clinical trials for targeted anti-inflammatory approaches including 
anti-TNF-α agents, further suggesting that this may be a more clinically relevant model 
(106, 107).  Although some reports suggested that CLP is not sufficient to produce AKI, 
most studies observe reproducible changes in classical markers of renal dysfunction 
including SCr and BUN (108-110). A significant disadvantage of the CLP model is the 
normal host response to isolate the infected region by creating an abscess (111).  Thus, 
drugs that promote abscess formation may be efficacious in the CLP model but have little 






Other Factors Limiting Clinical Relevance of Animal Models of Sepsis 
 All of the experimental models of sepsis described above have received 
considerable criticism because they ignore many other clinical factors that affect 
outcomes in septic patients.  Very few models attempt to mimic the supportive care 
(broad-spectrum antibiotics, fluid resuscitation, and vasopressors) administered to 
patients with suspected sepsis.  In addition, mostly young and otherwise healthy animals 
are used for study.  This is not truly representative of the normal population affected by 
sepsis, because the incidence of this disease rises with increasing age (112).  In addition, 
many septic patients have underlying comorbidities including chronic obstructive 
pulmonary disease (COPD), chronic liver disease, chronic kidney disease, and diabetes 
that are associated with poor outcomes (57, 113).  Significant efforts are now being made 
to address these shortcomings in experimental models of sepsis (78).   
Pathophysiology of Sepsis-induced AKI  
 As discussed above, incidence of and mortality associated with sepsis-induced 
AKI remains incredibly high despite implementation of better supportive measures to 
resuscitate septic patients.  Improved therapeutics directed towards limiting organ-
specific pathophysiology in septic AKI and promoting renal recovery are essential.  Key 
features of the pathogenesis of sepsis-induced AKI are discussed below.  
Macrovascular Hemodynamic Changes in Sepsis-induced AKI  
 Sepsis-induced AKI has traditionally been viewed as a pre-renal form of AKI 
resulting from renal hypoperfusion secondary to a systemic hypodynamic state.  




filtration rate as well as direct cellular injury if ischemia is prolonged (114).  There are 
very few studies investigating changes in renal blood flow in humans with sepsis, so 
current understanding of hemodynamic changes in the septic kidney relies heavily on 
animal models.  Early work by Kikeri et al. in rats demonstrated a significant decrease 
(~42%) in renal blood flow within 3.5 hours of intravenous administration of high dose 
LPS (40 mg/kg) in association with a rapid reduction in glomerular filtration rate.  These 
findings occurred in the absence of alterations in systemic hemodynamic parameters 
including mean arterial pressure and cardiac output (115).  Similar changes in renal blood 
flow have also been reported in some bacterial infusion and CLP models (116, 117).   
 Although early experimental findings largely confirmed the notion that 
hypoperfusion contributes to renal dysfunction in sepsis, new evidence has begun to 
challenge this canonical view.  Using a thermodilution renal vein catheter, Brenner et al. 
reported that renal blood flow was unchanged or increased up to 90 hours after intensive 
care unit admission in a small cohort of seven septic patients (118).  A significant 
reduction in glomerular filtration rate was noted in four of the seven patients followed 
despite relatively stable renal blood flow.  Studies performed in larger animals also 
support the notion that renal hypoperfusion may be absent in sepsis-induced AKI.  
Following intravenous infusion of Escherichia coli in sheep, renal vasodilation and 
elevated renal blood flow was observed in conjunction with development of a 
hyperdynamic state (119).  Although renal hyperperfusion occurred, serum creatinine 
increased approximately 4-fold in septic sheep when compared to controls.  Subsequent 
studies using a similar model revealed that recovery of renal function coincided with 




coli bacteremia (100).  Taken together, these findings provide strong evidence that sepsis-
induced AKI may develop independently of reduced renal blood flow.           
Microcirculatory Dysfunction in Sepsis-induced AKI 
 Although changes in renal blood flow are still disputed, microcirculatory 
dysfunction is widely accepted as an important contributor to septic AKI.  Studies in 
humans with sepsis have demonstrated that the density of perfused capillaries is 
significantly decreased in vascular networks supplying vital organs (120-122).  Loss of 
functional capillary density may occur due to an increase in microvascular shunting.  In 
dogs subjected to intravenous administration of LPS derived from E. coli, regional 
arterial-venous shunting was considerably increased when compared to control animals 
within 2 hours (15.1% vs. 4.0%) (123).  The overall effect of these changes is increased 
heterogeneity of blood flow in renal capillaries following development of sepsis.  In 
particular, a decrease in the number of renal peritubular capillaries with continuous 
perfusion in conjunction with an increase in capillaries with intermittent or no flow has 
been noted in both the endotoxin and CLP models of sepsis in mice (124, 125).   
Other functional changes in the microcirculation may also contribute to 
heterogeneity in microvascular flow.  Reduced deformability of circulating red blood 
cells (RBCs) and polymorphonuclear neutrophils (PMNs) has been observed in septic 
patients and may contribute to decreased capillary blood flow (126, 127). The systemic 
inflammatory response to sepsis also results in increased expression of cellular adhesion 
molecules by white blood cells (CD11b) and endothelial cells (ICAM-1, selectins).  
Aggregation of activated leukocytes due to interactions with the endothelium also 




hypercoagulable state and disseminated intravascular coagulation (DIC) that occlude 
small vessels by formation of microthrombi (127).  Together, the effects described above 
lead to development of local regions of hypoperfusion and hypoxia that contribute to 
cellular injury in the septic kidney (128). 
 Another important component of microvascular dysfunction in sepsis-induced 
AKI is loss of normal endothelial barrier function.  Changes in microvascular 
permeability may be attributed to direct structural damage to endothelial cells, cytokine-
mediated disruption of endothelial tight junctions, or CD18-dependent adhesion of PMNs 
to the endothelium (129-131).  Wang et al. demonstrated a significant increase in renal 
microvascular permeability as early as 6 hours after CLP in mice by measuring Evans 
blue dye extravasation (109).  The leaky capillary endothelium contributes to disruption 
of capillary flow, extracellular edema formation, and increased exposure of the renal 
parenchyma to a variety of inflammatory mediators that may exacerbate renal injury in 
the setting of sepsis (discussed in further detail below) (109).  In support of an important 
role for microvascular dysfunction in the pathophysiology of sepsis-induced AKI, a 
number of therapies targeted at restoring capillary flow and/or endothelial integrity have 
shown promise in preventing renal injury in animal models of sepsis (109, 132-135).   
Inflammatory Injury in Septic AKI 
 Pathogen recognition by the innate immune system leads to activation of 
circulating leukocytes and subsequent production of pro-inflammatory cytokines such as 
interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in the 
setting of sepsis (136).  Many of these mediators are implicated in the pathophysiology of 




kidney, and this protein has received considerable attention for its role in promoting AKI 
due to sepsis and other causes (137, 138).  Neutralization of TNF-α by the soluble decoy 
receptor TNFsRp55 prevented endotoxin-mediated reduction of glomerular filtration rate 
(GFR) in mice, suggesting that TNF-α is an important contributor to renal injury in septic 
AKI (139).  LPS-induced increases in blood urea nitrogen were also attenuated after pre-
treatment of mice with an anti-TNF-α antibody in a similar study (79).  Cunningham et 
al. further demonstrated that TNF-α acts directly on tumor necrosis factor receptor 1 
(TNFR1) expressed in the septic kidney to promote cellular injury (140).  Decreased 
histological evidence of tubular injury (tubular dilatation, flattening, and vacuolization), 
renal dysfunction, and apoptosis were observed in global TNFR1 knockout mice after 
systemic LPS exposure when compared to their wild-type controls.  To confirm the role 
of kidney-specific TNFR1 in pathogenesis of LPS-induced AKI, additional studies 
involving transplantation of kidneys between TNFR1+/+ and TNFR1-/- mice were 
performed.  Blood urea nitrogen (BUN) only significantly increased in response to 
endotoxin when TNFR1+/+ kidneys were transplanted into TNFR1-/- mice and not when 
TNFR1-/- kidneys were transferred to TNFR1+/+ recipients (140).  In further support of a 
role for TNF-α in this disease, systemic administration of recombinant TNF-α reproduces 
many of the effects of LPS and polymicrobial sepsis on renal function (141, 142).  Taken 
together, these findings provide strong evidence that TNF-α is an important mediator of 
kidney injury in the setting of sepsis.  Similar deleterious roles have been described for 
IL-1 and IL-6 in other forms of AKI (143, 144).  
 In addition to circulating pro-inflammatory cytokines, the septic kidney is also 




components are collectively referred to as pathogen-associated molecular patterns 
(PAMPs), and PAMPs mediate innate immune system activation through a variety of 
different pattern recognition receptors (PRRs) including Toll-like receptors (TLRs), C-
type lectin receptors (CLRs), NOD-like receptors (NLRs), and RIG-I-like receptors 
(RLRs) (145).  Tubular and mesangial cells in the kidney have been shown to express 
TLRs 1-4 and 6 (146, 147) that can interact with PAMPs during sepsis.  Recent work by 
Pierre Dagher’s laboratory indicates that TLR4 expression is increased in proximal and 
distal tubules, the glomerulus, and the renal vessels after induction of polymicrobial 
sepsis by CLP in rats (148).  The same group also demonstrated that LPS, a classical 
PAMP, is filtered at the glomerulus, enters the tubular lumen, and interacts with TLR4 on 
the apical surface of proximal tubule cells in the S1 segment (149).  Once LPS interacts 
with tubular TLR4, it undergoes fluid-phase endocytosis.  Internalization in S1 tubular 
cells results in oxidative damage in the distal S2 portion, further indicating cross talk 
between segments of the proximal tubule (149).  S1 cells appear to be protected from 
LPS-induced oxidative stress through increased expression of the antioxidant proteins 
heme oxygenase-1 (HO-1) and sirtuin 1 (SIRT1).  Using bone marrow chimeric mice, the 
authors further demonstrated that LPS internalization and reactive oxygen species 
generation is dependent on TLR4 expressed in the kidney and not in peripheral 
leukocytes (149).  These findings indicate an important role for renal TLR4 in 
pathogenesis of sepsis-induced AKI.  However, an essential role for extrarenal TLR4 in 
endotoxin-mediated renal injury in mice has also been described (150).  Pharmacological 
inhibition or genetic knockout of other pattern recognition receptors including TLR2 (a 




development of AKI following CLP in mice, although the issue of whether these effects 
are attributable to kidney-specific or systemic expression of these proteins remains 
unclear (151, 152).  Finally, activated leukocytes and injured renal cells may produce a 
number of endogenous molecules known danger-associated molecular patterns (DAMPs) 
that activate the innate immune system and further exacerbate the inflammatory response 
and renal dysfunction in septic AKI (153, 154).   
Tubular Injury in Sepsis-induced AKI   
 Development of microvascular dysfunction, local inflammatory responses, and 
oxidative stress in the septic kidney as described above culminates in direct injury to the 
renal proximal tubule (155). Unlike other forms of ischemic and toxic injury, sepsis-
induced AKI is not associated with widespread acute tubular necrosis (ATN) or apoptosis 
(156, 157).  However, Guo et al. noted an increase in renal caspase-3 activity in 
association with modestly increased terminal deoxynucleotidyl transferase-mediated 
dUTP nick-end labeling (TUNEL)-positive cells and DNA fragmentation after endotoxin 
administration in mice (158). The broad-spectrum caspase inhibitor z-VAD prevented 
LPS-induced elevation of blood urea nitrogen, serum creatinine, and tubular injury (158).  
Thus, apoptotic cell death may play a minor role in pathogenesis septic AKI. 
Although a limited increase in tubular apoptosis has been observed, there is a 
striking discrepancy between the degree of renal cell death and the severity of renal 
dysfunction in the septic kidney.  The histopathology of sepsis-induced AKI is 
predominantly characterized by heterogeneous, focal tubular injury including tubular 
dilatation, epithelial cell swelling, brush border flattening, and apical vacuolization (159).  




low molecular weight dextran, a marker of normal tubule cell function, is significantly 
delayed after systemic LPS administration in rats (160).  In addition, endotoxin exposure 
also disrupts reabsorption of bicarbonate ions [HCO3-] by inhibiting the Na+/H+ 
exchanger expressed in the basolateral membrane of medullary thick ascending limb 
(MTAL) cells (161).  These findings indicate that sub-lethal cellular injury is an 
important mediator of tubular and renal dysfunction in sepsis.  Of particular note in the 
histopathology of sepsis-induced AKI is apical vacuolization observed in the renal 
proximal tubule.  Recent studies utilizing transmission electron microscopy have 
demonstrated that the apical vacuoles described above actually represent swollen, 
dysfunctional mitochondria (162).  Thus, mitochondrial dysfunction may play an 
important role in tubular injury in the septic kindney.  The remainder of this review will 
focus on normal mitochondrial biology and the pathogenic contribution of mitochondrial 
injury and dysfunction to septic and other forms of AKI.  Figure 1-7 below summarizes 
the roles of microvascular dysfunction, inflammation, and tubular injury in the 






Figure 1-7: Pathophysiology of sepsis-induced AKI.  Sepsis induces profound 
alterations in microcirculatory flow in the kidney.  This alteration is characterized by a 
significant increment in the heterogeneity of flow, as well as an increase in the proportion 
of capillaries with intermittent or no flow (represented in the figure by darker hexagons in 
the peritubular capillary).  These areas of sluggish flow have been shown to colocalize 
with expression of oxidative stress in the tubular epithelial cells, suggesting causation. In 
addition, immunohistological studies have shown that oxidative stress is localized to the 
apex of the tubular epithelial cell and that it is associated to the formation of apical 
vacuoles. In addition, filtered LPS is recognized by S1 tubular epithelial cells through 
TLR4 and is internalized via endocytosis. This event has been shown to trigger an 
oxidative outburst, not in the S1 segment cells, but rather in the S2 segment cells. This 
seems to be associated with the expression in S1, but not in S2 epithelial cells of heme 
oxygenase 1 (HO-1) and Sirt1, both highly protective against oxidative damage. DAMPs 
= damage-associated molecular patterns; PAMPs = pathogen-associated molecular 
patterns; TNF-α = tumor necrosis factor-α; TLR4 = Toll-like receptor 4; ICAM = 
intercellular adhesion molecule; VCAM = vascular cell adhesion molecule.  Adapted 




GENERAL MITOCHONDRIAL BIOLOGY  
Mitochondrial Function  
 Mitochondria are subcellular organelles often viewed simply as the cellular 
“powerhouse” because of their essential role in ATP generation by oxidative 
phosphorylation.  In addition to their role in energy production, it is important to note that 
mitochondria regulate multiple aspects of cellular metabolism and homeostasis.  In 
particular, the mitochondrion is involved in intracellular calcium signaling and storage, 
fatty acid oxidation, heme and steroid biosynthesis, reactive oxygen species (ROS) 
generation, antioxidant defense mechanisms, apoptotic cell death, and cell cycle 
progression (163-168).  
Mitochondrial Structure 
 The mitochondrion is membrane-bound organelle possessing an outer 
mitochondrial membrane (OMM) and an inner mitochondrial membrane (IMM) that are 
made up of phospholipid bilayers.  The double membrane structure creates four distinct 
compartments within the mitochondria as follows: 1) the OMM containing various 
channel proteins known as porins and metabolic enzymes; 2) the IMM housing 
complexes I-IV of the ETC and ATP synthase; 3) the intermembrane space which is 
essential for maintenance of the proton gradient established by ETC activity; and 4) the 
mitochondrial matrix enclosed by the IMM that contains a variety of metabolic enzymes 
(e.g. enzymes involved in the citric acid cycle and fatty acid oxidation), the mitochondrial 
protein synthesis machinery, and mitochondrial DNA (mtDNA) (169). mtDNA is circular 
and double-stranded in structure and encodes 37 genes including 22 transfer RNAs 




complex I, 1 in complex III, 3 in complex IV, and 2 in ATP synthase) (170).  However, 
the vast majority of proteins located in the mitochondria (> 1500) are encoded in the 
nucleus, highlighting the importance of cross-talk between the nucleus and mitochondria 
in maintenance of organelle function and homeostasis (171). 
Mitochondrial Homeostasis 
 Mitochondrial homeostasis is governed by complex interplay between 
mitochondrial biogenesis, mitochondrial dynamics (fission/fusion), and mitochondrial 
quality control mechanisms (mitophagy) (172, 173).  Mitochondrial biogenesis is 
reviewed at length below.  Dynamics refers to the balance between fission and fusion, 
two processes that regulate mitochondrial morphology.  Fission involves organelle 
division resulting in generation of a series of small, rod- or sphere-shaped mitochondria 
(174).  Fission is largely mediated by interaction between the cytosolic GTPase Drp1 
(dynamin-related protein 1) and Fis1 (mitochondrial fission 1 protein) located on the 
OMM.  Fission is intimately related to induction of apoptosis in injured cells (174).  In 
contrast, fusion creates an elongated, reticular network of mitochondria.  Fusion is 
regulated by the activities of the mitofusins (Mfn1 and Mfn2) located in the OMM and 
OPA1 (optic atrophy 1) in the IMM (174).  Mitophagy represents a quality control 
mechanism by which injured and dysfunctional mitochondrial are isolated and 
subsequently degraded by lysosomal digestion.  The major pathway facilitating 
mitophagy involves PINK1 (PTEN-induced putative kinase 1) on the OMM and the 






Mitochondrial Biogenesis  
Mitochondrial Biogenesis Definitions 
 Mitochondrial biogenesis is broadly defined as the process by which cells 
generate new, functional mitochondria (176).  Conceptually, there are at least three 
potential mechanisms that might lead to increased mitochondrial mass in the cell: 1) 
growth and division of preexisting mitochondria; 2) de novo production of mitochondria 
from cytoplasmic precursors; and 3) generation from other membrane-bound cellular 
components (177).  There is now strong evidence that existing mitochondria are capable 
of growing and dividing, and this is likely the predominant process utilized for biogenesis 
(177).  Thus, biogenesis can be viewed more precisely as the growth and division of 
preexisting mitochondria for the purpose of increasing mitochondrial mass and ATP 
production (177, 178).  Biogenesis is necessary to maintain mitochondrial homeostasis 
under basal conditions and may be up-regulated in response to a variety of pathological 
states that alter cellular energy demands (178).  It is important to note that the biogenic 
process is complex and requires orchestration of multiple biological responses as follows: 
1) transcription and translation of nuclear-encoded mitochondrial targets; 2) recruitment 
of these nuclear-encoded products; 3) mitochondrial DNA (mtDNA) transcription and 
translation; and 4) assembly of both nuclear- and mitochondrial-derived proteins into a 
growing mitochondrial network (179).   
Regulation of Mitochondrial Biogenesis  
 Mitochondrial biogenesis is largely regulated at the transcriptional level by the 
PGC-1 family of transcriptional co-activators, which includes peroxisomal proliferator-




(PRC) that are responsible for coordinating both nuclear and mitochondrial responses to 
increase cellular mitochondrial content.  PGC-1α has been termed the “master regulator” 
of mitochondrial biogenesis and is abundantly expressed in tissues with high energy 
requirements including the heart, skeletal muscle, brown adipose tissue, and the kidney 
(180, 181).  PGC-1α was first identified as a coactivator for peroxisomal proliferator-
activated receptor γ (PPARγ) in a yeast two-hybrid screen, and subsequent studies 
revealed that PGC-1α-mediated coactivation of PPARγ is an important determinant of 
adipocyte fate (white adipose versus brown adipose tissue) and adaptive thermogenesis 
(180, 182).  PGC-1α is now recognized as a coactivator for an incredible variety of 
transcription factors including PPARs (PPARα, PPARδ, PPARγ), estrogen related 
receptors (ERRα, ERRβ, and ERRγ), nuclear respiratory factors (NRF-1 and NRF-2), and 
FOXO3 (forkhead box protein O3) (178, 183).  PGC-1α does not directly bind DNA but 
instead contains an N-terminal activation domain with three LXXLL motifs that allows 
for direct interaction with most of the nuclear transcription factors at the promoter region 
of target genes (184).  Once bound to its associated transcription factor, PGC-1α recruits 
other transcriptional coactivators including p300/CBP (CREB binding protein) and 
steroid receptor coactivator-1 (SRC-1) (185).  Both p300/CBP and SRC-1 possess 
intrinsic histone acetyltransferase (HAT) activity, allowing for relaxation of the 
chromatin structure and increased gene expression (186, 187).  In addition, active PGC-
1α also associates with another multiprotein coactivator complex known as Mediator 
(also know as the TRAP/DRIP complex) that is essential for recruitment of the general 
transcription machinery (including RNA polymerase II) to the promoter region (188, 




discussed below with a particular emphasis on their relevance to mitochondrial 
biogenesis.  
Transcriptional Regulation of Mitochondrial Biogenesis in the Nucleus 
Nuclear Respiratory Factors (NRF-1 and NRF-2)  
 The NRFs are structurally unrelated nuclear transcription factors that modulate 
transcription of nuclear-encoded mitochondrial genes.  Both NRF-1 and NRF-2 are 
ubiquitously expressed and enhance expression of target genes by interaction with NRF-
1/2 binding sites in their promoter regions (190, 191).  NRF-1 was first identified as a 
transcriptional regulator of cytochrome c, and subsequent studies have revealed an 
incredible array of mitochondrial genes with conserved NRF-1 binding sites (192).  In 
particular, NRF-1 promotes transcription of genes encoding components involved in 
oxidative phosphorylation (e.g. subunits of ETC complexes I-V, cytochrome c), 
mitochondrial DNA transcription and translation (mitochondrial transcription factor A, 
TFAM), mitochondrial protein import and assembly (Tom20, COX17), and heme 
biosynthesis (5-aminolevulinate synthase) (193, 194).  Similarly, NRF-2 (also known as 
GA binding protein, GABP) was first identified due to the presence of NRF-2 binding 
sites in the promoter region of the gene coding for subunit IV of cytochrome c oxidase 
(COXIV) (195, 196).  NRF-2 promotes transcription of a smaller set of targets than NRF-
1, but with similar functions including mitochondrial respiration (e.g. all nuclear-encoded 
subunits of cytochrome c oxidase), mitochondrial protein import (Tom20, Tom70), and 
transcription and translation of mitochondrial DNA (TFAM, mitochondrial transcription 
factor B1 and mitochondrial transcription factor B2) (193, 197).   It should be noted that 




2 (193). NRF-1 deficiency in mice results in embryonic lethality between embryonic days 
3.5 and 6.5, owing largely to depletion of mitochondrial DNA and loss of mitochondrial 
membrane potential in the blastocyst stage (198).  Similarly, NRF-2 knockout mice 
display lethality before implantation of the embryo (199). These findings provide strong 
evidence that the NRFs play essential roles in mitochondrial biogenesis and function.   
Estrogen-Related Receptors (ERRα, ERRβ, and ERRγ) 
The ERRs comprise a family of orphan nuclear receptors for which there is no 
known endogenous ligand.  ERRα is the most ubiquitous and abundant of the ERR 
isoforms, but all three isoforms are typically expressed in tissues with high metabolic 
demand including the heart, kidneys, skeletal muscle, and brown adipose tissue (200).  
Our current understanding indicates that ERRs are primarily regulated by interactions 
with transcriptional coactivators (PGC-1α and SRC-1) and corepressors (receptor 
interacting protein 140 or RIP140) (200).  Once associated with the appropriate 
coactivators, ERRs bind to ERR response elements (ERRE) in the promoter regions of 
target genes involved in multiple aspects of mitochondrial metabolism including β-
oxidation of fatty acids (e.g. medium-chain acyl-CoA dehydrogenase), the citric acid 
cycle (fumarase), oxidative phosphorylation (cytochrome c and subunits of NADH 
dehydrogenase), and ATP synthesis (multiple components of ATP synthase) (200, 201). 
ERRs can also enhance expression of other essential factors contributing to mitochondrial 
DNA transcription (mitochondrial transcription factor 2B, TFB2M), protein translation 
(multiple mitochondrial ribosome proteins), and the transcriptional response to induce 
biogenesis (NRF-2 and PPARα) (200, 202). ERRs therefore play a critical role in 




of this, ERRα-deficient mice display loss of mitochondrial mass, decreased electron 
transport chain activity, and reduced expression of mitochondrial genes in multiple tissue 
types (203-206).     
Peroxoisome Proliferator-Activated Receptors (PPARα, PPARγ, and PPARδ) 
 PPARs are nuclear transcription factors that modulate expression of genes 
involved in multiple aspects of lipid homeostasis including lipid synthesis, uptake, 
storage, and oxidation (192).  PPARγ is predominantly expressed in adipose tissue and 
regulates adipocyte differentiation and maturation, fatty acid synthesis, and lipid transport 
(207, 208).  PPARα and PPARδ are present in a variety of tissues including liver, heart, 
skeletal muscle, and brown adipose tissue (192).  PPARα and PPARδ promote expression 
of enzymes involved in uptake and oxidation of fatty acids (192, 209).  Since fatty acid 
oxidation generates substrates for the citric acid cycle (Acetyl-CoA) and the ETC 
(NADH and FADH2), PPARα and PPARδ are also important regulators of mitochondrial 
respiratory function.  The PPARs also enhance transcription of the uncoupling proteins 
UCP1 (PPARγ) and UCP2 (PPARα and PPARδ) (210). UCPs dissipate the proton 
gradient across the IMM and thus dictate mitochondrial oxidative phosphorylation, ROS 
generation, and adaptive thermogenesis (210, 211).  In addition, stimulation of PPARγ 
and PPARδ induces mitochondrial biogenesis in adipocytes and skeletal muscle 
myocytes, respectively (212-214).  Recent studies have documented the presence of a 
PPAR response element (PPRE) in the promoter region of the PGC-1α gene that appears 
to facilitate PPARγ- and PPARδ-mediated mitochondrial biogenesis (215, 216).  Since 
PGC-1α acts as a transcriptional coactivator for the PPARs, this PPRE permits a positive 




subsequent mitochondrial biogenesis.  However, evidence indicating that PPARs directly 
regulate expression of other components of the biogenic response such as electron 
transport chain proteins is lacking (192).     
Mitochondrial DNA Transcription and Replication in Mitochondrial Biogenesis 
 This discussion of mitochondrial biogenesis has thus far focused on coordinated 
nuclear responses that increase mitochondrial mass.  As discussed above, the 
mitochondrial genome also encodes components involved in normal mitochondrial 
function including 13 ETC proteins.  Thus, transcription and replication of mtDNA is 
also necessary for mitochondrial biogenesis.  Transcription of mtDNA requires 
association of nuclear-encoded proteins including mitochondrial RNA polymerase 
(POLRMT), TFAM, and a member of the mitochondrial transcription factor B family 
(TFB1M or TFB2M) (217).  Distinct promoters located on the heavy strand (HSP1 or 
HSP2) or light strand (LSP) allow for POLRMT binding and transcription initiation 
(218).  POLRMT is recruited to the appropriate promoter region by TFAM, an HMG-box 
protein that associates with enhancer regions upstream of HSP1/2 and LSP (219).  TFAM 
may also promote transcription by unwinding and bending mtDNA, thus allowing better 
access by POLRMT (220).  TFB1M and TFB2M associate with both POLRMT and 
TFAM and appear to increase transcription through an unknown mechanism, with 
TFB2M having more potent stimulatory activity than TFB1M (221, 222).  POLRMT-
mediated transcription initiated at HSP2 and LSP generates polygenic transcripts of the 
full length of mtDNA that are further processed by the activity of mitochondrial RNAse P 
into individual mRNAs, tRNAs, and rRNAs (223).  Transcription from HSP1 produces a 




Mitochondrial-encoded proteins are then synthesized by specialized ribosomes  
(mitoribosomes) located in the mitochondrial matrix (224).  
 A number of nuclear-encoded proteins are also necessary for mtDNA replication 
including DNA polymerase γ (POLγ), TWINKLE helicase, mitochondrial topoisomerase 
I (TOP1MT), and mitochondrial single-stranded binding protein (mtSSB) (217).  In 
addition, POLRMT and TFAM play essential roles in synthesizing an RNA primer from 
the LSP that is used by POLγ to initiate replication (225).  POLγ contains two subunits 
(140 kD and 55 kD in molecular weight) and is the only DNA polymerase present in 
mitochondria (226). The process by which POLγ synthesizes daughter DNA from the 
heavy and light mtDNA strands remains unclear, but a number of different models have 
been proposed (217).  Together, TWINKLE helicase, TOP1MT, and mtSSB are 
responsible for unwinding and maintenance of the mtDNA in a single-stranded state so 
that replication can proceed without interruption (227).   
It is important to note that although PGC-1α does not directly regulate mtDNA 
transcription or replication, it does promote expression of factors necessary for these 
processes (TFAM, TFBM1, TFBM2) via coactivation of nuclear transcription factors as 
described above.  These findings further illustrate the essential role of PGC-1α in 
orchestrating both nuclear and mitochondrial responses to enhance biogenesis.  Genetic 
manipulation studies have further demonstrated the importance of PGC-1α gene targets in 
mtDNA transcription and replication.  In particular, TFAM knockout in mice leads to 
lethality before embryonic day 10.5 that can be attributed to mtDNA depletion and 





Cellular Regulation of PGC-1α and Mitochondrial Biogenesis   
 Since its identification as the “master regulator” of mitochondrial biogenesis, 
extensive efforts have been made to characterize molecular mechanisms responsible for 
regulation of PGC-1α expression and activity.  Transcriptional modulation of PGC-1α is 
the most well-characterized, although post-translational modifications also play an 
important role in modulating activity and stability of this protein.  Major pathways 
regulating PGC-1α are described below.  However, it is important to note that these 
pathways are both tissue- and context-dependent, and relatively little is known about 
specific regulation of PGC-1α in the kidney.    
Positive Transcriptional Regulation of PGC-1α 
 The PGC-1α promoter contains a number of transcription factor binding sites that 
allow for modulation of PGC-1α transcript levels in the cell (192).  The most studied 
positive regulator of PGC-1α is cyclic AMP response element-binding protein (CREB) 
(229).  In skeletal muscle, exercise induces PGC-1α expression through activation of β2-
adrenergic receptor (β2-AR)-cAMP-PKA-CREB signaling pathway (230). Increased 
intracellular Ca2+ levels in skeletal muscle during endurance exercise also result in 
calcium/calmodulin-dependent protein kinase IV (CaMKIV)-mediated activation of 
CREB and subsequent transcription of PGC-1α (231).  Ca2+ also activates the myocyte 
enhancer factor 2 (MEF2) family of transcription factors, which are established 
modulators of PGC-1α expression, via the calcium-dependent phosphatase known as 
calcineurin A (CnA) (231).   
Activating transcription factor 2 (ATF2) is another factor capable of binding to 




phosphorylation and activation of ATF2 is a critical regulator of PGC-1α expression in 
brown adipose tissue (BAT) (232).  In particular, the p38 MAPK-ATF2-PGC-1α 
signaling pathway is essential for cold-inducible adaptive thermogenesis in BAT via up-
regulation of uncoupling protein 1 (UCP1) and subsequent mitochondrial heat generation 
(described above) (232). 
Regulation of PGC-1α transcription by nuclear receptors (PPARs, ERRs) is 
described in earlier sections of this review.  It should also be noted that there are other 
signaling pathways capable of inducing PGC-1α expression through as yet undefined 
transcriptional mechanisms.  Activation of nitric oxide synthase isoforms (endothelial, 
eNOS; inducible, iNOS; neuronal, nNOS) and NO generation potently stimulates PGC-
1α transcription in a variety of cell types via cGMP-dependent signaling (233). AMP-
activated protein kinase (AMPK) also increases PGC-1α mRNA content in skeletal 
muscle via an unknown mechanism (234).  Taken together, these findings demonstrate 
the incredible variety of transcriptional programs that regulate PGC-1α.   
Negative Transcriptional Regulation of PGC-1α  
    Relatively little is known about negative transcriptional regulators of PGC-1α, 
although some candidates have been identified.  In particular, the transcriptional 
corepressor receptor-interacting protein 140 (RIP140) acts to suppress PGC-1α and 
mitochondrial biogenesis.  Similar to PGC-1α, RIP140 makes use of ten leucine-rich 
LxxLL motifs to interact with a number of nuclear receptors including the ERRs and 
PPARs (235).  When associated with nuclear receptors, RIP140 recruits other 
corepressors to the promoter region of target genes including C-terminal binding protein 




act to modulate histone methylation and acetylation in a manner that suppresses gene 
transcription.  The net effect of RIP140 association with PPARs and ERRs is decreased 
expression of PGC-1α and its downstream targets (238, 239).  A similar repressive role 
has also been described for DNA methyltransferase 3B (DNMT3B), which methylates 
the PGC-1α promoter leading to suppression of PGC-1α transcription and mitochondrial 
biogenesis (240).   
 A recent series of studies by Remels et al. has also identified canonical NFκB 
signaling as a negative regulator of PGC-1α transcription in skeletal muscle cells (241, 
242).  In particular, activation of NFκB following treatment with pro-inflammatory 
cytokines (TNF-α, IL-1β) or overexpression of IKK-β resulted in decreased mRNA 
content of PGC-1α and ETC subunits.  These findings are in agreement with in vitro 
work performed in renal proximal tubule cells demonstrating TNF-α-mediated down-
regulation of PGC-1α and its downstream targets (162).  The PGC-1α promoter contains 
a putative NFκB binding site, suggesting that NFκB may negatively regulate transcription 
of this gene by direct association with the promoter region (243).  However, further 
studies are necessary to demonstrate functional binding of NFκB at this site. 
 The MEK/ERK signaling cascade has also been implicated as a potential 
suppressor of PGC-1α in pathological states.  In an animal model of Alzheimer’s disease 
(AD), intracerebroventricular injection of amyloid β (Aβ) in rats led to increased ERK1/2 
activation (phosphorylation) in association with reduced expression of PGC-1α and 
spatial memory deficits (244).  Blockade of ERK signaling using the pharmacological 
inhibitor U0126 reversed Aβ-induced down-regulation of PGC-1α and cognitive decline 




resulted in loss of PGC-1α mRNA and protein levels in a MEK/ERK-dependent manner 
(245). Unfortunately, the downstream mechanisms responsible for negative regulation of 
PGC-1α by the MEK/ERK signaling pathway have not been elucidated. 
Post-Translational Regulation of PGC-1α  
 Stability and activity of the PGC-1α protein is heavily modulated by post-
translational modification.  PGC-1α is phosphorylated by a variety of kinases including 
AMPK, p38 MAPK, Akt, and glycogen synthase kinase-3β.  Depending on the amino 
acid residue phosphorylated, these modifications can stimulate or reduce transcriptional 
coactivation by this protein.  In response to changes in the cellular AMP:ATP ratio, 
AMPK phosphorylates PGC-1α on threonine-177 and serine-538 residues and promotes 
its activity (246).  Phosphorylation by p38 MAPK at threonine-262, serine-265, and 
threonine-298 increases protein half-life and blocks association of PGC-1α with the 
transcriptional co-repressor p160MBP (247, 248).  Post-translational activation of PGC-
1α by both AMPK and p38 MAPK is thought to play an important role in physiological 
induction of mitochondrial biogenesis in skeletal muscle after endurance exercise (192).  
In contrast, Akt- and GSK-3β-mediated phosphorylation has inhibitory effects on PGC-
1α activity (249, 250).  
 Acetylation represents another post-translational modification responsible for 
regulating PGC-1α activity.  The PGC-1α protein contains at least 15 lysine residues that 
may be acetylated.  Acetylation status is largely determined by the opposing activity of 
the N-acetyltransferase GCN5 (general control nonderepressible 5) and the NAD+-
dependent deacetylase Sirtuin 1 (SIRT1) (251). GCN5 and SIRT1 are both well-




response to changes in metabolic demand (251).  In particular, deacetylation by SIRT1 
activates PGC-1α, whereas GCN5-mediated acetylation has inhibitory effects (252, 253).  
SIRT1 activation is involved the physiologic induction of skeletal muscle PGC-1α and 
mitochondrial biogenesis in response to caloric restriction in mice (254).  On the other 
hand, GCN5 expression and activity is increased in BAT and skeletal muscle of mice fed 
a high fat diet, leading to decreased expression of PGC-1α target genes and mtDNA 
content (255).  In addition to phosphorylation and acetylation, the PGC-1α protein is also 
subject to ubiquitination, methylation, and glycosylation (O-GlcNAc modification) (251).  
Further work is necessary to determine the physiological relevance of these 
modifications.  Figure 1-8 below summarizes major pathways regulating PGC-1α and 






Figure 1-8: Regulation of PGC-1α and mitochondrial biogenesis. A summary of the 
pathways involved in the promotion and mediation of mitochondrial biogenesis and 
accompanying signaling responses is outlined above. Because of the complexity of the 
networks involved, many intermediates as well as feedback interactions and other targets 
of the transcription factors could not be included. The indicated processes may regulate 
PGC-1 family members at the transcriptional level, post-translational level, or both as 
described above. Inhibitory factors such as RIP140, GCN5, and Akt are not shown. Red 
boxes indicate essential PGC-1α targets required for mitochondrial biogenesis.  AMPK = 
AMP-activated protein kinase; CAC = citric acid cycle; CamK = calcium-calmodulin-
dependent protein kinase; CO = carbon monoxide; eNOS = endothelial nitric-oxide 
synthase; FAO = fatty acid oxidation; GABP = GA-binding protein α (also known as 
NRF-2); GSK-3β = glycogen synthase kinase-3β; HO-1 = heme oxygenase 1; NO = nitric 
oxide; OXPHOS = oxidative phosphorylation; PKA = protein kinase A; PRC = PGC-1 






MITOCHONDRIAL DYSFUNCTION AND BIOGENESIS IN AKI 
Renal Proximal Tubule Cell Metabolism and Bioenergetics  
 Maintenance of cellular ATP levels in the renal proximal tubule is essential for 
reabsorption of solutes from the glomerular filtrate via active transport as well as energy-
dependent repair processes in the injured kidney.  Thus, pathological conditions resulting 
in reduced ATP levels contribute to tubular de-energization and subsequent loss of renal 
function characteristic of AKI (256, 257).  Early biochemical studies demonstrated that 
the proximal tubule does not rely heavily on glucose catabolism, with the lowest activity 
of the three major regulatory enzymes of glycolysis (hexokinase, HK; 
phosphofructokinase-1, PFK-1; and pyruvate kinase, PK) along the entire nephron 
segment (258).  In fact, the renal cortex, consisting primarily of renal proximal tubule 
cells, contributes to de novo synthesis of glucose from lactate via gluconeogenesis that 
can be released into the circulation (259).  Under normal conditions in vivo, the proximal 
tubule instead primarily utilizes mitochondrial oxidative phosphorylation to generate 
ATP via oxidation of alternate metabolic fuels including lactate, pyruvate, fatty acids, 
and amino acids (260, 261).  Experimental evidence indicates that renal proximal tubule 
cells have extremely high mitochondrial density (258, 262).  In addition, approximately 
70% of oxygen consumption in the tubule is used to drive the Na+/K+-ATPase that 
establishes the electrochemical gradient necessary for reabsorption of a variety of solutes 
in the glomerular filtrate (263, 264).  Thus, the structural changes described above in 
tubular mitochondria following sepsis-induced AKI is of particular interest since it may 
be a significant contributor to renal dysfunction.  Evidence for alterations in 




Evidence for Mitochondrial Dysfunction and Altered Homeostasis in Sepsis-induced 
AKI  
 There is now considerable experimental evidence identifying roles for 
mitochondrial dysfunction in the pathogenesis of septic AKI.  Tran et al. recently 
demonstrated reduced expression of whole kidney cytochrome c oxidase IV (COX IV), a 
subunit of complex IV of the electron transport chain (ETC), in association with 
mitochondrial swelling following systemic endotoxin exposure in mice (162).  
Cytochrome c oxidase activity was also markedly reduced in the renal cortex and the 
outer stripe of the outer medulla (OSOM) in this model (Figure 1-9 below).  Other groups 
have reported a rapid reduction (~2-fold) in renal ATP levels as early as five hours after 
LPS administration in rodents (265).  LPS and its downstream effector cytokine TNF-α 
have also been shown to directly suppress mitochondrial oxygen consumption in renal 





Figure 1-9: Mitochondrial dysfunction in endotoxin-induced AKI.  (A) Staining 
(brown) for cytochrome c oxidase enzyme activity on slices from snap-frozen kidneys 18 
hours after vehicle or LPS treatment. Cortex (C) and inner stripe of the outer medulla 
(ISOM) have the most intense staining, followed by outer stripe of the outer medulla 
(OSOM), with the weakest activity in the inner medulla (IM). Enzymatic activity is 
greatly reduced following LPS. Original magnification, ×4 (overview); ×40 (cortex, 
corticomedullary [CM] junction). (B) Western blot on whole kidney lysates for 
cytochrome c oxidase subunit IV. (C) Transmission EM of proximal tubules 
demonstrating swelling of mitochondria and rarefaction of cristae. n = 3–6 mice per 




Loss of renal mitochondrial respiratory function has also been reported in a CLP 
model of sepsis.  In particular, high-resolution respirometry revealed decreases in renal 
ETC complex I and complex II/III activities as early as six hours after induction of CLP 
in mice (267).  Inactivation of ETC complexes in the kidney was accompanied by a 
significant decline in ATP content by 36 hours in CLP animals when compared to sham 
controls.  The same study also demonstrated an important role for mitochondrial reactive 
oxygen species (ROS) generation in sepsis-induced renal injury and dysfunction in CLP 
mice (267).  The mitochondrial-targeted antioxidant Mito-TEMPO attenuated CLP-
induced changes in renal mitochondrial respiration, microcirculatory perfusion, oxidative 
stress, and glomerular filtration rate (267). 
It should be noted that sepsis-induced mitochondrial dysfunction has also been 
reported in experimental models examining other organ systems including the liver, the 
lungs, skeletal muscle, the brain, and the heart (268-272).  In addition, skeletal muscle 
biopsies taken from septic patients admitted to the intensive care unit revealed a 
significant association between morbidity/mortality and severe mitochondrial dysfunction 
characterized by decreased ATP content, reduced complex I activity, glutathione 
depletion, and elevated markers of oxidative stress (273).  Taken together, these findings 
indicate an important role for mitochondrial dysfunction and loss of mitochondrial 
homeostasis in the pathophysiology of sepsis-induced organ failure including AKI.  
 Evidence for Mitochondrial Dysfunction and Altered Homeostasis in Other Forms 
of AKI 
 Our laboratory has previously demonstrated loss of normal mitochondrial 




model of ischemia-reperfusion (I/R) injury results in persistent loss of electron transport 
chain (ETC) proteins including nuclear-encoded NADH dehydrogenase (ubiquinone) 1 
beta subcomplex 8 (NDUFB8) and ATP synthase β (ATPSβ) as well as mitochondrial-
encoded cytochrome c oxidase subunit I (COXI) in the renal cortex up to 6 days after 
injury (274).  These changes likely occur in concert with depletion of total mitochondrial 
mass, fragmentation and swelling of mitochondria, loss of mitochondrial membrane 
potential, and reduced ATP generation (275-277).  In addition, we have demonstrated 
that renal I/R in mice leads to a significant reduction in ADP-stimulated respiration (state 
3 respiration) in isolated renal mitochondria, further suggesting that loss of ETC protein 
expression may contribute to mitochondrial dysfunction in the injured kidney (278).  
Similar findings have also been documented in both glycerol-induced rhabdomyolysis 
and folic acid models of AKI (274, 279).  These data suggest that disruption of 
mitochondrial homeostasis and function is common to multiple forms of AKI. 
   Another important aspect of mitochondrial dysfunction in AKI is the development 
of oxidative and nitrosative stress.  Mitochondria may generate ROS and reactive 
nitrogen species (RNS) through activity of the ETC (especially complexes I and III), 
mitochondria-localized dehydrogenases (pyruvate dehydrogenase, α-ketoglutarate 
dehydrogenase, glycerol-3-phosphate dehydrogenase), mitochondrial oxidases (NADPH 
oxidase 4), and enzymes involved in β-oxidation of fatty acids (167).  Under normal 
conditions, between 0.4% and 4% of oxygen utilized by the ETC is converted to ROS via 
electron leak (280).  ROS/RNS generation is significantly increased in the renal proximal 
tubule after both ischemic and toxic insult. Increased ROS/RNS in turn leads to sub-lethal 




damage (167, 281).  Mitochondria-derived oxidative and nitrosative stress are established 
contributors to tubular insult in both ischemic and toxic AKI and have been extensively 
studied as potential therapeutic targets for renoprotection (282, 283).  In particular, 
another mitochondrial-targeted antioxidant, known as SkQR1 (a conjugate of 
plastoquinone and positively-charged rhodamine), has shown particular promise in 
attenuating oxidative stress and renal dysfunction as measured by BUN in both I/R and 
glycerol-induced rhabdomyolysis in rats (284).   
 Mitochondria also act as important regulators of apoptotic cell death in the setting 
of ischemic and nephrotoxic AKI.  Activation of the intrinsic and extrinsic pathways of 
apoptosis after cellular insult leads to mitochondrial outer membrane permeabilization 
(MOMP) and subsequent release of cytochrome c by the actions of pro-apoptotic 
members of the Bcl-2 family including Bax, Bad, and Bid (285).  Cytochrome c in turn 
triggers activity of initiator caspases (e.g. capase-9) that activate downstream effector 
caspases (e.g. caspases-3).  These executioner caspases are then responsible for 
proteolytic cleavage of a variety of cellular substrates, eventually leading to cell death via 
apoptosis (285).  Kelly et al. recently demonstrated increased cytochrome c release from 
the mitochondria after renal I/R injury in rats (286).  Localization of cytochrome c to the 
cytosol was accompanied by DNA fragmentation and nuclear condensation, further 
indicating induction of apoptotic cell death in this model.  In addition, treatment with the 
potent anti-inflammatory and anti-apoptotic agent minocycline attenuated I/R-mediated 
renal dysfunction and cell death (286).  MOMP has also been demonstrated in the 
proximal tubule following cisplatin nephrotoxicity and Bax knockout mice are protected 




Mechanisms of Mitochondrial Dysfunction and Altered Homeostasis in AKI 
Altered Mitochondrial Biogenesis as a Target in AKI  
 Despite considerable evidence linking mitochondrial dysfunction to the 
pathophysiology of AKI, the mechanisms responsible for these changes remain unclear.  
Our laboratory has begun to focus on disruption of normal mitochondrial homeostasis as 
a potential mediator of mitochondrial dysfunction in this setting. In particular, 
mitochondrial biogenesis plays an important role in regulating both mitochondrial content 
and function in the cell as described in previous sections. In the kidney, PGC-1α 
expression is localized to the proximal tubule, which relies heavily on mitochondrial ATP 
production to maintain its normal functions (288).  We have demonstrated that loss of 
ETC proteins including NDUFB8, ATPSβ, and COX1 following renal I/R injury in mice 
(described above) is associated with an early decrease in both PGC-1α and PGC-1β 
expression at the mRNA level (274).  Persistent suppression of PGC-1α transcript levels 
in the renal cortex was also noted following folic acid-induced AKI in mice. Reduced 
levels of PGC-1α in folic acid-treated mice correlated with decreased expression of 
downstream markers of mitochondrial biogenesis and homeostasis including mRNAs for 
mitochondrial transcription factor A (TFAM), NDUFB8, ATPSβ, and COXI as discussed 
above (279).  In addition, PGC-1α suppression in this model was associated with a 
significant and long-lasting (up to 14 days post-injury) decrease in renal cortical mtDNA 
copy number, a marker of cellular mitochondrial content (279).  Taken together, these 
findings indicate that disruption of mitochondrial biogenesis may be an important 





Evidence for Altered Renal Mitochondrial Biogenesis in Sepsis-induced AKI 
 Although mitochondrial dysfunction has been widely implicated in the 
pathogenesis of sepsis-induced AKI, whether suppression of renal mitochondrial 
biogenesis contributes to cellular injury in the septic kidney remains unclear.  Tran et al. 
recently demonstrated that renal PGC-1α expression is decreased at the mRNA and 
protein levels following systemic LPS exposure and CLP in mice.  PGC-1α suppression 
in these models was significantly correlated with both reduced expression of direct 
transcriptional targets of PGC-1α and renal dysfunction as indicated by BUN (162).  
Reduced cytochrome c oxidase activity in the renal cortex (described above) was also 
closely associated with acute down-regulation of PGC-1α, suggesting that suppression of 
renal PGC-1α may contribute to mitochondrial dysfunction in septic AKI.  Restoration of 
normal renal function in LPS-treated mice coincided with return of PGC-1α mRNA and 
protein to baseline levels, further indicating a potential role for mitochondrial biogenesis 
in both pathophysiology of and recovery from septic AKI (162).  A major limitation of 
this study is that it does not directly address whether mitochondrial biogenesis and total 
mitochondrial content is disrupted as a result of PGC-1α suppression. Thus, additional 
work is needed to define changes in mitochondrial biogenesis after sepsis-induced renal 
injury and to elucidate the mechanisms responsible for disruption of PGC-1α in this 
setting.         
Pharmacological and Genetic Induction of PGC-1α and Mitochondrial Biogenesis in 
Experimental Models of AKI 
 Further evidence that suppression of mitochondrial biogenesis contributes to the 




target this process in experimental models of AKI.  A variety of approaches have been 
employed to stimulate PGC-1α and mitochondrial biogenesis in the injured proximal 
tubule.  Our laboratory previously demonstrated that adenovirus-mediated overexpression 
of PGC-1α in rabbit primary RPTCs 24 hours after exposure to H2O2 in vitro restored 
mitochondrial function (cellular respiration, ATP production) and expression of ETC 
proteins (289).  In addition, PGC-1α overexpression was associated with return of sodium 
transport in these cells, suggesting that mitochondrial biogenesis might promote recovery 
of normal cellular function after injury (289).  Pharmacological stimulation of SIRT1 in 
vivo resulted in PGC-1α deacetylation/activation and ameliorated tubular injury and 
mitochondrial dysfunction in rats subjected to bilateral renal I/R injury (290).  Our group 
has also identified a number of targets/compounds including formoterol (a β2-
adrenoreceptor agonist), cGMP-specific phosphodiestarase inhibitors, and 5-HT1F 
agonists that potently stimulate mitochondrial biogenesis in RPTCs in vitro and facilitate 
recovery after AKI (278, 291, 292).  Figure 1-10 below summarizes a number of 
pharmacological approaches that have been used to promote mitochondrial biogenesis 
and prevent dysfunction in experimental models of AKI.  Despite promising results, these 
studies have yielded only partial restoration of mitochondrial and renal function, 
indicating a need for further characterization of mitochondrial dysfunction associated 
with AKI.  An alternate approach likely to generate novel therapeutic targets is 
identification of pathways leading to suppression of mitochondrial biogenesis in the 













Figure 1-10: Pharmacological targeting of mitochondrial dysfunction. Mitochondrial 
biogenesis (MB), the generation of new mitochondria, is a highly regulated cellular 
process controlled by the central mediator and transcriptional coactivator PGC-1α.  PGC-
1α expression and activity is regulated through diverse pathways including receptor 
tyrosine kinases, G-protein coupled receptors, naturetic peptide receptors and nitric oxide 
synthase through cGMP, as well as AMPK activation, and SIRT1-mediated 
deacetylation.  In response to various stimuli, mitochondria can undergo the process of 
fusion (enlargement by combination with other mitochondria) via mitofusin proteins, 
such as MFN1/2 and OPA1, or fission (size reduction by budding off of mitochondrial 
contents) via fission proteins, such as Drp1.  Damaged mitochondria are eliminated by 
selective degradation in lysosomes.  EGF = epidermal growth factor; VEGF = vascular 
endothelial growth factor; RTKs = receptor tyrosine kinases; β2AR = β2-adrenergic 
receptor; 5HTR = serotonin receptor; GC-A/B = guanylyl cyclase A/B; eNOS = 
endothelial nitric oxide synthase; NO = nitric oxide; sGC = soluble guanylate cyclase; 
cGMP = cyclic guanosine monophosphate; cAMP = cyclic adenosine monophosphate; 
AMPK = AMP-activated kinase; SIRT1 = sirtuin 1; PPAR = peroxisome proliferator-
activated receptor; ERR = estrogen related receptor; NRF1 =  nuclear respiratory factor-
1; PGC-1α = peroxisome proliferator-activated receptor gamma coactivator-1 alpha; Ac = 
acetyl; TCA = tricarboxylic acid cycle; OXPHOS = oxidative phosphorylation; TOM = 
translocase of the outer membrane; TIM = translocase of the inner membrane; MFN2 = 
mitofusin 2; OPA1 = optic atrophy 1; DRP1 = dynamin-related protein 1; mtDNA = 












Stimulation of Glycolytic Metabolism in Response to Mitochondrial Dysfunction in 
AKI 
 As discussed above, renal function depends heavily on the proximal tubule for 
reabsorption of solutes from the glomerular filtrate via active transport. Mitochondrial 
injury may therefore contribute to renal dysfunction in AKI by interfering with energy 
production that drives this transport.  Although renal proximal tubule cells have very low 
glycolytic capacity under normal conditions (see above), glycolysis may be induced in 
response to mitochondrial insult in these cells to produce ATP and preserve cellular 
function.  The glycolytic pathway facilitates the conversion of glucose to pyruvate (or 
lactate under anaerobic conditions) with a net gain of 2 ATP per molecule of glucose 
metabolized.  There are three major regulatory steps in glycolysis: 1) hexokinase (HK) 
catalyzes the conversion of glucose to glucose-6-phosphate, the first committed step of 
glycolysis; 2) phosphofructokinase (PFK) catalyzes the phosphorylation of fructose-6-
phosphate to fructose-1,6-bisphosphate; and 3) pyruvate kinase (PK) which is responsible 
for the conversion of phosphoenolpyruvate to pyruvate.  Early work by Dickman and 
Mandel demonstrated that purified rabbit proximal tubules induce glycolytic metabolism 
after hypoxia or pharmacological inhibition of oxidative phosphorylation (293).  In 
particular, exposure to hypoxia (1% O2), the complex I inhibitor rotenone, or the 
uncoupler FCCP stimulated anaerobic glycolysis and lactate production in isolated 
tubules.  Further studies demonstrated that glycolytic induction restored tubular ATP 
content and Na+/K+-ATPase function. Inhibition of glycolytic metabolism using 2-
deoxyglucose after rotenone treatment increased cell death as indicated by increased 




induction of anaerobic glycolysis in response to suppression of mitochondrial oxidative 
phosphorylation may aid in preservation of tubular viability and function.  Additional 
experimental evidence indicates that anaerobic glycolysis is increased in the proximal 
tubule and other nephron segments in vivo following renal ischemia or exposure to the 
nephrotoxicant mercuric chloride in rodents (294-296).  However, whether glycolytic 
metabolism is increased in the renal cortex of the septic kidney to provide ATP and 
promote cell survival despite mitochondrial dysfunction remains unclear.   
 PROJECT GOALS 
 As discussed above, incidence of sepsis is increasing and sepsis is the most 
common contributing factor to the development of AKI in the intensive care setting.  
Therapy for both sepsis and AKI are primarily limited to supportive care, and mortality 
associated with these conditions remains extremely high, highlighting the incredible need 
for development of novel targets.  Our laboratory and others have identified suppression 
of mitochondrial biogenesis as a pathogenic mechanism contributing to tubular injury and 
renal dysfunction after AKI.  Although mitochondrial dysfunction has been widely 
reported in the septic kidney, it is unclear whether disruption of mitochondrial biogenesis 
plays a role in renal injury.  Thus, the first goal of this study was to better characterize 
changes in PGC-1α and mitochondrial biogenesis in sepsis-induced AKI.  In order to 
address this objective, I studied time- and dose-dependent effects of systemic LPS 
exposure in mice on PGC-1α, downstream markers of mitochondrial biogenesis, and 
mitochondrial content in the renal cortex (Chapter 2).  A related aim was to define the 
molecular mechanisms responsible for acute suppression of PGC-1α and subsequent 




that disruption of mitochondrial biogenesis is common to the pathophysiology of multiple 
forms of AKI in experimental models, our laboratory has not addressed how this 
phenomenon occurs.  I hypothesized that renal cortical mitochondrial biogenesis is 
disrupted following LPS-induced AKI through suppression of PGC-1a expression by 
TLR4-dependent activation of MEK/ERK and/or NFkB signaling pathways and that this 
disruption contributes to loss of mitochondrial homeostasis (Chapter 2).  My work 
focused on MEK/ERK and NFκB based on earlier studies suggesting that they negatively 
regulate PGC-1α (discussed above).   
 An additional goal of this study was to determine metabolic changes in the renal 
cortex that might support cellular and organ function in the face of mitochondrial 
dysfunction associated with sepsis-induced AKI.  I concentrated on glycolysis as a 
potential alternative mechanism for ATP generation to support tubular cell viability and 
transport function based on previous work discussed above.  In particular, I proposed that 
glycolytic metabolism is induced in the renal cortex in sepsis-induced AKI to produce 
ATP and preserve renal function in response to mitochondrial dysfunction.  In order to 
complete this goal, I assessed changes in glycolytic enzyme activity and end products 
(lactate, pyruvate) in renal cortical tissue following systemic LPS administration in mice.  
I also examined other pathways of glucose metabolism (gluconeogenesis, glycogen 
synthesis, and the pentose phosphate shunt) in this model (Chapter 3).  
 The final aim of this study was to use findings generated in Chapters 2 and 3 to 
generate a novel therapeutic approach and test this methodology in a more clinically 
relevant animal model of sepsis. I demonstrate in Chapter 2 that the MEK/ERK inhibitor 




mitochondrial biogenesis.  However, there are several limitations to the endotoxin model, 
and several treatments developed based on this model have failed to show efficacy in 
humans.  I therefore determined the effects of GSK1120212 on development of AKI 
following cecal ligation and puncture (CLP).  The CLP model shares several similarities 
with human cases of sepsis, making it much more clinically relevant (discussed above).  
Based on my earlier findings, I hypothesized that post-treatment with a MEK/ERK 
inhibitor would attenuate the systemic inflammatory response and renal injury following 





  Chapter 2:  
Suppression of Mitochondrial Biogenesis through Toll-like Receptor 4 
(TLR4)-dependent Mitogen-activated Protein Kinase Kinase (MEK) / 
Extracellular Signal-regulated Kinase (ERK) Signaling in Endotoxin-
Induced Acute Kidney Injury 
ABSTRACT  
Although disruption of mitochondrial homeostasis and function is a widely 
accepted pathophysiological feature of sepsis-induced AKI, the molecular mechanisms 
responsible for this phenomenon are unknown. In this study, we examined changes in 
mitochondrial biogenesis and associated signaling mechanisms in a mouse model of 
lipopolysaccharide (LPS)-induced AKI.  Down-regulation of PGC-1α, a master regulator 
of mitochondrial biogenesis, was noted at the mRNA level at 3 h and protein level at 18 h 
in the renal cortex and was associated with loss of renal function following LPS 
treatment.   LPS-mediated suppression of PGC-1α led to reduced expression of 
downstream regulators of mitochondrial biogenesis and electron transport chain (ETC) 
proteins along with a reduction in renal cortical mitochondrial DNA content.  
Mechanistically, TLR4 knockout mice were protected from renal injury and disruption of 
mitochondrial biogenesis after LPS. Immunoblot analysis revealed activation of TPL-
2/MEK/ERK signaling in the renal cortex by LPS.  Pharmacological inhibition of 
MEK/ERK signaling attenuated renal dysfunction and loss of PGC-1α, and was 
associated with a reduction in pro-inflammatory cytokine (e.g TNF-α, IL-1β) expression 
at 3 h post-LPS.  Neutralization of TNF-α also blocked PGC-1α suppression, but not 
renal dysfunction, following LPS-induced AKI.  Finally, systemic administration of 




homeostasis.  These findings indicate an important role for the TLR4/MEK/ERK 
pathway in both LPS-induced renal dysfunction and suppression of MB. 
TLR4/MEK/ERK/TNF-α signaling may represent a novel therapeutic target to prevent 






Acute kidney injury (AKI) is characterized by a rapid decrease in renal function 
over the course of hours to days and is associated with significant morbidity and 
mortality (~40%) (50).  Despite recent efforts to better understand AKI, mortality 
associated with this clinical disorder remains unchanged over the last five decades (49, 
297).  Sepsis is the most common contributing factor to the development AKI, mortality 
resulting from AKI is almost doubled in septic patients (~70%) and treatment is limited 
to dialysis and supportive care (50, 51, 297-299).  Taken together, these data reveal a 
significant need for further study of the pathophysiological mechanisms underlying renal 
injury with an emphasis on identifying therapeutic targets to improve clinical outcomes in 
septic AKI.    
Much of the difficulty in developing effective therapies for sepsis-induced AKI 
stems from the multi-factorial nature of the disease.  Septic AKI is thought to arise as a 
result of complex interactions involving alterations in renal hemodynamics, 
microvascular/endothelial cell dysfunction, and direct effects of inflammatory cells and 
their products (cytokines/chemokines) on the kidney (114).  The degree to which changes 
in global renal blood flow (RBF) contribute to renal injury remains a topic of intense 
debate.  However, it is generally accepted that microvascular dysfunction leads to 
sluggish capillary flow and subsequent development of local regions of hypoperfusion 
and hypoxia in the septic kidney (124, 125, 155).  Reduced microvascular flow also 
amplifies injury by prolonging exposure of the renal parenchyma to inflammatory cells 
and various inflammatory molecules including pro-inflammatory cytokines such as tumor 




of cellular injury in sepsis-induced AKI (134, 140, 141, 300).  Data from post-mortem 
studies and experimental models indicate that tubular cell apoptosis and necrosis are 
relatively limited in the septic kidney when compared to other forms of AKI (157, 158).  
However, histological findings including tubular cell vacuolization, tubular dilatation, 
and the presence of swollen mitochondria provide strong evidence that sub-lethal injury 
to the proximal tubule may play an important role the development of sepsis-induced 
AKI (157, 162, 301).  
The overt structural changes noted in tubular mitochondria following sepsis-
induced AKI is of particular note given that the proximal tubule relies heavily on 
mitochondrial generation of ATP to drive active transport of electrolytes and fluids.  
Thus, mitochondrial dysfunction and/or dysregulation in the proximal tubule may 
contribute to loss of renal function in AKI (49, 256).  Recent studies demonstrated 
suppression of peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) in 
experimental models of sepsis-induced AKI including systemic endotoxin exposure and 
cecal ligation and puncture (CLP) (162). PGC-1α, the so-called “master regulator of 
MB,” promotes transcriptional activity in both the nucleus and mitochondria to facilitate 
generation of new, functional mitochondria in response to a variety of physiological 
stimuli (302, 303). Loss of PGC-1α following sepsis-induced AKI was closely associated 
with renal and mitochondrial dysfunction.  In addition, proximal tubule-specific PGC-1α 
knockout delayed recovery of renal function following saline resuscitation in mice treated 
with LPS (162).  These findings indicate that suppression of PGC-1α and MB may play 
an important role in the development of renal injury.  However, an important limitation of 




addition, a better understanding of the molecular alterations underlying disruption of MB 
may lead to development of novel therapies to restore renal function after sepsis-induced 
AKI.  
The aim of the current study was to determine the signaling mechanisms 
responsible for suppression of MB in the renal cortex following endotoxic AKI.  We 
report here that LPS exposure leads to down-regulation of PGC-1α and mitochondrial 
markers in the renal cortex. LPS-induced renal dysfunction and disruption of MB was 
dependent on TLR4/MEK/ERK and production of the pro-inflammatory cytokine TNF-
α. Inhibition of the TLR4/MEK/ERK/TNF-α signaling may offer a novel therapeutic 






LPS Model of Sepsis-Induced AKI  
 Six to eight week old male C57BL/6 mice were acquired from the National 
Institutes of Health National Cancer Institute / Charles River Laboratories (Frederick, 
MD).  Mice were given an intraperitoneal (i.p.) injection of 0.5, 2, or 10 mg/kg 
lipopolysaccharide (LPS) derived from Escherichia coli serotype O111:B4 (Sigma 
Aldrich, St. Louis, MO).  Control mice received an i.p. injection of an equal volume of 
0.9% normal saline.  Mice were euthanized at 1, 3, and 18, and 42 h after LPS 
administration and kidneys and serum were harvested for molecular analysis.  For 
experiments utilizing TLR4-deficient animals, TLR4KO mice on a C57BL/6 background 
and wild-type C57BL/6 mice were used.  All studies were conducted in accordance with 
the recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health.  Animal use was approved by the Institutional Animal Care 
and Use Committee at the Medical University of South Carolina.    
 To determine the role of MEK/ERK signaling in LPS-induced AKI, the MEK 
inhibitor GSK1120212 (also known as Trametinib) was obtained from Selleckchem 
Chemicals (Houston, TX).  GSK1120212 is a potent and specific inhibitor of MEK1/2 
which has been previously used in mouse models (304, 305).  Mice received an i.p. 
injection of GSK1120212 (1 mg/kg) or vehicle control (DMSO) 1 h prior to 
administration of LPS.   
 In order to assess the effects of TNF-α on regulation of MB in this model, rat 
anti-TNF-α neutralizing antibody (clone MP6-XT22) and the appropriate rat IgG1 κ 




CA).  Mice were randomly assigned to one of three groups: 1) control, 2) LPS + isotype 
control antibody (25 mg/kg), and 3) LPS + anti-TNF-α neutralizing antibody (25 mg/kg).  
Isotype control antibody and anti-TNF-α neutralizing antibody were administered 
intravenously (i.v.) 1 hr prior to LPS via tail vein injection.  Control mice received an i.v. 
injection of vehicle control (PBS).   
 Recombinant mouse TNF-α was obtained from BioLegend to evaluate whether 
TNF-α alone reproduced LPS-mediated changes in renal function and/or MB.  Wild-type 
C57BL/6 male mice (6 to 8 weeks in age) were treated i.v. with either vehicle control 
(diluent), 20 µg/kg recombinant murine TNF-α, or 50 µg/kg TNF-α via tail vein 
injection.  Animals were euthanized at 18 h after TNF-α administration and kidneys and 
serum were collected for analysis. 
Human Renal Proximal Tubule Cell Culture 
 Primary human renal proximal tubule cells (hRPTECs) were acquired from Lonza 
BioResearch (Allendale, NJ).  Passage 4 – 11 hRPTECs were maintained in T-75 culture 
flasks and plated in 35 mm dishes for all experiments. Cells were grown in REBM basal 
medium supplemented with 0.5% FBS, EGF, insulin, GA-1000, hydrocortisone, 
transferrin, triiodothyronine, and epinephrine and maintained at 37°C in a 5% CO2 
humidified incubator as instructed by the manufacturer.  Once cells reached ~90% 
confluence, they were treated with LPS (Sigma, described above), recombinant human 
TNF-α, recombinant human CD14, recombinant human LBP (all from R&D Systems, 
Minneapolis, MN) at various doses for 3 or 24 h as indicated.  




Blood Urea Nitrogen Measurement 
 Blood urea nitrogen (BUN) was determined using the QuantiChrom Urea Assay 
kit (BioAssay Systems, Hayward, CA) based on the manufacturer’s directions.  All 
values are expressed as blood urea nitrogen concentration in milligrams per deciliter.  
Quantitative Real-Time PCR Analysis of mRNA Expression  
 Total RNA was isolated from renal cortical tissue with the TRIzol reagent (Life 
Technologies, Grand Island, NY).  The iScript Advanced cDNA Synthesis Kit for RT-
qPCR (Bio-Rad, Hercules, CA) was used to produce a cDNA library from 1 µg total 
RNA according to the manufacturer’s protocol.  Quantitative real-time PCR was 
performed with the generated cDNA using the SsoAdvanced Universal SYBR Green 
Supermix reagent (Bio-Rad).  Relative mRNA expression of all genes was determined by 
the 2-ΔΔCt method and the 18S ribosomal RNA (18S rRNA) was used as a reference gene 







Table 2-1: Primer sequences used for RT-qPCR. 
 
















































Sense 5’-	  TAGAACGCAAAATCTTAGGG-3’ 
ENSMUSG00000064341 





Antisense 5’-	  GTGTGGGTGAGGAGCACGTA-3’ 
Mouse  
IL-1β 







































Sense 5’-	  CTCAACACGGGAAACCTCAC-3’ 
NR_003286.2 





Analysis of Mitochondrial DNA Content 
 Mitochondrial DNA content was determined by quantitative real-time PCR 
analysis.  Total DNA was isolated from the renal cortex using the DNeasy Blood and 
Tissue Kit (Qiagen, Valencia, CA) as described in the manufacturer’s protocol.  
Extracted DNA was quantified and 5 ng was used for PCR.  Relative mitochondrial DNA 
content was assessed by the mitochondrial-encoded NADH Dehydrogenase 1 (ND1) and 
was normalized to nuclear-encoded β-Actin.  Primer sequences for ND1 and β-Actin 
were: ND1 sense: 5’-TAGAACGCAAAATCTTAGGG-3’; ND1 antisense: 5’-
TGCTAGTGTGAGTGATAGGG-3’; β-Actin sense: 5’-
GGGATGTTTGCTCCAACCAA-3’; and β-Actin antisense: 5’-
GCGCTTTTGACTCAGGATTTAA-3’.   
Immunoblot Analysis  
 Protein was extracted from renal cortex using RIPA buffer (50 mM Tris-HCl, 150 
mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, pH 7.4) with 
protease inhibitor cocktail (1:100), 1 mM sodium fluoride, and 1 mM sodium 
orthovanadate (Sigma Aldrich).  Total protein amount was determined by BCA protein 
assay.  Equal protein quantities (50 – 100 µg) were loaded onto 4 – 15% SDS-PAGE gels 
(Bio-Rad).  Proteins were resolved by gel electrophoresis and transferred onto 
nitrocellulose membranes (Life Technologies).  Membranes were blocked in 2.5% BSA 
and incubated overnight with primary antibody at 4°C.   Primary antibodies used in these 
studies included NGAL/Lipocalin-2 (1:1000), phospho-TPL2 (1:500), total TPL2 
(1:1000, all from Abcam, Cambridge, MA), phospho-ERK1/2 (1:1000), total ERK1/2 




R&D systems, Minneapolis, MN), PGC-1 (1:100, Cayman Chemical, Ann Arbor, MI), 
and β-Actin (1:1000, Santa Cruz Biotechnology, Dallas, TX).  Membranes were 
incubated with the appropriate horseradish peroxidase(HRP)-conjugated secondary 
antibody before visualization using enhanced chemiluminescence (Thermo Scientific, 
Waltham, MA) and the GE ImageQuant LAS4000 (GE Life Sciences, Pittsburgh, PA).  
Optical density was determined using NIH ImageJ software (version 1.46).  
Statistical Analysis 
 All data are shown as mean ± S.E.M. When comparing two experimental groups, 
an unpaired, two-tailed t-test was used to determine statistical differences.  A one-way 
analysis of variance (ANOVA) followed by Tukey’s post-hoc test was performed for 
comparisons of multiple groups.  A p-value < 0.05 was considered statistically 






Endotoxin Exposure Leads to Acute Kidney Injury in Mice 
 To confirm the effects of systemic LPS exposure on renal function, we measured 
BUN at 3 and 18 h after administration in mice.  BUN increased 1.9-fold and 3.8-fold 3 h 
and 18 h post-LPS, respectively, indicating a time-dependent reduction in renal function 
(Figure 2-1A).  These findings are consistent with other studies reporting markedly 
reduced glomerular filtration rate (GFR) and elevated BUN with 4 h of endotoxin 
exposure in mice (79).  To confirm proximal tubule injury in this model, we also 
measured protein expression of kidney injury molecule-1 (KIM-1) and neutrophil 
gelatinase-associated lipocalin (NGAL) in the renal cortex by immunoblot analysis at 18 
h. KIM-1 and NGAL increased ~5- and ~2-fold, respectively, in mice receiving LPS 
when compared to vehicle-treated controls (Figure 2-1B,C). No changes were noted in 
KIM-1 and NGAL protein levels at 3 h post-LPS, although their mRNAs were up-
regulated at this time point (data not shown).  Together, these findings indicate that 
systemic LPS exposure results in rapid development of AKI and specifically leads to 






Figure 2-1: Systemic LPS administration induces renal dysfunction and tubular 
injury in mice.  Six to eight week old male C57BL/6 mice were injected i.p. with 
lipopolysaccharide (10 mg/kg) or saline vehicle and euthanized at 3 and 18 h.  Renal 
function at 3 and 18 h after LPS was determined by BUN (n = 7 animals / group) (A).    
Immunoblot analysis of renal cortical KIM-1 (B) and NGAL (C) expression was used to 
assess tubular injury (n = 4 animals / group).   Data are shown as mean ± S.E.M. for each 
group.  Different superscripts above bars indicate statistically significant differences (p < 





LPS-Induced AKI Leads to Persistent Suppression of PGC-1α  
 Because disruption of MB and homeostasis has been associated with loss of renal 
function and delayed recovery in multiple experimental models of AKI, we hypothesized 
that systemic endotoxin exposure would lead to disruption of PGC-1α. (162, 274, 290). 
PGC-1α mRNA was reduced by 70% as early as 3 h after LPS and progressively 
decreased at the 18 h time point to ~10% of control (Figure 2-2A).  In addition, a ~70% 
decrease in PGC-1α protein expression was noted at 18 h after LPS exposure (Figure 2-
2B).  To determine whether LPS has a dose-dependent effect on renal cortical PGC-1α 
expression, mice were treated with 0.5 mg/kg and 2 mg/kg of LPS and PGC-1α mRNA 
was examined 3 h after administration.  Interestingly, lower doses of LPS (0.5 mg/kg and 
2 mg/kg) reduced PGC-1α transcript ~55% and ~45%, respectively, similar to the 10 
mg/kg dose (~60%) (Figure 2-2C). 
 To further characterize the effects of endotoxin on MB, we measured mRNA 
expression of other members of the PGC-1 family, PGC-1β and PRC, in the renal cortex.  
Transcript levels of PGC-1β were decreased ~60% in LPS-treated mice at 3 and 18 h 
compared to vehicle-treated controls.  In contrast, PRC mRNA increased 1.7-fold as early 
as 3 h post-administration and remained elevated at 18 h (2-fold) (Figure 2-2D).  These 
data demonstrate that systemic LPS exposure results in suppression of PGC-1α and PGC-






Figure 2-2: LPS-induced AKI is associated with suppression of PGC-1α  expression 
in the renal cortex. Total RNA and protein were extracted from the renal cortex of 
vehicle- and LPS-treated mice.  Time-dependent changes in PGC-1α mRNA expression 
at 1, 3, and 18 h after LPS exposure (10 mg/kg) were determined by qPCR analysis (n = 
5 – 6 / group) (A).  Protein levels of PGC-1α were assessed by Western blot (n = 4 / 
group) (B).  To determine dose dependent effects of endotoxin on renal cortical PGC-1α 
expression, a separate group of mice were treated with varying doses of LPS (0.5 mg/kg, 
2 mg/kg, and 10 mg/kg) and PGC-1α mRNA was measured (n = 6 / group) (C).  Time-
dependent changes in other members of the PGC-1 family (PGC-1β, PRC) were also 
determined by qPCR (n = 6 / group) (D).  Values are expressed as relative expression 
compared to time-point controls and are presented as mean ± S.E.M.  Statistically 





PGC-1α  Suppression by LPS Results in Disruption of Mitochondrial Homeostasis 
 To determine whether mitochondrial homeostasis was altered in the renal cortex 
as a result of reduced PGC-1α expression following endotoxin administration, we 
assessed mRNA expression of downstream mediators of MB, (NRF-1, TFAM) as well as 
nuclear-encoded (NDUFS1, NDUFB8, ATPSβ) and mitochondrial-encoded (COX1, 
ND1) components of the electron transport chain.  A ~38% decrease in NRF-1 mRNA 
was observed 3 h post-LPS which recovered to control levels by 18 h.  Transcript levels 
of TFAM, NDUFS1, NDUFB8, ATPSβ, and COX1 were also decreased (~25%, 43%, 
42%, 25%, and 31%, respectively) at the 18 h time-point and these decreases correspond 
with the reduction in PGC-1α protein (Figure 2-3A).  We also assessed mitochondrial 
DNA copy number as a marker of mitochondrial quantity.  Relative mitochondrial DNA 
content in the renal cortex was reduced by ~50% at 18 h after LPS and remained lower 
up to 42 h (Figure 2-3B).  In addition, a modest, but significant reduction in protein levels 
of TFAM, NDUFS1, NDUFB8, and ATPSβ was noted by 42 h post-LPS (Figure 2-
3C,D).  These findings indicate that suppression of PGC-1α following systemic 
endotoxin exposure is associated with widespread disruption of transcriptional regulation 






Figure 2-3: Disruption of mitochondrial homeostasis in endotoxic AKI.  Total RNA 
and DNA were harvested from renal cortical tissue of mice treated with saline vehicle or 
LPS (10 mg/kg, i.p.) at 1, 3, 18, and 42 h.  Expression of key regulators of mitochondrial 
biogenesis (NRF-1, TFAM), nuclear-encoded components of the ETC (NDUFS1, 
NDUFB8, ATPSβ), and mitochondrial-encoded respiratory proteins (COX1, ND1) were 
measured at the mRNA level (n = 6 / group) (A).  Relative mitochondrial DNA content in 
the renal cortex was determined by qPCR analysis (n = 5 – 6 animals / group) (B).  
Protein levels of TFAM, NDUFS1, NDUFB8, and ATPSβ were determined by 
immunoblot analysis (C,D).  Data are shown as expression relative to vehicle-treated 





TLR4 is Required for Endotoxin-Induced AKI and Disruption of Mitochondrial 
Homeostasis  
 Although LPS primarily signals through activation of Toll-like receptor 4 (TLR4), 
recent studies have identified TLR4-independent signaling pathways which contribute to 
endotoxic shock in mice (94, 95).  To determine whether TLR4 signaling is responsible 
for both endotoxin-induced AKI and suppression of MB, we utilized TLR4 knockout 
mice (TLR4KO) and wild-type controls and assessed renal function and mitochondrial 
homeostasis 18 h post-LPS.  As expected, systemic LPS exposure in wild-type mice 
resulted in an increase in BUN (Figure 2-4A).  However, TLR4KO mice were completely 
protected from endotoxic AKI.  These findings are in agreement with previous studies 
demonstrating an essential role for TLR4 in LPS-induced renal dysfunction in mice 
(150).        
 We next determined the role of TLR4 in endotoxin-mediated suppression of PGC-
1α and MB.  A 73% decrease in PGC-1α mRNA was noted in wild-type mice subjected 
to LPS while PGC-1α mRNA in TLR4KO mice was similar to controls (Figure 2-4B). 
COX1 mRNA and mitochondrial DNA content were also decreased (~40% and ~30%, 
respectively) in wild-type mice 18 h after LPS exposure and remained unchanged in 
TLR4KO mice (Figure 2-4C,D).  Taken together, these data reveal an essential role for 






Figure 2-4: TLR4 is necessary for development of LPS-induced AKI and 
suppression of mitochondrial biogenesis.  Wild-type and TLR4 knockout mice were 
treated with LPS (10 mg/kg, i.p.) or saline vehicle and euthanized at 18 h for biochemical 
analysis.  BUN was used to assess renal function after LPS exposure (A).  Transcript 
levels of PGC-1α (B) and COX1 (C) as well as mitochondrial DNA copy number (D) 
served as markers of mitochondrial homeostasis (n = 3 – 4 / group for all analyses, p < 





LPS-Induced AKI Leads to Activation of TPL-2/ERK Signaling in the Renal Cortex 
 TLR4 is known to initiate signaling by a number of different mediators, most 
notably NFκB and members of the mitogen-activated protein kinase (MAPK) family 
including extracellular signal-related kinases 1/2 (ERK1/2), p38 MAPKs, and c-Jun N-
terminal kinases (JNKs) (307, 308).  Previous studies showed that ERK1/2 activation 
may negatively regulate expression of PGC-1α in multiple organs including the brain and 
skeletal muscle (244, 245).  In addition, TPL-2 is thought to be a critical for activation of 
ERK1/2 in response to LPS (309, 310).  We hypothesized that the TPL-2/ERK signaling 
would be activated in the renal cortex and that this pathway contributes to disruption of 
MB in endotoxin-induced AKI.  Phosphorylated TPL-2 (Thr209) increased 1.5-fold 1 h 
after LPS treatment and returned to control levels at 3 h (Figure 2-5). A 5-fold elevation 
of ERK1/2 phosphorylation was observed 1 h after LPS treatment and remained elevated 
at 3 h (Figure 2-5B,D).  These findings indicate that TPL-2/ERK signaling is activated 







Figure 2-5: Systemic LPS exposure enhances TPL-2/ERK signaling in the renal 
cortex.   Mice were treated with LPS (10 mg/kg, i.p.) or vehicle as described above.  
Immunoblot analysis revealed increased phosphorylated/activated TPL-2 (Thr209) (A) 
and ERK1/2 (Thr202/Tyr204) (B) in the renal cortex of LPS-treated mice at 1 h.  Levels 
of phospho-TPL-2 and phospho-ERK1/2 were normalized to their respective total protein 
content and actin was used as a secondary loading control.  Data are presented as 
phosphorylated / total ratio relative to vehicle controls (mean ± S.E.M.; n = 4 / group for 





Early ERK Activation Mediates LPS-Induced Renal Injury and Suppression of MB  
 To further elucidate the role of ERK1/2 signaling in LPS-induced AKI and 
disruption of mitochondrial homeostasis, mice were treated with the potent and selective 
MEK1/2 inhibitor GSK1120212 (GSK112) (1 mg/kg) 1 h prior to LPS administration.  
MEK1/2 are directly responsible for phosphorylation of ERKs and thus inhibition of 
MEK1/2 by GSK112 will prevent downstream activation of ERK1/2.  In the first 
experiment, mice were euthanized 3 h post-LPS to determine the early effects of ERK 
activation on renal dysfunction and MB. Pre-treatment with GSK112 attenuated 
endotoxin-mediated elevation of BUN at 3 h (Figure 2-6A) and markedly reduced the 
increase in renal cortical KIM-1 transcript levels in LPS-treated mice (Figure 2-6B).  
GSK112 alone did not have an effect on either BUN or renal cortical KIM-1 (Figure 2-
6A,B).  Interestingly, GSK112 administration in mice receiving LPS also blocked 
suppression of PGC-1α mRNA expression (Figure 2-6C).  Immunoblot analysis 
demonstrated effective blockade of ERK1/2 activation in mice treated with MEK1/2 
inhibitor (Figure 2-6D).  These data identify a novel role for early TLR4-mediated 
ERK1/2 activation in both renal dysfunction and suppression of MB in the renal cortex in 
LPS-induced AKI.  In contrast, preliminary experiments demonstrated that multiple 
pharmacological inhibitors of NFκB signaling including TPCA-1, BAY11-7085, and 
PPM-18 had no effected on LPS-induced disruption of PGC-1α and MB (data not 
shown).               
 A separate group of mice was pretreated with GSK112 (1 mg/kg) or vehicle 
control and serum and kidneys were collected at 18 h post-LPS for biochemical analysis.  




(~2.1 fold vs. control) (Figure 2-7A).  In addition, GSK112 pretreatment partially 
blocked LPS-induced increase in renal cortical KIM-1 mRNA expression, indicating a 
reduction in tubular injury (Figure 2-7B).  A modest effect of GSK112 administration on 
transcript levels of PGC-1α and its transcriptional target NDUFS1 was also noted in LPS 
mice (Figure 2-7C,D).  Taken together, these findings indicate that rapid activation of 
ERK1/2 in the renal cortex following systemic endotoxin exposure contributes to the 





Figure 2-6: Inhibition of MEK/ERK signaling prevents early changes in renal 
function and mitochondrial biogenesis in endotoxic AKI. Mice were pre-treated with 
the MEK1/2 inhibitor GSK1120212 (GSK112; 1 mg/kg) 1 h prior to systemic LPS 
exposure.  Serum and kidneys were collected at 3 h post-LPS to determine the role of 
MEK/ERK signaling in early pathophysiology.  Renal function was assessed by changes 
in BUN (A).  The effects of MEK/ERK inhibition on tubular injury were determined by 
measuring KIM-1 mRNA expression in the renal cortex (B).  PGC-1α transcript levels 
were determined by qPCR (C).  Inhibition of ERK1/2 activation was confirmed by 
immunoblot analysis of phosphorylated and total ERK1/2 levels in the renal cortex (D).  











Figure 2-7: Effects of GSK1120212 on LPS-induced AKI and suppression of 
mitochondrial biogenesis at 18 h.  Mice receiving GSK1120212 (GSK112; 1 mg/kg) 1 
h prior to endotoxin administration were euthanized at 18 h post-LPS for biochemical 
analysis.  Renal dysfunction and tubular injury were determined by BUN (A) and KIM-1 
mRNA expression (B), respectively.  Transcript levels of PGC-1α (C) and NDUFS1 (D) 
were determined by qPCR analysis.  Values are presented as mean ± S.E.M. for n ≥ 6 / 
group.  Superscripts above bars are used to denote statistically significant differences 





TNF-α, but not LPS, Induces Down-regulation of PGC-1α in Renal Proximal 
Tubule Cells In Vitro 
 TLR4-mediated activation of ERK1/2 is known to induce expression of pro-
inflammatory cytokines including TNF-α and IL-1β (311-313). Recent reports also 
indicate that these cytokines may negatively regulate PGC-1α expression and MB in a 
variety of cell types including renal proximal tubule cells and skeletal muscle cells (162, 
242).  We therefore examined whether LPS alone or the downstream cytokine target of 
MEK/ERK signaling, TNF-α, were necessary for suppression of PGC-1α transcription in 
primary human renal proximal tubular epithelial cells (hRPTECs) in vitro.  Cells were 
treated with varying doses of LPS (1 µg/ml or 10 µg/ml) or recombinant human TNF-α 
(10 ng/ml or 100 ng/ml) and mRNA expression of PGC-1α was determined by qPCR at 3 
and 24 h post-treatment.  Cells exposed to LPS were also supplemented with necessary 
accessory proteins including recombinant human CD14 (100 ng/ml) and recombinant 
human LPS binding protein (LBP, 100 ng/ml).  No changes in PGC-1α transcript levels 
were noted following exposure of hRPTECs to LPS at any of the doses or time points 
studied (Figure 2-8A,B).  However, TNF-α treatment (both 1 ng/ml and 10 ng/ml) 
resulted in rapid and persistent suppression of PGC-1α mRNA levels by 3 h (Figure 2-
8C,D).  These data indicate that LPS is not capable of directly disrupting PGC-1α 
expression in renal proximal tubule cells in vitro.  Instead, downstream effectors of LPS-






Figure 2-8: Effects of LPS and TNF-α on renal proximal tubule epithelial cell PGC-
1α expression in vitro.  Primary human RPTECs were treated with LPS (1 µg/ml or 10 
µg/ml) in the presence of rhCD14 (100 ng/ml) and rhLBP (100 ng/ml) and mRNA 
content of PGC-1α were determined at 3 h (A) and 24 h (B) by qPCR analysis.  In a 
separate experiment, cells were exposed to rhTNF-α (10 ng/ml or 100 ng/ml) and PGC-
1α transcript levels were assessed at 3 h (C) and 24 h (D) as described above.  Data are 
shown as mean ± S.E.M for n = 6 / group. Different superscripts above indicate 





Early ERK Activation Promotes Expression of Pro-Inflammatory Cytokines in the 
Renal Cortex After LPS Administration   
 Since TNF-α induced direct suppression of PGC-1α in renal proximal tubule cells 
in vitro, we next examined ERK1/2 signaling in the expression of TNF-α and IL-1β in 
the renal cortex following systemic endotoxin administration in mice. LPS administration 
resulted in a robust increase in TNF-α (~12 fold) and IL-1β (~3.3 fold) mRNA at 3 h and 
GSK112 inhibition of MEK/ERK partially attenuated the early increase in mRNA 
expression of both pro-inflammatory cytokines (Figure 2-9A).  However, pretreatment 
with GSK112 had no effect on expression of either TNF-α or IL-β at 18 h post-LPS 
(Figure 2-9B).  These findings reveal an important role for TLR4-induced ERK signaling 







Figure 2-9: MEK/ERK signaling controls early renal expression of pro-
inflammatory cytokines in response to endotoxin.  Inflammatory changes were 
evaluated in the renal cortex of mice treated with LPS and GSK1120212 (GSK112; 1 
mg/kg) as described above.  qPCR was used to determine mRNA levels of TNF-α and 
IL-1β at both 3 h (A)  and 18 h (B) post-LPS.  Values are expressed as relative 





Involvement of TNF-α  in LPS-Mediated Suppression of PGC-1α  
 Because pro-inflammatory cytokines have been implicated as a potential 
mechanism for suppression of PGC-1α in renal proximal tubules and ERK signaling 
promoted TNF-α expression in the kidney cortex, we utilized a neutralizing antibody 
directed against murine TNF-α to further elucidate its role in this process.  Mice were 
treated i.v. with either TNF-α neutralizing antibody (25 mg/kg) or the appropriate isotype 
control antibody (25 mg/kg) 1 h prior to LPS.  TNF-α neutralization had no effect on the 
LPS-induced increase in BUN at 18 h (Figure 2-10A).  However, suppression of PGC-1α 
mRNA levels was partially attenuated in mice receiving the anti-TNF-α antibody (Figure 
2-10B).   
 Surprisingly, TNF-α neutralization had no effect on the observed decreases in 
NDUFB8, NDUFS1, ATPSβ, and COX1 transcripts, and mitochondrial DNA content 
(Figure 2-10C,D).  Taken together, these data indicate that the TLR4/ERK/TNF-α 
signaling axis may act as a critical mechanism for suppression of MB in the setting of 






Figure 2-10: TNF-α  mediates suppression of PGC-1α  in the renal cortex of LPS-
treated mice.   Mice were treated with anti-TNF-α neutralizing antibody or the 
appropriate isotype control antibody 1 h prior to systemic LPS exposure and renal 
function and mitochondrial homeostasis were evaluated at 18 h.  Renal dysfunction was 
determined by measuring BUN (A).  Transcript levels of PGC-1α (B) and mitochondrial 
biogenesis markers (C) were assessed.  qPCR analysis was used to determine relative 
mitochondrial DNA content (D).  Data are mean ± S.E.M. (n = 4 / group; different 




Recombinant TNF-α  is Sufficient to Produce Kidney Injury and Disrupt MB in the 
Renal Cortex  
 To further characterize the effects of TNF-α on renal dysfunction and 
mitochondrial homeostasis, mice received i.v. injections of low dose recombinant murine 
TNF-α (20 µg/kg), high dose TNF-α (50 µg/kg), or the appropriate vehicle.  TNF-α 
dosing was based on preliminary experiments and previous reports to determine the 
appropriate doses which have no effect on renal function (low dose) or produce renal 
injury (high dose) (141).  As expected, an increase in BUN was noted only in mice 
receiving high dose TNF-α (Figure 2-11A). Renal dysfunction in these animals was 
associated with a 55% decrease in renal cortical PGC-1α mRNA (Figure 2-11B).  Both 
low and high dose TNF-α suppressed transcript levels of both nuclear-encoded 
(NDUFS1) and mitochondrial-encoded (ND1, COX1) respiratory proteins (Figure 2-
11C).  A modest, but not statistically significant, decrease in mitochondrial DNA content 
was observed in animals treated with high dose TNF-α (Figure 2-11D).  These findings 
indicate that recombinant TNF-α is sufficient to cause both renal injury and suppression 





Figure 2-11: Recombinant TNF-α  induces AKI and renal mitochondrial 
dysfunction in mice.  Mice were treated with recombinant TNF-α at variable doses (20 
µg/kg or 50 µg/kg) or the appropriate diluent.  Serum was collected at 18 h and BUN was 
determined (A).  Total RNA and DNA were extracted from the renal cortex to assess 
expression of PGC-1α (B), downstream targets (C) and relative mitochondrial DNA 
content (D) by qPCR.  Values are mean ± S.E.M. from n = 6 animals/group (p < 0.05 









DISCUSSION   
Disruption of mitochondrial homeostasis is an important contributor to initiation 
and progression of both tubular injury and renal dysfunction in AKI (162, 170, 274). 
Mitochondrial turnover is regulated by a complex interplay between fission/fusion, 
autophagy/mitophagy, and MB (172, 173). Our laboratory and others have recently 
demonstrated alterations in MB in experimental models of AKI (178, 274, 278, 279).  
MB is tightly controlled by the PGC-1 family of transcriptional co-activators including 
PGC-1α, PGC-1β, and PRC which coordinate both nuclear and mitochondrial responses 
to increase cellular mitochondrial content.  PGC-1α is considered a “master regulator” of 
MB in organs with high energy demand including the kidney (180, 181) PGC-1α 
expression is localized to renal proximal tubule cells which rely on mitochondrial ATP 
production to facilitate active transport of solutes, indicating that MB may be essential for 
tubular function (288).  
 Recent studies characterized mitochondrial dysfunction in sepsis-induced AKI 
(162, 267).  Tran et al. demonstrated that mitochondrial dysfunction was associated with 
acute down-regulation of PGC-1α in the kidney following endotoxin exposure or cecal 
ligation and puncture (CLP) in mice (162).  PGC-1α suppression in these models was 
correlated with both reduced expression of transcriptional targets of PGC-1α and renal 
dysfunction.  Restoration of normal renal function in LPS-treated mice given saline 
resuscitation at the 18 h time point coincided with return of PGC-1α mRNA and protein 
to baseline levels, further indicating a potential role for MB in both pathogenesis of and 
recovery from septic AKI.  Proximal tubule-specific PGC-1α knockout in mice resulted 




findings provide strong evidence that PGC-1α and MB may be viable therapeutic targets 
in sepsis-induced AKI.   
          Systemic endotoxin exposure in mice led to rapid deterioration of renal function as 
measured by BUN at 3 h, and further increases in BUN and renal cortical KIM-1 and 
NGAL at 18 h. Despite relative minimal renal histological findings, these data provide 
strong molecular evidence for involvement of tubular insult in the pathophysiology of 
sepsis-induced AKI. 
 Progressive renal dysfunction and tubular cell injury were closely associated with 
a reduction in PGC-1α mRNA and protein in the renal cortex after endotoxin 
administration.  These findings are similar to previous studies reporting negative 
correlations between BUN and PGC-1α transcript levels in mice receiving LPS or CLP 
(162).  Interestingly, lower doses of LPS that did not induce renal dysfunction acutely 
had a similar effect on PGC-1α mRNA and PGC-1α protein levels did not change at the 
3 h time point when renal and tubular injury were first observed as indicated by increased 
BUN and KIM-1 mRNA expression. These findings indicate that suppression of PGC-1α 
and subsequent MB is unlikely to be the initial causative factor and alone is not sufficient 
for the development of sepsis-induced AKI.   
Early increases in circulating pro-inflammatory cytokines and renal microvascular 
dysfunction are also important mediators of renal injury in mice following systemic LPS 
exposure (124, 140).  However, suppression of renal cortical PGC-1α and MB likely 
contribute to disease progression through disruption of energy-dependent tubular 




demonstrating that both global and proximal-tubule specific PGC-1α knockout leads to 
persistent renal injury in LPS-induced AKI in mice (162).            
We also measured transcript levels of PGC-1β and PRC.  PGC-1β expression was 
decreased, but not as markedly as PGC-1α.  In contrast, PRC mRNA levels rose after 
LPS treatment similar to findings reported in I/R- and glycerol-induced AKI (274). Given 
the relative lack of knowledge regarding the role of PGC-1β and PRC in renal 
mitochondrial homeostasis, it is difficult to interpret these findings and further work is 
warranted.   
 Previous studies showed that TLR4 is required for LPS-induced renal dysfunction 
(150). However, a number of TLR4-independent actions of LPS have been described (94, 
95). As predicted, TLR4-deficient mice did not develop renal injury and markers of MB 
and mitochondrial DNA content did not decrease following endotoxin exposure.  These 
findings demonstrate that TLR4 is required for suppression of renal PGC-1α and MB in 
LPS-induced AKI.  It is important to note that the MB response to sepsis is tissue-
specific. Up-regulation of hepatic PGC-1α and PGC-1β is markedly enhanced in TLR4-
deficient mice after sepsis, suggesting that TLR4 may be an important negative regulator 
of MB (315). Further studies are needed to evaluate the possibility that TLR4 activation 
is a common mechanism underlying suppression of MB in multiple forms of AKI.   
 Binding of LPS to TLR4 activates a number of downstream signaling mediators, 
most notably nuclear factor kappa B (NFκB) and mitogen-activated protein kinases 
(MAPKs) including ERK1/2, p38 MAPKs, and JNKs (307, 308). We observed rapid (1 
h) activation of TPL-2/MEK/ERK signaling in the renal cortex.  These findings are 




phosphorylation after LPS exposure in the medullary thick ascending limb of the kidney 
(161).  Although TPL-2 is known to be required for LPS-induced ERK1/2 activation in 
macrophages, this is the first study to demonstrate increased TPL-2 phosphorylation in 
the renal cortex in response to systemic endotoxin exposure (309, 310). A recent study 
did reveal that TPL-2 knockout mice are protected from kidney I/R, although this effect 
was not attributed to the MAPK function of TPL-2 (316).  
 MEK/ERK signaling has been implicated as a negative regulator of both PGC-1α 
and MB.  Pharmacological inhibition of MEK reversed reductions in protein levels of 
PGC-1α and downstream regulators of MB (NRF-1, TFAM) in the hippocampi of rats 
receiving intracerebroventricular injections of amyloid β (244). In addition, blockade of 
ERK activation prevented palmitate-induced down-regulation of PGC-1α in skeletal 
muscle myotubes in vitro (245). The MEK1/2 inhibitor GSK1120212 (GSK112) blocked 
ERK1/2 activation and reduced early renal dysfunction and tubular injury (3 h) in mice 
subjected to systemic LPS.  The protective effects of GSK112 were associated with 
restoration of renal cortical PGC-1α expression.  These findings indicate an important 
role for MEK/ERK signaling in LPS-induced renal injury and suppression of MB.  In 
mice followed to 18 h post-LPS, GSK112 partially attenuated loss of renal function and 
injury to the proximal tubule.  However, only modest effects were noted on PGC-1α 
expression and mitochondrial DNA content.  This may indicate that the TPL-
2/MEK/ERK pathway is essential for early suppression of PGC-1α in the renal cortex 
after endotoxic AKI, but other signaling mechanisms contribute to late-phase disruption 




regulator of PGC-1α transcriptional activity (242, 317).  Further work is necessary to 
address the role of NFκB in LPS-induced mitochondrial dysfunction.  
 MEK/ERK activation downstream of TLR4 results in activation of a 
transcriptional program to increase cytokine expression in response to LPS (309, 318).  In 
addition, pro-inflammatory cytokines have been implicated in regulation of PGC-1α and 
MB (162, 242).  Administration of exogenous TNF-α reduced expression of PGC-1α and 
its transcriptional targets in primary human renal epithelial cells in vitro (162).  In 
addition, TNF-α and IL-1β induced disruption of MB in skeletal muscle cells (242). As 
expected, inhibition of MEK/ERK signaling attenuated early up-regulation of both TNF-
α and IL-1β in the renal cortex of LPS-treated mice.  Mice pretreated with an anti-TNF-α 
neutralizing antibody and exposed to LPS exhibited less PGC-1α mRNA loss. The partial 
restoration of PGC-1α following TNF-α neutralization may indicate that multiple pro-
inflammatory cytokines (TNF-α, IL-1β, IL-6) signal through similar mechanisms to 
suppress PGC-1α in the setting of sepsis-induced AKI.   To our knowledge, this is the 
first study to report the effects of TNF-α neutralization on PGC-1α and subsequent MB 
in vivo.  We did not detect an effect of anti-TNF-α on BUN 18 h post-LPS.  However, an 
earlier study using the same TNF-α neutralizing antibody before endotoxin 
administration noted a significant reduction in BUN at the 4 h time point (79).  However, 
we were able to reproduce the effects of LPS on renal dysfunction and suppression of 
PGC-1α expression by administration of recombinant TNF-α in naïve mice.  Together, 
these findings strongly implicate TNF-α as a downstream mediator of TLR4/MEK/ERK 




 A significant decrease in cortical peritubular capillary flow has been noted as 
early as 2 h post-LPS exposure in mice indicating that LPS has rapid effects on renal 
hemodynamics (124).  A limitation of the current study is that it does not address whether 
modulation of TLR4/MEK/ERK and TNF-α signaling might improve microvascular 
function and thereby restore glomerular filtration in response to LPS.  TNF-α 
neutralization using the soluble decoy receptor TNFsRp55 has been shown to restore both 
glomerular filtration and renal plasma flow after systemic exposure to a lower dose of 
LPS (5 mg/kg) (139). Future studies using conditional, tissue-specific knockout TLR4 
and downstream signaling targets in the tubular epithelium, vascular endothelium, and 
vascular smooth muscle may address whether the renal protective effects observed in this 
study are due to direct actions of pharmacological agents on the tubular epithelium or 
indirect actions on the renal vasculature.   
 The current study identifies a novel mechanism mediating injury and suppression 
of MB in a mouse model of septic AKI.  In particular, the TLR4/TPL-2/MEK/ERK/TNF-
α signaling axis was required for early renal dysfunction and disruption of mitochondrial 
homeostasis in LPS-induced AKI.  This pathway may represent a viable therapeutic 
target in the treatment of sepsis-associated AKI.  Further studies are warranted to 
determine whether this mechanism is common to other forms of AKI and to identify the 





 Chapter 3:  
Renal cortical hexokinase activation through the EGFR/PI3K/Akt 
signaling pathway in endotoxin-induced acute kidney injury 
ABSTRACT 
While disruption of energy production is an important contributor to renal injury, 
metabolic alterations in sepsis-induced renal injury remain understudied.  In this study, 
we assessed changes in glycolytic metabolism in the renal cortex in a mouse model of 
sepsis-induced AKI.  A specific and rapid increase in hexokinase (HK) activity (~2 fold) 
was observed 3 hr after lipopolysaccharide (LPS) exposure and maintained up to 18 h in 
association with a decline in renal function as measured by BUN.  LPS-induced 
hexokinase activation occurred independently of changes in expression of high affinity 
hexokinase isoforms or mitochondrial localization indicating post-translational regulation 
of hexokinase activity in this model.  No other changes in glycolytic enzymes were 
observed. LPS-mediated hexokinase activation was not sufficient to increase glycolytic 
flux as indicated by reduced or unchanged pyruvate and lactate levels in the renal cortex.  
In addition, HK activation did not lead to increased glycogen production in the renal 
cortex.  LPS-induced hexokinase activation was associated with an increase in glucose-6-
phosphate dehydrogenase activity, suggesting that hexokinase activation may facilitate 
pentose phosphate pathway flux for NADPH.  Mechanistically, LPS-induced HK 
activation was attenuated by pharmacological inhibitors of EGFR and Akt, suggesting 
that EGFR/PI3K/Akt signaling may be involved in this phenomenon.  Our findings 
indicate that LPS rapidly increases renal cortical HK activity in an EGFR- and Akt-
dependent manner and that HK activation is associated with an increase in glucose 





Acute kidney injury (AKI) is defined as an abrupt decline in renal function which 
occurs over a period of hours to days (1).  A number of factors may lead to the 
development of AKI including sepsis, ischemia/reperfusion (I/R) injury, trauma, or 
exposure to nephrotoxic agents.  Among the leading causes of AKI, sepsis is thought to 
be the most common contributor to AKI (approximately 50% of all cases) in the intensive 
care unit (ICU) setting (50).  Despite increased understanding of the pathophysiology 
underlying AKI, mortality from the disease remains near 40% and has not changed over 
several decades (49, 297, 319).  AKI in the setting of sepsis increases this mortality by 
almost 2-fold (297, 298).  Unfortunately, currently available treatments for sepsis-
induced AKI include supportive care and renal replacement therapy. A better 
understanding of the mechanisms leading to renal damage as well as recovery in septic 
AKI is essential for development of therapeutic strategies to improve outcomes in this 
disease.   
 The pathophysiology of sepsis-induced AKI is widely recognized as multi-
factorial, involving microvascular, immunological, and tubular components that 
contribute to renal dysfunction.  The microvascular component is characterized by 
reduced capillary flow leading to local areas of hypoperfusion (135, 320, 321).  
Infiltration of both macrophages and neutrophils also exposes the septic kidney to a 
diverse array of pro-inflammatory factors (322, 323).  Finally, tubular damage 
characterized by tubular cell vacuolization, mild tubular dilatation, and mitochondrial 
swelling has been noted in septic AKI (162, 301).  Although histopathology in sepsis-




proximal tubule for reabsorption and secretion of solutes including sodium, glucose, and 
amino acids from the glomerular filtrate via active transport processes.  Therefore, any 
pathological condition resulting in reduced ATP levels may contribute to tubular de-
energization and subsequent loss of renal function characteristic of AKI (256, 257). 
 Our laboratory demonstrated that I/R and glycerol-induced AKI leads to rapid and 
sustained mitochondrial dysfunction in the renal cortex characterized by suppressed 
expression of mitochondrial biogenesis markers and electron transport chain components 
at the mRNA and protein levels (274).  Disruption of normal mitochondrial homeostasis 
in these models was closely associated with proximal tubule cell injury and loss of renal 
function (274).  Tran et al. recently reported similar findings following systemic exposure 
to lipopolysaccharide (LPS; a component of gram-negative bacterial cell walls), a well-
established model of sepsis-induced AKI.  In particular, LPS administration resulted in a 
marked reduction in cytochrome c oxidase activity and protein levels as well as down-
regulation of a number of mitochondrial genes in the renal cortex.  Suppression of 
mitochondrial mRNAs correlated significantly with renal function as measured by blood 
urea nitrogen (BUN) (162).  LPS-induced mitochondrial dysfunction results in a 
significant decline (~50%) in renal ATP content within 5 hr. of exposure in rodents, 
likely contributing to changes in renal function in this model of septic AKI (265).  
Disruption of renal mitochondrial function and ATP production has also been reported in 
the cecal ligation and puncture model (CLP) of sepsis (324).  What remains understudied 
are metabolic alterations which may facilitate both proximal tubule cell energy 




 Under normal conditions in vivo, renal proximal tubule cells primarily utilize 
oxidative phosphorylation via mitochondria to generate ATP and have very low 
glycolytic capacity.   Early work characterizing renal metabolism demonstrated the 
proximal tubules possesses the lowest activities of glycolytic enzymes (including 
hexokinase [HK], phosphofructokinase [PFK], and pyruvate kinase [PK] – the three 
major regulatory steps) along the entire nephron segment (258, 325).  These findings 
have led to considerable debate concerning the ability of the proximal tubule to induce 
glycolytic metabolism as an alternate means of ATP generation.  However, both in vitro 
and in vivo work indicates that a variety of stressors including ischemia/hypoxia, 
nephrotoxicants, elevated intracellular calcium, and inhibition of mitochondrial 
respiration may increase glycolytic flux in the proximal tubule (293, 296, 326).  
Glycolytic induction appears to play an important role in maintaining tubular cell 
viability, producing ATP, and preserving transport processes (293, 295, 322).  In 
addition, recent studies have demonstrated that glycolytic metabolism is rapidly increased 
in the cortex in response to renal ischemia in vivo (327).  These findings indicate that 
glycolysis may provide an alternate means of energy generation in response to tubular 
insult.   
We hypothesized that glycolysis would be rapidly induced in the renal cortex in 
response to LPS-induced renal injury.  To test this hypothesis, an extensive 
characterization of renal cortical glycolytic enzyme activity and expression after LPS 
challenge was performed.  We report herein that LPS exposure results in a rapid (within 3 




pathway.  Surprisingly, HK activation by LPS was not sufficient to enhance glycolysis in 







 Male C57BL6 mice (6 to 8 weeks of age, 20 – 25 g body weight) were obtained 
from Charles River.  Mice received an intraperitoneal injection of 10 mg/kg LPS from 
Escherichia coli O111:B4 (Sigma Aldrich Catalog No. L4130, Lot No. 052M4016V) as 
previously described.(162)  Control mice were injected i.p. with an equal volume of 0.9% 
saline vehicle.  Mice were euthanized at 3, 6, and 18 h after LPS injection and serum and 
kidneys were collected for biochemical analysis.  All experiments were carried out in 
strict accordance with the recommendations in the Guide for the Care and Use of 
Laboratory Animals of the National Institutes of Health.  Animal use was approved by 
the Institutional Animal Care and Use Committee at the Medical University of South 
Carolina.    
Administration of Gefitinib and MK-2206  
 For studies examining the role of EGFR and PI3K/Akt signaling in LPS-induced 
renal injury, the EGFR inhibitor gefitinib and the Akt inhibitor MK-2206 were obtained 
from Selleckchem Chemicals (Houston, TX).(328, 329)  Mice were randomly assigned to 
three groups: 1) LPS + vehicle control (5% DMSO, 40% 2-hydroxypropyl-β-
cyclodextrin), 2) LPS + gefitinib (100 mg/kg), or 3) LPS + MK-2206 (100 mg/kg).  One 
hour prior to LPS administration, mice were given an intraperitoneal injection as 
described above.  Mice were sacrificed at 3 h after LPS injection and serum and kidneys 
harvested for analysis.  Appropriate dosing of gefitinib was based on previous studies 
demonstrating inhibition of EGFR activity in mouse models of both acute kidney injury 




Blood Urea Nitrogen Measurement  
Blood urea nitrogen (BUN) was measured using a QuantiChrom Urea Assay Kit 
(BioAssay Systems, Hayward, CA) according to the manufacturer’s protocol.  Values are 
expressed as blood urea nitrogen concentration in milligrams per deciliter.   
Hexokinase Activity Assay  
   Renal cortical hexokinase activity was determined using a Hexokinase 
Colorimetric Assay Kit (BioVision Incorporated, Milpitas, CA).  Briefly, renal cortical 
tissue was homogenized in ice-cold Hexokinase Assay Buffer.  Homogenized tissue was 
then centrifuged at 12,000 r.p.m. for 10 mins to clear debris.  The resulting supernatant 
was collected and 15 µL samples were loaded into a 96-well plate and adjusted to a final 
volume of 50 µL.  After addition of HK reaction mix to each well, absorbance at 450 nm 
was measured in kinetic mode using an Infinite M200 PRO spectrophotometer (Tecan 
Systems, Inc., San Jose, CA).  NADH generation as a result of conversion of glucose to 
glucose-6-phosphate by hexokinase was calibrated to a standard curve using the provided 
NADH standard.  Background samples without reaction mix were also included to 
correct for endogenous NADH levels.  Protein content for each sample was determined 
by the BCA protein assay and values are expressed as milliunits of hexokinase activity 
per mg protein content.    
Phosphofructokinase Activity Assay  
 Phosphofructokinase (PFK) activity in the renal cortex was assessed using the 
Phosphofructokinase Activity Colorimetric Assay Kit (BioVision Incorporated).  Renal 
cortical tissue was extracted in ice-cold PFK Assay Buffer and centrifuged at 12,000 




determination of protein concentration by the BCA protein assay. Interfering small 
molecules were removed using 10 kD molecular weight cutoff centrifugal filters (VWR, 
Radnor, PA).  The concentrated protein samples were then diluted and PFK activity was 
determined based on the manufacturer’s protocol using an Infinite M200 PRO 
spectrophotometer in kinetic mode (Tecan Systems).  
Pyruvate Kinase Activity Assay  
 Cortical pyruvate kinase (PK) activity was determined using the Pyruvate Kinase 
Activity Colorimetric Assay Kit (BioVision Incorporated).  Renal cortical tissue was 
homogenized in cold Pyruvate Kinase Assay Buffer and cleared of debris by 
centrifugation at 12,000 r.p.m. for 10 mins.  Samples were then assayed for pyruvate 
kinase activity as directed by the manufacturer by determining changes in optical density 
at 570 nm using an Infinite M200 PRO spectrophotometer in kinetic mode (Tecan 
Systems).  A portion of the sample was also used for determination of protein content via 
the BCA protein assay.      
Analysis of mRNA Expression  
 Total RNA was isolated from renal cortex samples using the TRIzol reagent (Life 
Technologies, Grand Island, NY).  A cDNA library was generated from 2 µg RNA by 
reverse transcription reaction using the iScript Advanced cDNA Synthesis Kit for RT-
qPCR according to the manufacturer’s protocol (Bio-Rad, Hercules, CA).  Quantitative 
real-time PCR was then performed with cDNA using the SsoAdvanced SYBR Green 
Supermix (Bio-Rad).  mRNA expression of genes of interest was calculated by the 2-ΔΔCt 














Gene Primer Sequence Accession No. 
HPRT 
Sense 5’- GCTTACCTCACTGCTTTCCG-3’ 
NM_013556 













































Immunoblot Analysis  
 Tissue samples from the renal cortex were lysed in RIPA buffer (50 mM Tris-
HCl, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, pH 7.4) 
containing protease inhibitor cocktail (1:100), 1 mM sodium orthovanadate, and 10 mM 
sodium fluoride (Sigma Aldrich).  Total protein content was determined by BCA protein 
assay. Equal amounts of protein (50 – 100 µg) were resolved on 4 – 15% Mini-
PROTEAN TGX SDS-PAGE gels (Bio-Rad).  Proteins were then transferred to 
nitrocellulose membranes and blocked in 2.5% BSA for 1 hr.  Membranes were 
incubated with primary antibody overnight at 4°C.  Primary antibodies included HK1, 
HK2, PFKP, PKM1/2, PDH, phospho-Akt (Ser 473), Total Akt, phospho-p42/p44 
MAPK (Thr202/Tyr204; p-ERK1/2), and Total p42/p44 MAPK (all from Cell Signaling 
Technology, Danvers, MA; 1:1,000 dilution), VDAC/Porin (Abcam, Cambridge, MA; 
1:1,000), and β-Actin (Santa Cruz Biotechnology, Dallas, TX; 1:10,000).  Membranes 
were then incubated in horseradish peroxidase (HRP)-conjugated secondary for 1 hr at 
room temperature.  Proteins were visualized using enhanced chemiluminescence reagents 
(Thermo Scientific, Waltham, MA) and a GE ImageQuant LAS4000 digital imaging 
system.  NIH ImageJ Software (v 1.46) was used to measure optical density of 
immunoblots.  
Mitochondrial Fractionation 
 Mitochondria were isolated from whole kidneys by differential centrifugation as 
previously described (332). Whole kidneys were washed and finely minced in isolation 
buffer (250 mM sucrose, 1 mM EGTA, 10 mM HEPES, 1 mg/ml fatty acid free BSA, pH 




(Talboys Engineering, Montrose, PA).  Nuclei and cellular debris were pelleted by 
centrifugation at 1,000g for 10 mins.  The remaining supernatant was centrifuged at 
10,000g for 5 mins. to produce a mitochondrial pellet.  The mitochondrial fraction was 
washed once in isolation buffer and re-pelleted by centrifugation.  The resulting 
mitochondrial pellet was resuspended in RIPA buffer and mitochondrial localization of 
HK1 and HK2 was determined by immunoblot analysis as indicated above.    
Assessment of Renal Cortical Glucose, Pyruvate, and Lactate Levels  
 Levels of glucose, pyruvate, and lactate in the renal cortex were determined using 
enzymatic assay kits (Glucose Fluorometric Assay Kit, Pyruvate Fluorometric Assay Kit, 
and Lactate Fluorometric Assay Kit; BioVision Incorporated).  Renal cortical tissue was 
extracted in ice-cold Glucose, Pyruvate, or Lactate Assay Buffer and centrifuged at 
10,000g for 10 min to remove cellular debris.  A portion of the sample was used for 
determination of protein content by the BCA protein assay.  The remaining sample was 
deproteinized by centrifugation through 10 kD cutoff centrifugal filters (VWR) to prevent 
enzymatic degradation of metabolites.  After deproteinization, levels of pyruvate and 
lactate were determined according to the manufacturer’s instructions using an Infinite 
200 PRO fluorometer at 535/587 nm (excitation/emission).  
Determination of Glycogen Content  
 Renal cortical glycogen content was determined using a Glycogen Fluorometric 
Assay Kit (BioVision Incorporated).  Tissue samples were extracted in ice-cold 1X PBS 
and immediately boiled to inactivate enzymes responsible for glycogen degradation.  




glycogen content based on the manufacturer’s protocol using an Infinite 200 PRO 
fluorometer at 535/587 nm (excitation/emission).  
Glucose-6-phosphate Dehydrogenase Activity Assay  
Glucose-6-phosphate dehydrogenase (G6PDH) activity was determined using the 
Glucose-6-phosphate Dehydrogenase Activity Colorimetric Assay kit (Biovision Inc.).  
Renal cortical tissues were homogenized in ice-cold phosphate-buffered saline (PBS) and 
centrifuged at 10,000g to remove any residual cellular debris.  Twenty-five (25) µL 
samples were loaded in duplicate into a 96-well plate and brought to 50 µL in the G6PDH 
assay buffer provided.  A portion of the homogenized sample was aliquoted for protein 
estimation by the BCA assay.  G6PDH activity was then determined based on the 
manufacturer’s instructions using an Infinite M200 PRO spectrophotometer in kinetic 
mode (Tecan Systems).  Data are shown as milliunits of G6PDH activity per gram of 
protein.   
Statistical Analysis  
 Data are presented as mean ± S.E.M.  Statistical comparisons between two groups 
were performed using an unpaired, two-tailed t-test.  For multiple comparisons, a one-
way analysis of variance (ANOVA) was performed followed by Tukey’s post-hoc test.  A 
p-value < 0.05 was considered statistically significant.  All statistical analysis was 






LPS Induces Specific Increases in Renal Cortical Hexokinase Activity  
 Because suppression of both mitochondrial function and gene expression has been 
reported in multiple animal models of AKI, including sepsis-induced AKI, we 
hypothesized that glycolytic metabolism would increase in the renal cortex following 
LPS exposure (162, 274).  We first measured activities of the three major rate-limiting 
enzymes in the glycolytic pathway, hexokinase (HK), phosphofructokinase (PFK), and 
pyruvate kinase (PK), in the renal cortex at 3, 6, and 18 hr after LPS exposure. Renal 
cortical hexokinase activity increased approximately 2-fold as early as 3 hr post-LPS and 
remained elevated for at least 18 hr (Figure 3-1A).  However, PFK and PK activities were 
unchanged through 18 hr (Figure 3-1C,D).  BUN progressively increased from 
approximately 32 mg/dl in vehicle-treated mice to 61 mg/dl and 122 mg/dl at 3 hr and 18 
hr after LPS administration, respectively (Figure 3-1B).  Taken together, these findings 
indicate that HK is specifically and rapidly activated in the renal cortex of mice subjected 





Figure 3-1: HK activation and renal dysfunction after LPS exposure.  Male C57BL/6 
mice were injected with lipopolysaccharide (10 mg/kg, i.p.) or saline vehicle and 
euthanized at 3, 6, and 18 hr.  Renal cortical tissue was isolated and activities of 
hexokinase [HK] (n = 3 – 11) (A), PFK [PFK] (n = 3 – 6) (C), and PK [PK] (n = 3 – 6) 
(D) were measured using standard biochemical assays.  Decline in renal function at 3 and 
18 hr post-LPS was confirmed by measuring BUN (n = 5) (B).  Data are expressed as 
mean ± S.E.M. for each group.  Different superscripts above bars indicate statistically 





LPS-Induced HK Activation Occurs Independently of Changes in Isoform 
Expression  
 Because HK activity in the renal cortex increased following LPS exposure, we 
determined the effects of LPS on the expression of HK isoforms at both the mRNA and 
protein level via qPCR and immunoblotting at 3 and 18 hr post-LPS.  HK1 mRNA levels 
did not change in response to LPS exposure at any of the time.  HK2 gene expression 
increased ~33-fold at 3 hr in LPS-treated mice but returned to baseline levels by 18 hr 
post-LPS.  LPS administration also resulted in increases in HK3 mRNA levels at both the 
3 hr (approximately 2-fold) and 18 hr (approximately 5-fold) (Figure 3-2A,B).  Although 
increased gene expression of HK2 and HK3 was observed in LPS-treated mice, 
immunoblot analysis revealed no changes in protein levels of HK1 or HK2 at 18 hr after 
LPS administration (Figure 3-2C,D).  These data demonstrate that rapid HK activation in 
the renal cortex of LPS-treated mice is independent of changes in HK isoform expression, 
suggesting that post-translational modification by phosphorylation, which has been 





Figure 3-2: Systemic LPS exposure does not alter HK isoform expression at the 
protein level.  RNA and protein were isolated from the renal cortex of mice treated with 
LPS or vehicle control.  Relative expression of HK1, HK2, and HK3 at the transcript 
level at 3 hr (A) and 18 hr (B) after LPS administration was determined by RT-qPCR (n 
= 4 – 6).  Immunoblot analysis revealed no changes in protein expression of HK1 or HK2 
isoforms at the 18 hr time point (n = 9) (C,D).  Data were normalized to fold-change in 
expression compared to vehicle controls and are presented as mean ± S.E.M. for each 





LPS Exposure Does Not Alter Mitochondrial Localization of HK1 or HK2 
 Both HK1 and HK2 isoforms possess mitochondrial binding domains which allow 
for their association with the outer mitochondrial membrane (OMM) in association with 
the voltage-dependent anion channel (VDAC) (334, 335).  Because mitochondrial 
binding of HK has been demonstrated in the kidney and may result in increased HK 
activity, we determined the effects of LPS administration on HK1 and HK2 localization 
to the OMM.  Mitochondria were isolated by differential centrifugation from kidneys of 
vehicle- and LPS-treated mice at 18 h.  Protein levels of HK1 and HK2 in the 
mitochondrial fraction were determined by immunoblot analysis using VDAC as a 
mitochondrial loading control.  No differences were noted in the mitochondrial 
localization of either HK1 or HK2 following LPS administration (Figure 3-3A,C,D).  
Purity of mitochondrial fractions was confirmed by immunoblotting for VDAC, α-
Tubulin, and Lamin B1 (Figure 3-3B).  These findings demonstrate that LPS-induced 







Figure 3-3: Effects of LPS on mitochondrial localization of HK1 and HK2.  Whole 
kidneys were harvested from mice treated as described above and the mitochondrial 
fraction was isolated by differential centrifugation.  Immunoblot analysis was performed 
to examine changes in mitochondrial localization of HK isoforms.  Mitochondrial VDAC 
was used as a loading control.  Representative immunoblots demonstrating 
mitochondrial-associated HK1 or HK2 isoforms 18 hr after LPS exposure (A).  Purity of 
mitochondrial (M) and cytosolic (C) fractions was assessed by immunobloting for VDAC 
(mitochondrial marker), α-Tubulin (cytosolic marker), and Lamin B1 (nuclear marker) 
(B).  Densitometric analysis revealed no change in mitochondrial localization of HK1 or 





LPS Administration Does Not Alter Expression of Other Glycolysis-Related 
Enzymes in the Renal Cortex 
 Because we hypothesized that glycolytic metabolism would increase in the renal 
cortex in LPS-induced AKI to support cellular function, we also examined expression of 
a number of glycolysis-related enzymes in the renal cortex of mice exposed to LPS.  In 
particular, genes and proteins involved in cellular glucose uptake (GLUT1/Slc2a1), 
glycolytic metabolism (PFKP, PFKL, PFKM, PGK1, PKM), pyruvate conversion into 
lactate (LDHA), and pyruvate entry into the TCA cycle (PDK1, PDH).  No increases 
were noted in gene expression of glycolysis-related enzymes at 18 hr post-LPS (Figure 3-
4A).  Transcript levels of the glycolytic enzymes phosphofructokinase, muscle type 
(PFKM) and phosphoglycerate kinase 1 (PGK1) were significantly decreased (~40%) 
following LPS exposure (Figure 3-4A).  In addition, no changes in protein expression of 
glycolysis-related enzymes were observed in mice treated with LPS (Figure 3-4B,C).  
Taken together, these data indicate that LPS exposure does not result in changes in gene 





Figure 3-4: LPS administration does not increase expression of other glycolysis-
related enzymes in the renal cortex.  RNA and protein were harvested from the renal 
cortex of mice treated with saline vehicle or LPS as described above.  Expression of 
GLUT1, PFKL, PFKM, PGK1, PKM, LDHA, and PDK1 mRNAs (A) were determined 
by RT-qPCR analysis (n = 6).  Representative immunoblots demonstrating no change in 
expression of PFKP, PKM1/2, PDH, or LDHA (B, C) 18 hr after systemic LPS 
administration (n = 9).  Data were normalized change in expression relative to control 





LPS-induced HK Activation Does Not Enhance Glycolytic Flux in the Renal Cortex 
 To determine whether LPS-induced activation of HK was sufficient to increase 
glycolytic metabolism, we next measured end products of glycolysis.  Mice were treated 
with LPS or vehicle control and kidneys were harvested at 3 hr and 18 hr after injection 
to determine pyruvate and lactate in renal cortical tissue.  LPS exposure resulted in 
significant decreases in pyruvate content (~50%) at both the 3 and 18 hr time points 
(Figure 3-5A).  Cortical lactate levels were also significantly reduced to approximately 
40% of control levels at 3 hr post-LPS.  However, lactate content returned to baseline 
levels by the 18 hr time-point (Figure 3-5B).  The changes observed in both pyruvate and 
lactate levels did not result in an increase in the lactate-to-pyruvate ratio at 18 hr post-
LPS (Figure 3-5C).   These findings demonstrate that, although LPS exposure results in 
activation of HK in the renal cortex, increased HK activity is not adequate to increase 





Figure 3-5: LPS-induced HK activation does not increase renal cortical glycolytic 
flux.  Lactate and pyruvate were isolated from the renal cortices of mice treated with 
either saline or LPS and measured by standard biochemical assays.  Systemic LPS 
exposure resulted in a decrease in renal cortical pyruvate levels at both 3 and 18 hr time 
points (A).  Lactate levels were lower at 3 hr post-LPS but returned to baseline levels by 
18 hr (B).  No significant changes were noted in the lactate:pyruvate ratio, although there 
was trend toward an increase at 18 hr after LPS (C).  Data are presented as mean ± 





Increased HK Activity after LPS Exposure Does Not Promote Glycogen Synthesis 
Because increased HK activity due to LPS exposure in the renal cortex did not 
result in enhanced glycolytic flux, we sought to determine whether HK activation in this 
setting has an alternate physiological role.  Conversion of glucose to glucose-6-phosphate 
by hexokinase has been described as a rate-limiting step in glycogen synthesis in a 
variety of model systems including rodent skeletal muscle (336-338).  Thus, we measured 
glucose and glycogen levels following LPS exposure to determine whether HK activation 
in this model may result in glycogenesis.  Glucose levels in the renal cortex were reduced 
3 hr after LPS administration (~30% reduction) and remained lower at 18 (Figure 3-6A).  
Measurement of glycogen content revealed no change in LPS-treated mice at 3 hr and a 
~60% reduction at 18 hr (Figure 3-6B).  Our results demonstrate that LPS-induced HK 
activation does not stimulate glycogen synthesis. 
HK Activation in the Renal Cortex is Associated with Increased Pentose Phosphate 
Pathway Activity 
 We next questioned whether renal cortical HK activation following systemic LPS 
exposure might facilitate glucose flux through the pentose phosphate pathway (PPP) to 
produce NADPH for use as a reducing agent in glutathione regeneration.  Since 
endotoxin exposure is known to rapidly up-regulate oxidative stress in the proximal 
tubule, we anticipated that any changes observed in NADPH and/or glutathione levels 
would be difficult to interpret as markers of PPP activity in this model (149).  Instead, we 
measured activity of glucose-6-phosphate dehydrogenase (G6PDH) activity, the rate-
limiting step of the PPP as a marker of glucose metabolism through this pathway (339).  




administration (Figure 3-6C).  These data indicate that HK activation following 





Figure 3-6: LPS-induced increases in HK activity do not promote glycogen synthesis 
in the renal cortex but are associated with increased G6PDH activity.  Glucose (A) 
and glycogen content (B), and G6PDH activity (C) were evaluated in the renal cortex at 
different time points following systemic LPS administration in mice and were normalized 
to wet tissue weight (glucose, glycogen) or protein content (G6PDH activity).  Data are 
shown as mean ± S.E.M. for each group (n = 5 – 6).  Different superscripts above bars 





LPS-induced HK Activity in the Renal Cortex is Mediated by EGFR and Akt  
 To understand the mechanism by which LPS exposure increases HK activation, 
we investigated the role of the epidermal growth factor receptor (EGFR).  Earlier studies 
from our laboratory and others have shown that EGFR ligands (EGF, HB-EGF) stimulate 
hexokinase activity in renal proximal tubule cells (RPTC) (340-343).  LPS is also known 
to induce EGFR transactivation in a variety of cell types including epithelial cells and 
renal medullary collecting duct cells (344-348).  One hour prior to LPS administration, 
mice were treated with the EGFR inhibitor gefitinib (100 mg/kg) or vehicle control and 
kidneys were harvested 3 hr post-LPS.  This dose has previously been reported to inhibit 
EGFR signaling following AKI in mice (330).  LPS-induced renal cortical HK activity 
was completely blocked by gefitinib, suggesting an essential role for EGFR in this 
process (Figure 3-7A).   
 Because EGFR is known to activate PI3K/Akt signaling, we determined whether 
Akt is responsible for EGFR-mediated HK Activation.  To demonstrate Akt activation 
following systemic LPS exposure, mice were treated with LPS or vehicle control and 
kidneys harvested 1 hr later for immunoblot analysis of phosphorylated and total Akt.  
LPS exposure resulted in a ~1.5-fold increase in expression of phospho-Akt without a 
change in total Akt (Figure 3-7C,D).  Based on these findings, another group of mice 
were pretreated with the pan-Akt inhibitor MK-2206 (100 mg/kg) 1 hr prior to LPS 
injection and kidneys harvested 3 hr post-LPS.  MK-2206 is an allosteric inhibitor of Akt 
and exhibits high selectivity over other kinases because it requires the Pleckstrin 
homology domain for its activity (349).  LPS-induced HK activity was attenuated 











Figure 3-7: HK activation following LPS exposure is mediated through EGFR/Akt 
signaling.  One hour prior to LPS administration, as described above, mice were treated 
with a single dose of either gefitinib (100 mg/kg, i.p.) (A), MK-2206 (100 mg/kg) (B) or 
vehicle control.  HK activity was determined in the renal cortex at 3 hr after systemic 
LPS administration (n = 5 – 12).  Immunoblot analysis revealed increased 
activation/phosphorylation of Akt 1 hr after LPS exposure (C, D).  Levels of 
phosphorylated Akt were normalized to total protein expression and presented as fold 
change versus control animals (n = 4).  Data are expressed as mean ± S.E.M for each 
experimental group.  Superscripts above bars indicate statistically significant differences 






Mitochondrial dysfunction is an important contributor to the pathophysiology of 
multiple forms of AKI (173, 274).  Although histological changes in sepsis-induced AKI 
are limited, post-mortem and experimental studies have demonstrated mitochondrial 
swelling in the relative absence of overt tubular cell death (162, 301, 350).  On the 
molecular level, sepsis-induced AKI results in suppression of mitochondrial genes which 
is associated with functional decline (162).  Patil et al. recently demonstrated reduced 
renal electron transport chain complex I and complex II/III activity occurring as early as 
6 h after cecal ligation and puncture in mice (324). Furthermore, a reduction of renal ATP 
levels has been observed in rodent models of sepsis-induced AKI which correlated well 
with renal dysfunction (265, 324, 351). Taken together, these data provide strong 
evidence that mitochondrial dysfunction plays a central role in the pathophysiology of 
sepsis-induced AKI.  To this point, therapies that restore mitochondrial function and/or 
reduce oxidative stress have proven beneficial in experimental models (135, 324).  
           We hypothesized that renal proximal tubule cells might respond to mitochondrial 
dysfunction by increasing glycolytic flux to generate ATP.  Although the proximal tubule 
has been viewed as having very low glycolytic capacity, studies have revealed that 
glycolysis may be induced in RPTCs in response to a cellular insult (258, 325, 352).  
Dickman and Mandel demonstrated that proximal tubules in vitro increase glycolytic 
metabolism in response to hypoxia, mitochondrial uncoupling, and inhibition of complex 
I of the electron transport chain (ETC) (293).  Inhibition of the Na+/K+-ATPase and 
glycolysis in proximal tubules following complex I inhibition indicated that glycolytic 




that anaerobic glycolysis is increased in the renal cortex during ischemia but rapidly 
returns to baseline levels after reperfusion (327).  These data provide strong evidence that 
glycolytic metabolism can be activated for energy production in the proximal tubule.   
 We performed a comprehensive evaluation of the glycolytic pathway to examine 
activities of the major regulatory enzymes, mRNA and protein levels of key components 
of glucose metabolism, and end products of glycolysis (pyruvate and lactate).   We 
observed an increase in renal cortical HK activity as early as 3 h after LPS exposure in 
mice that was maintained for at least 18 h without an up regulation of any other 
glycolytic enzymes nor an increase in flux through the glycolytic pathway as measured 
by renal cortical pyruvate and lactate levels.   
 To our knowledge, this is the first demonstration of rapid, specific activation of 
hexokinase in the renal cortex after systemic LPS administration.  Three high-affinity HK 
isoforms (Km values in the micromolar range) are expressed in the mammalian kidney 
(HK1, HK2, and HK3) (335, 353).	   	  HK1 is constitutively expressed/active and accounts 
for approximately 70% of total renal HK activity under normal conditions.  In contrast, 
HK2 appears to be regulated in response to a variety of stimuli (354-356).  Little is 
known about the regulation of HK3 expression/activity.  Together, HK2 and HK3 
account for the remainder of renal HK activity (~30%) (342).   
The experimental method used to measure hexokinase activity in this study does 
not distinguish which HK isoform is activated following systemic LPS exposure. 
Therefore, we measured HK isoforms at both the mRNA and protein levels in the renal 
cortex.  Although early changes were noted in mRNA levels of HK2, no changes were 




expression increased at both 3 and 18 h time points.  We were not able to measure HK3 
protein due to the lack of a validated antibody with reactivity to mouse HK3.  An 
anabolic role (PPP or glycogen synthesis) has been proposed for HK2 and HK3 since 
these isoforms are subjected to inhibition by glucose-6-phosphate and Pi, whereas HK1 is 
thought to mainly facilitate glycolytic metabolism (357).              
Given that HK isoform expression did not change after LPS exposure, we 
investigated whether HK activation might be attributed to increased mitochondrial 
localization.  Recent evidence revealed that mitochondrial localization of HK isoforms 
may serve a number of physiological roles including direct coupling of glucose 
phosphorylation to the intramitochondrial ATP pool, reducing feedback inhibition by G-
6-P, and preventing initiation of apoptosis by pro-apoptotic members of the Bcl-2 family 
(334, 358-361).  However, we did not observe any changes in mitochondrial localization 
of either HK1 or HK2 in response to systemic LPS exposure.  In contrast to HK1 and 
HK2, HK3 does not possess a mitochondrial localization sequence and is thought to be 
predominantly peri-nuclear in location (362).  Taken together, these data suggest that 
renal cortical HK activation in endotoxin-induced AKI is likely due to a post-translational 
modification (i.e. phosphorylation) which regulates HK activity (333, 363).    
Although HK activity rapidly increased and was sustained up to 18 h after LPS 
exposure, we observed no changes in pyruvate and lactate content indicative of increased 
glycolysis.  For the purposes of this study, glycolytic flux was defined as the conversion 
of glucose to pyruvate as well as downstream generation of lactate.  Lactate:pyruvate 
ratios were compared under different experimental conditions as an indicator of 




pyruvate to lactate, resulting in increased lactate with a corresponding equimolar 
reduction in pyruvate.  Pyruvate content was decreased approximately 2-fold at both 3 
and 18 h, whereas lactate levels trended toward a decrease at 3 h but returned to baseline 
levels by 18 h post-LPS.  These findings are in agreement with recent reports of renal 
cortical pyruvate depletion in both I/R and glycerol-induced AKI in mice (327).  The 
same study also reported glycolytic induction in the renal cortex only occurs during the 
ischemic period and is reversed after reperfusion (327).  However, it should be noted that 
some of the analyses performed here, including pyruvate and lactate measurements, are 
not sufficiently powered to detect small changes between groups.  Thus, it is possible that 
there are minimal changes in glycolytic flux in the renal cortex up to 18 h after LPS 
exposure that we were not able to distinguish.    
Using a combination of micro-ultrasound and blood oxygen level-dependent MRI, 
Tran et al. demonstrated that although renal perfusion is markedly decreased in LPS-
treated mice, there is minimal change in tissue oxygenation (162).  Thus, the lack of renal 
hypoxia may explain why we did not detect increases in lactate following systemic LPS 
administration.  However, the importance of hypoperfusion/hypoxia in renal 
pathophysiology remains unclear.  Changes in renal blood flow following endotoxin 
exposure are local and dynamic at the dose used in this study.  Wu et al. reported the 
disruption in cortical peritubular capillary flow at 10 h after LPS administration in mice.  
Peritubular capillary dysfunction observed in this study was correlated with an increase in 
tubular NAD(P)H autofluorescence, suggesting that local hypoxia may contribute to 
cellular injury after LPS (124).  In light of these findings, it is important to note that our 




Our analysis of glycolytic enzyme activities was restricted to the major rate-
limiting enzymes in the glycolysis pathway (HK, PFK, PK).  In addition, we measured 
mRNA and protein expression of other enzymes involved in glucose metabolism in the 
renal cortex following LPS exposure (e.g. GLUT1, PGK, LDHA, PDH, PDK1).  There 
was no evidence of increased mRNA or protein expression of any of these components, 
indicating that LPS-induced AKI does not result in early activation of a transcriptional 
program to facilitate glycolysis in the renal cortex.  We cannot rule out the possibility that 
activities of one or more of these enzymes are increased after endotoxin exposure without 
an associated increase in expression.  However, the data presented here demonstrating 
minimal changes in the lactate:pyruvate ratio, specific HK activation and an absence of 
increases in expression of other glycolytic components provide considerable evidence 
indicating that glycolysis is minimally activated at early time points (3 and 18 h) 
following endotoxin-induced AKI.  Further studies are necessary to determine whether 
glycolytic metabolism might be activated in the chronic phase.    
In addition to glycolysis, G-6-P has multiple fates that include flux through the 
pentose phosphate pathway (PPP) to produce NADPH and nucleotide/amino acid 
precursors, glycogen synthesis, and the hexosamine biosynthetic pathway.  Zager et al. 
reported that pyruvate depletion in the renal cortex following ischemic and nephrotoxic 
forms of AKI was partially attributed to an increase in gluconeogenesis and glycogen 
synthesis (327).  Interestingly, generation of glucose-6-phosphate by HK is thought to be 
a rate-limiting step in glycogen synthesis in a number of tissues and has been associated 
with glycogen supercompensation in rat skeletal muscle (336-338, 364).  In contrast to 




cortical glucose and glycogen content.  Together, these data indicate that gluconeogenesis 
and glycogen content are not up-regulated in the septic kidney.  These findings are 
consistent with the reduction in renal glucose and gluconeogenic enyzmes in the kidney 
after endotoxin administration in rats (365, 366).       
 Glucose-6-phosphate generated following HK activation in the renal cortex may 
also be utilized by the pentose phosphate pathway (PPP).  Through the PPP, G-6-P is 
further metabolized by the rate-limiting enzyme glucose-6-phosphate dehydrogenase 
(G6PDH) to generate NADPH and biosynthetic precursors (335).  Reduced NADPH 
levels in G6PDH deficient mice were associated with increased renal oxidative stress, 
inflammation, and dysfunction indicating an important role for NADPH in antioxidant 
defense in the kidney (367).  Given that oxidative stress rapidly develops in the proximal 
tubule following systemic LPS exposure, these findings suggest an alternate hypothesis 
that HK activation may contribute to PPP activity (149).    Interestingly, G6PDH activity 
was increased (~3.5 fold) in the renal cortex of mice exposed to LPS.  These findings 
provide strong evidence that glucose-6-phoshphate formed as a result of hexokinase 
activation is selectively metabolized via the PPP.    The importance of the PPP in 
NADPH production and thus anti-oxidant defense following AKI has received little 
attention.       
 Our laboratory previously demonstrated that activation of EGFR signaling in 
primary rabbit proximal tubule cells lead to a rapid increase in both glycolysis and PPP 
activity (340).  Further studies demonstrated that EGFR ligands are capable of increasing 
HK activity in multiple renal cell types including proximal tubule cells and mesangial 




studies demonstrating that TLR4 rapidly transactivates the EGFR via protease mediated 
EGFR ligand shedding (347, 348).   In addition, EGFR activation can contribute to the 
pathology and recovery of multiple forms of AKI (368).  Results presented here 
demonstrate that EGFR signaling is required for HK activation in LPS-induced AKI.   
 We next focused on Akt as a downstream mediator of EGFR-induced HK 
activation in LPS-treated mice based on extensive evidence indicating that Akt modulates 
both HK activity and localization through phosphorylation (363, 369).  Site-directed 
mutagenesis has further revealed that HK2 is phosphorylated by Akt on threonine 473 
within an Akt consensus sequence in cardiomyocytes in vitro (333).  We examined 
signaling changes in the renal cortex that might precede HK activation and noted 
increased activation of Akt as early as 1 h after LPS administration which is consistent 
with other reports (370, 371).  Inhibition of Akt by MK-2206 attenuated increases in HK 
activity following LPS exposure.  Taken together, these findings provide strong evidence 
that the EGFR/Akt signaling pathway is responsible for LPS-mediated hexokinase 
activation in the renal cortex.   
In conclusion, the present study reports the novel finding of rapid activation of 
renal cortical HK activity in a mouse model of sepsis-induced AKI.  HK was activated 
following LPS-induced AKI via an EGFR/Akt-dependent signaling mechanism.  
Surprisingly, the increase in HK activity observed in this model was associated with 
minimal changes in glycolysis and glycogen synthesis and was strongly linked with an 
increase in G6PDH, the rate limiting enzyme in the PPP.  The production of reducing 





Chapter 4:  
Delayed Administration of the MEK/ERK Inhibitor GSK1120212 
Attenuates Systemic Inflammatory Responses and Multi-Organ Injury 
Following Cecal Ligation and Puncture in Mice 
ABSTRACT 
Sepsis-induced organ injury is a consequence of both direct and indirect effects of 
innate immune system activation by infectious organisms.  The MEK/ERK signaling 
pathway has been identified as an essential target of innate immunity necessary for 
mediating pro-inflammatory responses in the setting of sepsis.  We previously 
demonstrated that a potent and specific inhibitor of MEK1/2, GSK1120212, prevents 
endotoxin-induced renal injury in mice, indicating that the MEK/ERK signaling cascade 
may represent a novel therapeutic target in sepsis-induced AKI and organ dysfunction. 
We assessed efficacy of GSK1120212 in a more clinically relevant experimental model 
of sepsis induced by cecal ligation and puncture (CLP) in mice.  GSK1120212 inhibition 
of MEK/ERK signaling 6 h after CLP attenuated increases in circulating pro-
inflammatory cytokines (TNF-α, IL-1β, IL-6, and GM-CSF) and hypothermia at 18 h.  
GSK1120212 also attenuated multi-organ injury as determined by clinical markers serum 
creatinine, alanine aminotransferase, lactate dehydrogenase, and creatine kinase.  At the 
organ level, GSK1120212 post-treatment completely restored peritubular capillary 
perfusion in the kidney.  Restoration of microvascular perfusion in the renal cortex was 
associated with reduced mRNA expression of well-characterized markers of proximal 
tubule injury including KIM-1, NGAL, and HO-1.  MEK/ERK blockade attenuated CLP-
mediated up-regulation of cytokines (TNF-α, IL-1β, IL-6) in the renal cortex, indicating 




pro-inflammatory response in sepsis.  Taken together, these data reveal that the 
MEK/ERK inhibitor GSK1120212 attenuates systemic inflammation, and multi-organ 
damage in a clinically relevant model of sepsis, even with delayed administration.  
Because GSK1120212 has been used safely and effectively used in humans, we propose 
that this drug might represent a readily translatable approach to limit organ injury in 





Sepsis is a leading cause of morbidity and mortality in the intensive care setting 
(56, 57, 59).  The clinical course in septic patients is often complicated by dysfunction of 
multiple vital organs including the kidneys, lung, liver, and brain (372, 373).  Acute 
kidney injury (AKI) develops in up to 60% of patients diagnosed with sepsis or septic 
shock, and septic AKI is associated with an extremely high risk of mortality (~70%) 
(298, 374, 375).  Clinical management of sepsis remains limited to non-specific 
supportive care aimed at maintaining organ homeostasis and preventing further infection 
(376).  Although recent initiatives to implement early, goal-directed measures have 
shown modest benefits in septic patients, mortality resulting from this condition remains 
unacceptably high (68, 377).  Thus, development of novel therapeutics that directly target 
organ injury and dysfunction remains a top priority in sepsis research. 
 Organ insult in the setting of sepsis is initiated by activation of pattern recognition 
receptors (PRRs), including the Toll-like receptors (TLRs), by pathogen-associated 
molecular patterns (PAMPs) derived from the causative organism(s).  Activation of TLRs 
expressed on immune cells (including dendritic cells, macrophages, neutrophils, and B 
lymphocytes), endothelial cells, and epithelial cells leads to an overwhelming systemic 
response characterized by production of acute phase cytokines (TNF-α, IL-1β, and IL-6), 
chemokines, and other pro-inflammatory mediators (82).  Development of AKI involves 
combined local and peripheral effects of these factors, which ultimately contribute to 
microvascular dysfunction and direct tubular injury in the septic kidney (155).  The 




MAPKs are a major downstream target of TLRs and other PRRs responsible for 
induction of inflammatory signaling (89, 378, 379).   
ERK1/2 are serine/threonine kinases that regulate a variety of cellular processes 
including survival, differentiation, migration, proliferation, transcription, and metabolism 
via phosphorylation of a vast array of target proteins (380).  Canonical ERK1/2 signaling 
is initiated by binding of growth factors (VEGF, IGF-1, EGF) to their respective receptor 
tyrosine kinases (RTKs) leading to downstream activation of the Ras/Raf/MEK/ERK 
pathway.  However, more recent evidence indicates that other cellular signaling entities, 
including TLRs, also activate ERK1/2.  TLR4 stimulation by lipopolysaccharide (LPS), a 
critical mediator of gram-negative sepsis, increases ERK1/2 activity in macrophages by 
engaging the tumor progression locus-2 (TPL-2)/mitogen activated protein kinase kinase-
1/2 (MEK1/2)/ERK1/2 cascade.  ERK1/2 activation in this context plays a critical role in 
mediating the immune response to PAMPs by increasing transcription and translation of 
pro-inflammatory cytokines (TNF-α, IL-1β) and chemokines (CXCL2) in multiple cell 
types (310-312, 381, 382). Despite considerable evidence linking MEK/ERK signaling to 
innate immunity, studies investigating this pathway as a potential therapeutic target for 
prevention of unchecked inflammation and organ dysfunction in the setting of sepsis are 
lacking.  
We recently demonstrated that the FDA-approved MEK1/2 inhibitor 
GSK1120212 (also known as trametinib or JTP-74057) attenuates renal injury following 
systemic LPS exposure in mice (142). Pharmacological blockade of MEK/ERK signaling 
reversed endotoxin-induced increases in blood urea nitrogen (BUN) and mRNA 




both 3 and 18 h time points.  Restoration of renal function following GSK1120212 
administration was associated with decreased expression of TNF-α and IL-1β transcripts 
in the renal cortex, further suggesting that MEK/ERK signaling may regulate organ-
specific inflammatory responses in this model.   
A subsequent study by Shi-Lin et al. showed that GSK1120212 significantly 
inhibits LPS-induced TNF-α production in mouse primary bone marrow-derived 
macrophages and human peripheral blood mononuclear cells (PBMCs) (383).  In 
addition, MEK/ERK inhibition prevented mortality resulting from co-administration of 
LPS and the sensitizing agent D-galactosamine in mice in association with decreased 
levels of circulating TNF-α (383).   Since GSK1120212 has been safely used in the clinic, 
these findings suggest that targeted MEK/ERK inhibition may have translational potential 
as a novel therapy for sepsis-induced AKI and organ dysfunction in humans (384-386). It 
should be noted that clinical relevance of endotoxin models in rodents is limited due to a 
number of differences from human sepsis.  Most importantly, systemic LPS exposure in 
mice leads to a massive, transient increase in serum pro-inflammatory cytokine levels 
(TNF-α, IL-1β, IL-6) whereas elevations in these cytokines are more protracted and 
several orders of magnitude lower in septic humans (387). In addition, therapies that have 
shown promise in experimental endotoxin models including inhibitors of TNF-α and IL-1 
have largely failed to improve mortality and other secondary outcome measures in 
clinical trials for sepsis likely due in part to the differences noted above. 
The purpose of the current study was to evaluate efficacy of the MEK/ERK 
inhibitor GSK1120212 in a clinically relevant model of sepsis induced by cecal ligation 




at 6 h following CLP attenuated the systemic inflammatory response and development of 
hypothermia.  GSK1120212 administration also prevented development of AKI and 
mutliple organ injury in CLP animals.  In the kidney, MEK/ERK inhibition restored 
microvascular perfusion and reduced expression of the tubular injury markers including 
kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), 
and heme oxygenase-1 (HO-1) at the mRNA level.  The renoprotective effects of 
GSK1120212 were associated with decreased renal expression of pro-inflammatory 
cytokines including TNF-α, IL-1β, and IL-6. Taken together, our data provide evidence 
that the FDA-approved MEK/ERK inhibitor GSK1120212 may be a viable drug to 






Mouse Cecal Ligation and Puncture Model of Sepsis  
 Male C57BL/6 mice aged 40 weeks were obtained from Harlan Laboratories 
(Indianapolis, IN).   Cecal ligation and puncture was performed as previously described 
(109, 159).  Briefly, 1.5 cm of the cecum was isolated and ligated with a 4-0 silk suture 
under isoflurane anesthesia after midline laparotomy.  The ligated cecum was then 
punctured with a 21-gauge needle and gently pressed to produce a ~1 mm column of 
fecal material from each puncture site.  Sham animals underwent midline laparotomy 
followed by isolation of the cecum, but the cecum was not ligated or punctured.  Mice 
were treated with imipenem/cilastatin (14 mg/kg) and 1.5 ml of warm saline (40 ml/kg) at 
6 h post-CLP.  Mice were euthanized 18 h after CLP and kidneys and serum were 
collected for analysis.   All experiments were carried out in accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health.  Animal use was approved by the Institutional Animal Care 
and Use Committee at the University of Arkansas for Medical Sciences.   
Administration of GSK1120212  
 GSK1120212 (Selleckchem, Houston, TX) was formulated in vehicle solution 
containing 1% DMSO in Neobee M-5 (Spectrum Chemical, New Brunswick, NJ) (388).   
GSK1120212 is a specific and potent allosteric inhibitor of MEK1/2 signaling that has 
been used in animal models and humans (304, 305, 389, 390).  Mice were treated with 1 
mg/kg GSK1120212 or an equal volume of vehicle solution via intraperitoneal (i.p.) 




Determination of Circulating Cytokine Levels  
 Measurement of serum levels of TNF-α, IL-1β, IL-6 and GM-CSF was performed 
using the Inflammatory Cytokine Mouse Magnetic 4-Plex Panel for the Luminex 
platform (Life Technologies, Grand Island, NY). Detection of cytokines was performed 
using a Bio-Rad Bio-Plex 200 system (Bio-Rad Laboratories, Hercules, CA) and 
quantified using a standard curve and protein standards supplied in the kit.  For values 
that fell below the lower limit of detection of the assay in sham animals, values were 
recorded as the lower limit (TNF-α – 22.4 pg/ml; IL-1β – 28.1 pg/ml; IL-6 – 9.8 pg/ml; 
GM-CSF – 16.06 pg/ml).      
Intravital Microscopy and Assessment of Peritubular Capillary Perfusion  
 To assess changes in renal microcirculation after CLP, intravital video 
microscopy was performed as previously described (109, 135).  Mice were anesthetized 
with isoflurane and FITC-labeled dextran (2 µmol/kg in 3 ml/kg normal saline) was 
injected via the penile vein to visualize microvascular flow.  After 10 minutes, the left 
kidney was exposed by a flank incision and placed on a glass stage above an inverted 
Zeiss Axiovert 200M fluorescent microscope with an Axiocam HSm camera (Zeiss, Jena, 
Germany).  Ten second videos were acquired at ~30 frames per second from five 
randomly selected, non-overlapping fields for each animal.  Core body temperature was 
maintained at 35-37°C with a heating lamp.  Roughly 150 capillaries from each animal 
were selected for analysis and categorized into three categories based on the degree of 
perfusion as follows: “continuous flow” where red blood cell movement was 
uninterrupted throughout the video; “intermittent flow” where red blood cell movement 




movement was observed throughout the video.  Data are shown as percentage (mean ± 
S.E.M.) of vessels in each category.    
Serum Chemistries  
Blood urea nitrogen (BUN) was measured using the QuantiChrom Urea Assay kit 
as directed by the manufacturer (BioAssay Systems, Hayward, CA).  Serum creatinine 
(SCr) was assessed using the Creatinine Enzymatic Reagent Set based on the provided 
protocol (Pointe Scientific, Canton, MI).  Alanine aminotransferase (ALT), creatine 
kinase (CK), and lactate dehydrogenase (LDH) were measured using standard 
biochemical assay kits from BioVision (Milpitas, CA) as directed.      
Quantitative Real-Time PCR Analysis of Gene Expression  
 Total RNA was extracted from renal cortex tissue samples using the TRIzol 
reagent (Life Technologies).  One microgram of total RNA was reversed transcribed into 
a cDNA library using the iScript Advanced cDNA Synthesis Kit for quantitative real-
time polymerase chain reaction (qRT-PCR) based on the manufacturer’s protocol (Bio-
Rad).  qRT-PCR was then performed with the synthesized cDNA using SsoAdvanced 
Universal SYBR Green Supermix (Bio-Rad).  Relative mRNA content for all genes of 
interest was calculated by the 2-ΔΔCt method as previously described using β-actin as a 









Table 4-1: Primer sequences for RT-qPCR 
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Immunoblot Analysis  
 Protein was isolated from the renal cortex in radioimmunoprecipitation assay 
(RIPA) buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 
1% Triton X-100, pH 7.4) containing protease inhibitor cocktail (1:100), 1 mM sodium 
fluoride, and 1 mM sodium orthovanadate (Sigma-Aldrich, St. Louis, MO).  Protein 
quantification was performed using the BCA protein assay.  Equal quantities of protein 
were loaded onto 4-15% SDS-PAGE gels (Bio-Rad) and resolved by gel electrophoresis. 
Primary antibodies used for this study included phospho-ERK1/2 (Thr202/Tyr204, 
1:1000) and total ERK1/2 (1:1000, Cell Signaling Technology, Danvers, MA), and β-
Actin (1:1000, Santa Cruz Biotechnology, Dallas TX). Proteins of interest were imaged 
using enhanced chemiluminescence (ECL) reagents and the GE ImageQuant LAS4000 
digital imaging system (GE Life Sciences, Pittsburgh, PA).  Optical densitometry was 
performed using NIH ImageJ software (version 1.46). 
Statistical Analysis  
 All data are presented as mean ± S.E.M. A one-way analysis of variance 
(ANOVA) followed by Neuman-Keuls post hoc test was performed for statistical 
comparisons.  A P value less than 0.05 was considered statistically significant.  All 
statistical tests were completed using GraphPad Prism software (GraphPad Software, San 





RESULTS            
GSK1120212 Reverses CLP-induced Systemic Inflammatory Cytokine Production 
and Hypothermia 
 Because MEK/ERK signaling is thought to be necessary for generation of pro-
inflammatory cytokines in response to innate immune system activation in sepsis, we first 
determined effects of GSK1120212 on the systemic inflammatory response following 
CLP in mice using the Luminex platform to measure serum TNF-α, IL-1β, IL-6, and GM-
CSF (383).  Serum levels of TNF-α were below the lower limit of detection (22.4 pg/ml) 
in sham animals, but rose after CLP (~400 pg/ml).  Interestingly, post-treatment with 
GSK1120212 at 6 h after CLP induction significantly attenuated (~50%) the increase in 
TNF-α (Figure 4-1A).  In a similar manner, serum levels of IL-1β, IL-6, and GM-CSF 
were elevated in mice subjected to CLP.  Delayed MEK/ERK inhibition by GSK1120212 
partially reduced these circulating pro-inflammatory cytokines at 18 h post-CLP (Figure 
4-1B,C,D).     
In addition, we measured core body temperature as a secondary index of the 
systemic response.  Development of hypothermia is strongly correlated with 
physiological dysfunction and mortality in the CLP model (391, 392).  At 6 hours after 
CLP, both CLP + vehicle and CLP + GSK1120212 animals had markedly reduced core 
body temperatures (~7°C decrease) in comparison to vehicle-treated sham controls 
(Figure 4-2).  GSK1120212 did not have a significant effect on body temperature at 18 h 
in sham animals.  However, post-treatment with this drug completely attenuated CLP-
induced hypothermia (Figure 4-2).  Taken together, these data indicate that GSK1120212 




Figure 4-1: Delayed MEK/ERK inhibition partially attenuates pro-inflammatory 
cytokine production after CLP.   Male C57BL/6 mice were treated with the MEK/ERK 
inhibitor GSK1120212 (1 mg/kg, i.p.) at 6 h post-CLP or sham surgery and euthanized 18 
hr after CLP. Serum was collected and circulating levels of the pro-inflammatory 
cytokines TNF-α (A), IL-1β (B), IL-6 (C), and GM-CSF (D) were determined using a 
multiplex Luminex assay (n ≥ 6 per group). For animals that fell below the lower limit of 
detection of the assay in sham animals, values were recorded as equal to the lower limit 
(TNF-α – 22.4 pg/ml; IL-1β – 28.1 pg/ml; IL-6 – 9.8 pg/ml; GM-CSF – 16.06 pg/ml).  
Data are expressed as mean ± S.E.M. for each group.  Different superscripts above bars 





Figure 4-2: GSK1120212 post-treatment reverses CLP-induced hypothermia. Core 
body temperature in CLP mice receiving either GSK1120212 (1 mg/kg, i.p.) or the 
appropriate vehicle was monitored via a rectal temperature probe.  Data are presented as 
mean ± S.E.M. for each group (n ≥ 6 per group). *p < 0.05 vs. time-point sham control; 







GSK1120212 Post-treatment Partially Attenuates AKI and Multiple Organ Injury 
After CLP  
 Given that MEK/ERK inhibition effectively blocked the systemic inflammatory 
response, we assessed the effects of GSK1120212 on organ/cellular damage following 
CLP. SCr and BUN, used as measures of renal dysfunction, increased 2-fold and 4-fold, 
respectively 18 h post-CLP when compared to sham controls (Figure 4-3A,B).  Post-
treatment with GSK1120212 at 6 h completely reversed the CLP-induced rise in SCr, but 
had no effect on BUN (Figure 4-3A,B).  In addition, we measured serum markers of 
hepatic (ALT), skeletal muscle/myocardial (CK), and general cellular damage (LDH) to 
further evaluate the efficacy of GSK1120212 in sepsis.  CLP resulted in elevations in 
ALT (~5.4-fold), CK (~6.7-fold), and LDH (~4-fold) at 18 h (Figure 4-3C,D,E). These 
findings are consistent with previous reports of multi-organ injury following CLP in mice 
(104, 159).  Importantly, delayed GSK1120212 administration partially attenuated 
increases in hepatic (ALT), skeletal muscle/myocardial (CK), and cellular damage (LDH) 
after CLP (Figure 4-3C,D,E).  These findings reveal that MEK/ERK blockade decreases 





Figure 4-3: GSK1120212 post-treatment decreases CLP-induced organ injury.  
Serum creatinine (A), blood urea nitrogen (B), alanine aminotransferase (C), creatine 
kinase (D), and lactate dehydrogenase (E) were assessed at 18 h after CLP or sham 
surgery as indicators of organ and cellular injury.  Data are shown as mean ± S.E.M. for 
each group (n ≥ 5 animals per group).  Different superscripts above bars indicate 




Effects of Delayed GSK1120212 Administration on Renal Peritubular Capillary 
Perfusion Following CLP  
 Microvascular dysfunction is a common contributor to sepsis-induced organ 
injury, including AKI, and is thought to occur secondary to cytokine-induced disruption 
of endothelial cell integrity (393-395).  In particular, a marked reduction in renal 
peritubular capillary perfusion has been noted in multiple experimental models of sepsis 
in association with development of local areas of hypoxia and oxidative stress (135, 393, 
396).  We next determined the effects of GSK1120212 on microvascular perfusion in the 
kidney following CLP using intravital video microscopy.  A significant decrease in the 
portion (~50%) of peritubular capillaries with continuous red blood cell flow was noted 
in mice subjected to CLP along with a concomitant increase in capillaries classified by 
continuous (~10%) or no flow (~30%) (Figure 4-4).  Interestingly, GSK1120212 
administration at 6 h post-CLP completely reversed the deficiencies in peritubular 
capillary perfusion described above.  These data indicate that MEK/ERK inhibition by 
GSK1120212 may protect the renal microvasculature and improve perfusion after CLP 





Figure 4-4: Effects of GSK1120212 on alterations in peritubular capillary perfusion 
following CLP.  Peritubular capillary perfusion was assessed by intravital video 
microscopy (IVVM) in sham and CLP mice treated with GSK1120212 or vehicle as 
described above.  The observed microvasculature was classified based on degree of 
perfusion as having “continuous,” “intermittent,” or “no flow.”  A significant reduction in 
the percentage of peritubular capillaries with continuous flow, along with an increase in 
vessels with intermittent or no flow was observed after CLP.  GSK1120212 post-
treatment completely reversed CLP-induced deficiencies in peritubular capillary 
perfusion.  Data are expressed as percentage of peritubular capillaries in each category  
(mean ± S.E.M.).  Different superscripts above bars indicate statistically significant 




GSK1120212 Partially Prevents Endothelial Cell Activation After CLP 
 Endothelial cell activation and subsequent expression of adhesion molecules plays 
an important role in microvascular dysfunction and immune cell infiltration in the septic 
kidney (322).  Since GSK1120212 prevented CLP-induced disruption of microvascular 
flow in the kidney, we next questioned whether MEK/ERK inhibition alters endothelial 
cell activation in this model.  To address this question, we measured expression of 
endothelial cell adhesion molecules including intracellular adhesion molecule-1 (ICAM-
1) and E-selectin at the mRNA level by qPCR.  Transcript levels of ICAM-1 and E-
selectin increased approximately 8-fold and 22-fold, respectively, at 18 h post-CLP 
(Figure 4-5A,B).  GSK1120212 administration did not alter expression of either of these 
markers, although there was a non-significant trend toward increased E-selectin in the 
CLP + GSK1120212 group (Figure 4-5A,B).   
In order to further assess the effects of GSK1120212 on endothelial cell 
activation, we also measured protein levels of ICAM-1 in renal cortical tissue by 
immunoblot analysis.  A modest, but significant increase (~1.5-fold) in ICAM-1 was 
observed in vehicle-treated CLP mice at 18 h (Figure 4-5C).  Interestingly, ICAM-1 
protein expression returned to control levels in CLP animals treated with GSK1120212 
(Figure 4-5C).  These data indicate that blockade of MEK/ERK signaling may partially 





Figure 4-5: Pharmacological blockade of MEK/ERK has modest effects on 
endothelial cell activation in the renal cortex.  Total RNA and protein were isolated 
from renal cortical tissues at 18 h after CLP in order to analyze markers of endothelial 
cell activation.  mRNA expression of ICAM-1 (A) and E-selectin (B) were determined by 
RT-qPCR.  Immunoblot analysis of ICAM-1 protein levels (C and D) revealed minor 
effects of GSK1120212 on endothelial cell activation after CLP. Data are shown as fold-
change relative to sham + vehicle controls (mean ± S.E.M.; n ≥ 6 per group). Different 




Effects of GSK1120212 Post-treatment on CLP-induced Renal Proximal Tubular 
Injury   
 Given that inhibition of the MEK/ERK pathway by GSK1120212 restored renal 
microvascular perfusion after CLP induction and that microvascular dysfunction plays an 
essential role in development of AKI in the setting of sepsis, we next investigated the 
effects of this pharmacological intervention on renal proximal tubule cell injury.  
Expression of well-characterized markers of tubular insult including kidney injury 
molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and heme 
oxygenase-1 (HO-1) were first assessed in the renal cortex by qPCR (37, 43, 397).  When 
compared to sham controls, a robust increase in KIM-1 mRNA content (~83-fold) was 
observed in the renal cortex following CLP (Figure 4-6A).   Treatment of CLP animals 
with GSK1120212 reduced KIM-1 transcript levels by approximately 52% (Figure 4-
6A).  Likewise, delayed MEK/ERK inhibition significantly reduced CLP-mediated 
induction of NGAL (~44% decrease vs. CLP + vehicle group) and HO-1 (~54% 
decrease) (Figure 4-6B,C).  Although GSK1120212 had significant effects on 
transcriptional up-regulation of tubular injury markers, no changes were noted in renal 
cortical KIM-1 and NGAL protein levels in drug-treated animals at 18 h post-CLP when 
assessed by immunoblot analysis (Figure 4-7A,B).  It should be noted, however, that 
there was considerable variability in KIM-1 and NGAL proteins in both CLP + vehicle 
and CLP + GSK1120212 treatment groups.  Taken together, these findings suggest that 
pharmacological targeting of the MEK/ERK signaling cascade may partially ameliorate 





Figure 4-6: Delayed GSK1120212 administration attenuates transcriptional up-
regulation of tubular injury markers in the renal cortex after CLP.  Total RNA was 
isolated from the renal cortex of mice treated with GSK1120212 or vehicle control after 
CLP or sham surgery.  Transcript levels of markers of proximal tubular injury including 
KIM-1 (A), NGAL (B), and HO-1 (C) were determined by qPCR analysis.  Data are 
shown as fold change relative to sham + vehicle animals (mean ± S.E.M.; n ≥ 5 mice per 
experimental group.  Superscripts above bars indicate statistically significant differences 




Figure 4-7: MEK/ERK inhibition by GSK1120212 has no effect on renal cortical 
KIM-1 and NGAL protein content. Protein levels KIM-1 (A) and NGAL (B) in the 
renal cortex were determined by immunoblot analysis at 18 h in sham and CLP animals.  
β-actin was used as a loading control for normalization of densitometry.  Data are 
presented as mean ± S.E.M. for each group (fold change relative to sham control; n = 6 
mice per group).  Different superscripts above bars indicate statistically significant 




 MEK/ERK Inhibition Does Not Alter ROS/RNS Generation in the Proximal 
Tubule Following CLP 
 As shown above, treatment with GSK1120212 restored renal peritubular capillary 
perfusion and partially attenuated proximal tubular injury following CLP in mice.  In 
order to further elucidate the mechanisms by which MEK/ERK inhibition protects the 
proximal tubule, we next assessed oxidative stress in the renal cortex using intravital 
video microscopy to detect oxidation of dihydrorhodamine-123 to rhodamine as an index 
of ROS/RNS generation.  Faint rhodamine fluorescence was observed in sham animals 
(Figure 4-8).  Fluorescence intensity was significantly elevated (~6-fold) at 18 h 
following CLP, indicating an increase in oxidative stress in the proximal tubule. 
However, contrary to our expectations, GSK1120212 administration at 6 h post-CLP had 
no effect on rhodamine fluorescence (Figure 4-8).  Thus, GSK1120212-mediated 
protection of the proximal tubule after CLP is not associated with a reduction in tubular 















Figure 4-8: GSK1120212 post-treatment does not attenuate CLP-induced oxidative 
stress in the renal proximal tubule. CLP mice were treated with either vehicle or 
GSK1120212 at 6 h post-CLP as described above.  Oxidative stress was assessed using 
intravital video microscopy to quantify oxidation of dihydrorhodamine-123 to rhodamine 
as an index of tubular ROS/RNS generation.  Data are expressed as arbitrary units (A.U.) 
of rhodamine fluorescence per µm2 (mean ± S.E.M.; n ≥ 5 per group).  Superscripts above 





GSK1120212 Attenuates Up-regulation of Pro-inflammatory Cytokines in the Renal 
Cortex After CLP  
 In addition to oxidative stress, direct effects of pro-inflammatory cytokines (TNF-
α, IL-1β) on the proximal tubule also play an important role in development of sepsis-
induced AKI (134, 140, 142).  Given that pharmacological blockade of MEK/ERK had 
no effect on oxidative stress generation in the proximal tubule, we next questioned 
whether GSK1120212-mediated attenuation of tubular injury in the CLP model might be 
associated with a decrease in inflammatory changes in the renal cortex.  In order to 
answer this question, we measured renal cortical mRNA expression of pro-inflammatory 
cytokines by qPCR analysis.  Transcript levels of TNF-α, IL-1β, and IL-6 increased  
~3.4-, 3.5-, and 74-fold, respectively, in the renal cortex in CLP animals when compared 
to their sham controls (Figure 4-9A,B,C).  Delayed treatment with GSK1120212 at 6 h 
post-CLP either fully (TNF-α) or partially (IL-1β, IL-6) attenuated these changes (Figure 
4-9A,B,C).  Taken together, these data indicate that MEK/ERK signaling is essential for 
up-regulation of pro-inflammatory cytokines in the renal cortex following CLP.  In 
addition, inhibition of MEK/ERK-mediated renal cortical inflammatory changes is 





Figure 4-9: MEK/ERK signaling mediates renal expression of pro-inflammatory 
cytokines after CLP.  Inflammatory changes were evaluated in the renal cortex of CLP 
mice treated with GSK1120212 (1 mg/kg, i.p.) as described above.  qPCR was used to 
determine mRNA levels of TNF-α (A), IL-1β (B) and IL-6 (C) at 18 h post-CLP.  Values 
are expressed as relative expression vs. control (mean ± S.E.M.) for n ≥ 6 / group (p < 





MEK/ERK Inhibition Does Not Reverse Suppression of Renal PGC-1α and 
Subsequent Mitochondrial Biogenesis Following CLP 
 Our laboratory and others have previously demonstrated suppression of PGC-1α 
and subsequent mitochondrial biogenesis in multiple experimental models of AKI (274, 
279).  In addition, we recently showed that MEK/ERK signaling is required for acute (< 3 
h) disruption of PGC-1α expression and mitochondrial biogenesis in the kidney following 
systemic exposure to lipopolysaccharide (LPS), another model of sepsis-induced AKI.  
Thus, we next investigated whether reduced tubular injury following GSK1120212 
administration might be associated with restoration of renal proximal tubule cell 
mitochondrial biogenesis in the CLP model.  Renal cortical mRNA expression of PGC-
1α was significantly reduced (~80%) at 18 h in mice subjected to CLP compared to sham 
controls (Figure 4-10A).  In addition, transcription of downstream targets of PGC-1α 
including nuclear-encoded components of the ETC (NDUFS1) and mitochondrial-
encoded ETC proteins (ND1) were decreased following CLP (Figure 4-10C,E).  CLP did 
not have an effect on TFAM or COX1 mRNAs in vehicle-treated mice (Figure 4-10B,D).  
Interestingly, GSK1120212 treatment did not restore expression of PGC-1α or its 
downstream targets.  In fact, transcript levels of TFAM, COX1, and ND1 were 
significantly lower in the CLP + GSK1120212 group when compared to CLP + vehicle 
animals (Figure 4-10B,D,E).  These findings provide strong evidence that delayed 
MEK/ERK blockade by GSK1120212 is insufficient to reverse suppression of PGC-1α 





Figure 4-10: Delayed GSK1120212 therapy has no effect on CLP-mediated 
suppression of PGC-1α and mitochondrial biogenesis.  Sham and CLP mice were 
treated with GSK1120212 or the appropriate vehicle at 6 h as described above.  
Transcript levels of PGC-1α (A) and downstream targets in mitochondrial biogenesis 
including TFAM (B), NDUFS1 (C), COX1 (D), and ND1 (E) were determined in renal 
cortical samples using qPCR analysis.  Data are mean ± S.E.M. (n ≥ 6 per experimental 






Sepsis is defined as an unchecked inflammatory response resulting from 
activation of the innate immune system in the presence of infection (136).   Clinically, 
sepsis is associated with significant mortality and morbidity characterized by injury to 
multiple organ systems (104, 372, 396).   Innate immune system activation in the setting 
of sepsis is largely mediated through activation of PRRs by microbial products 
collectively referred to as pathogen-associated molecular patterns (PAMPs).  Stimulation 
of PRRs initiates signaling through a variety of downstream targets that act to promote 
the pro-inflammatory response including multiple MAPK signaling pathways involving 
MEK/ERK, JNK, and p38 MAPKs (378, 379).   
Although members of the JNK and p38 MAPK families have classically been 
implicated in the host response to infection, more recent evidence suggests that 
MEK/ERK signaling may control multiple aspects of the pro-inflammatory state 
associated with sepsis.  Exposure of macrophages to lipopolysaccharide (LPS), a classical 
TLR4 agonist, has been shown to activate the MEK/ERK cascade in vitro (381, 383). 
MEK/ERK signaling is required for transcriptional up-regulation of TNF-α and IL-1β in 
certain populations of LPS-treated macrophages (381, 383, 398). In addition, ERK 
activation in response to LPS in macrophages promotes nucleocytoplasmic transport and 
subsequent translation of TNF-α mRNA, indicating that the MEK/ERK signaling 
pathway may facilitate TNF-α biosynthesis by both transcriptional and post-
transcriptional mechanisms (310).  The molecular machinery necessary for stimulation of 
the MEK/ERK cascade in response to LPS includes TLR4 and its downstream effector 




MEK.  Interestingly, TPL-2 is essential for endotoxin-induced TNF-α production in 
macrophages, and TPL-2-deficient mice are significantly protected against lethality 
following systemic administration of LPS and D-galactosamine (310).  These data 
suggest that the MEK/ERK signaling pathway represents a novel and viable therapeutic 
target for the treatment of sepsis and sepsis-induced organ dysfunction.  Unfortunately, 
studies that directly target MEK/ERK in animal models of sepsis are lacking.  
 We recently used the potent and specific MEK1/2 inhibitor GSK1120212 in a 
mouse model of endotoxin-induced AKI.  Administration of GSK1120212 (1 mg/kg, i.p.) 
inhibited LPS-induced phosphorylation of ERK1/2 in the renal cortex, indicating that in 
vivo administration of low dose GSK1120212 is sufficient to block this signaling cascade 
in the LPS model (142).   GSK1120212 pre-treatment at 1 h before systemic LPS 
exposure in mice attenuated early (< 3 h) development of renal dysfunction as measured 
by BUN.  Preservation of renal function by MEK/ERK blockade was associated with 
reduced expression of KIM-1, a well-characterized marker of proximal tubule injury, and 
pro-inflammatory cytokines (TNF-α, IL-1β) in the renal cortex of LPS-treated mice 
(142). A subsequent study demonstrated that MEK/ERK inhibition by GSK1120212 also 
blocked TNF-α production in macrophage cell lines and isolated human PBMCs exposed 
to LPS in vitro (383).  GSK1120212 treatment also prevented death of mice exposed to 
LPS and D-galactosamine in association with a reduction in circulating levels of TNF-α 
(383).   
GSK1120212 is a highly potent allosteric inhibitor with IC50 values of 0.92 nM 
and 1.8 nM for MEK1 and MEK2, respectively in an in vitro protein kinase assay (304).  




activity seen on a panel of over 100 kinases including other members of the MAPK 
family (304). GSK1120212 has been safely and effectively used in humans and recently 
received FDA approval as a chemotherapeutic agent for use in BRAF-mutant melanoma 
(384-386).  Thus, this drug has a number of favorable properties that make it an ideal 
candidate for clinical use in sepsis.  However, the endotoxin models used to date to 
evaluate efficacy of GSK1120212 suffer from a number of severe limitations. Studies 
delivered this compound either before or concurrent with LPS administration which 
would not be feasible in the clinical setting.  In addition, neither study employed 
supportive measures commonly used in the intensive care unit such as fluid replacement, 
broad-spectrum antibiotics, and/or vasopressor agents (78).  It should also be noted that 
the inflammatory response to LPS in mice is much more rapid and of a higher magnitude 
than that observed in septic humans (387).  These fundamental differences likely explain 
why therapies developed using endotoxin models (such as anti-TNF-α agents) have 
largely failed to improve outcomes in septic patients (399).  Thus, we sought to determine 
the efficacy of GSK1120212 in attenuating systemic inflammatory responses and organ 
injury in a more clinically relevant model of sepsis. 
We employed a well-established sepsis model induced by cecal ligation and 
puncture (CLP) in mice.  CLP is widely considered the “gold standard” of sepsis models 
because it produces a much lower grade and sustained pro-inflammatory response when 
compared to LPS models (77).  The model used here also incorporates supportive 
measures commonly used in the clinic including a broad-spectrum β-lactam antibiotic 
(imipenem/cilastatin) and fluid resuscitation with saline in aged mice to better reflect the 




chose to delay GSK1120212 administration until 6 h post-CLP, a time when organ injury 
and microvascular dysfunction is already established (104, 135, 159).   
Delayed inhibition of MEK/ERK signaling attenuated CLP-induced increases in 
all pro-inflammatory cytokines measured including TNF-α, IL-1β, IL-6, and GM-CSF.  
Among these, the most significant inhibitory effect was observed on TNF-α.  These 
findings are consistent with earlier studies demonstrating that MEK/ERK signaling is 
required for maximal induction of TNF-α synthesis in immune cells exposed to TLR 
agonists (310, 318, 378, 383, 400).  Interestingly, serum levels of TNF-α, IL-1β, and IL-6 
may all serve as reliable predictors of mortality resulting from sepsis in the clinical 
setting, and IL-6 appears to be the single best predictor of poor outcomes in septic 
patients (401, 402).  In addition, IL-6 has been validated as a marker of disease burden 
following CLP in mice (102).  The observed decreases in circulating pro-inflammatory 
cytokines in CLP animals treated with GSK1120212 likely indicate reduced disease 
severity.  These findings suggest that MEK/ERK inhibition may prevent CLP-induced 
mortality, although we did not assess this outcome.  In support of this, GSK1120212 also 
reversed development of hypothermia, a widely used indicator of physiologic dysfunction 
and impending death in septic mice (391, 392). 
Reducing systemic pro-inflammatory cytokines alone may have significant effects 
on organ dysfunction in the setting of sepsis.  Cunningham et al. elegantly demonstrated 
that LPS-induced AKI is mediated by TNF-α acting on TNF receptor 1 (TNFR1) 
expressed on renal cells (140).  Administration of a single dose of recombinant TNF-α is 
sufficient to cause AKI and subsequent renal dysfunction in rodents (141, 142).  Similar 




that commonly become dysfunctional in sepsis including the liver and the lung (403, 
404). Thus, it is important to note that the systemic effects of MEK/ERK inhibition may 
be beneficial in for preventing injury and dysfunction in multiple organ systems.  
As discussed above, multiple organ dysfunction syndrome (MODS) is a common 
consequence of sepsis, and injury to multiple organs including the kidney, lungs, liver, 
and skeletal/cardiac muscle contributes to morbidity and mortality resulting from this 
disease. Our previous study demonstrated that GSK1120212 attenuates early changes in 
renal dysfunction and proximal tubular injury after endotoxin administration in mice.  We 
therefore examined organ/cellular injury in the CLP model to better demonstrate efficacy 
of this drug in sepsis.  Delayed GSK1120212 administration reversed renal dysfunction 
as assessed by changes in SCr after CLP.  However, there was no change in BUN in 
GSK1120212-treated animals. Reasons for the observed discrepancy in SCr and BUN are 
unclear.  It should be noted that BUN can be altered by a number of extrarenal factors in 
sepsis including increased protein catabolism, glucocorticoid production, and 
extracellular fluid volume (405).  In addition, the change in BUN after CLP may also 
reflect increased tubular reabsorption of urea rather than glomerular filtration rate (GFR).  
GSK1120212 also had protective effects on clinical markers of injury to the liver (ALT), 
skeletal/cardiac muscle (CK), and general cellular injury (LDH).   Taken together, these 
findings indicate that MEK/ERK inhibition by GSK1120212 is effective in preventing 
multiple organ system injury in sepsis.   
For the remainder of our studies, we focused on CLP-induced AKI.  The 
pathophysiology of sepsis-induced AKI and is complex and multi-factorial in nature.  




peritubular capillary flow, development of local areas of hypoxia and hypoperfusion, and 
increased exposure of the renal parenchyma to circulating pro-inflammatory molecules 
due to reduced flow (124, 125, 155).  There is now strong experimental evidence 
indicating that therapeutic targeting of renal microvascular dysfunction may reverse 
sepsis-induced AKI (109, 132, 406).  As expected, CLP reduced the percentage of 
peritubular capillaries with continuous flow, and this phenomenon occurred in 
conjunction with an increase in the proportion of vessels characterized by intermittent or 
no flow.  Treatment with GSK1120212 completely restored renal microvascular 
perfusion after CLP.  These findings are in agreement with earlier studies demonstrating 
that MEK/ERK signaling plays in an important role in development of increased 
endothelial cell permeability and dysfunction in response to inflammatory insult in vitro 
(407, 408).   
Since pharmacological blockade of the MEK/ERK cascade restored renal 
microvascular perfusion after CLP, we also wondered whether this approach might alter 
vascular endothelial cell activation.  Activated endothelial cells in the kidney contribute 
to sepsis-induced AKI by expressing chemokines and a variety of cellular adhesion 
molecules including ICAM-1 and E-selectin, which together promote infiltration of 
immune cells into renal parenchyma (409).  Mice deficient in either ICAM-1 or E-
selectin are protected from development of renal dysfunction in experimental models of 
sepsis (322, 410).  In order to assess endothelial cell activation, we measured changes in 
renal cortical expression of ICAM-1 and E-selectin after CLP.  MEK/ERK inhibition by 
GSK1120212 had no effect on the robust increases in ICAM-1 and E-selectin transcript 




in ICAM-1 protein levels in CLP mice treated with GSK1120212.  Given the relatively 
minor (~25%) nature of this reduction in ICAM-1 protein expression, the physiological 
relevance of this finding is likely limited.  There remains considerable debate concerning 
the role of MEK/ERK and other MAPK signaling cascades in regulation of cellular 
adhesion molecule expression in response to inflammatory stimuli (411, 412).  However, 
our findings provide strong evidence indicating that ERK signaling plays a relatively 
insignificant role in renal endothelial cell activation in the CLP model of sepsis.   
Restoration of renal microvascular perfusion following treatment with 
GSK1120212 was associated with a reduction in transcriptional up-regulation of multiple 
markers of tubular injury.  In particular, we observed substantial increases in mRNA 
expression of KIM-1, NGAL, and HO-1 in renal cortical tissue at 18 h after CLP, which 
is consistent with previous reports (413).  GSK1120212 treatment partially attenuated 
changes in each of these markers of tubular injury.  These findings are in agreement with 
our previous studies employing MEK/ERK inhibition in the LPS model and suggest that 
inhibition of MEK/ERK signaling may partially prevent insult to the renal proximal 
tubule following sepsis-induced AKI (142).  However, we did not detect changes in renal 
cortical protein levels of KIM-1 or NGAL at 18 h after CLP.  Interpretation of these data 
is difficult given that GSK1120212 was administered only 12 h prior to analysis of 
tubular injury.  It is not clear whether this short time frame would be sufficient to allow 
for the transcriptional changes described above to result in appreciable changes in protein 
levels of KIM-1 and NGAL.  Further studies are necessary to determine whether 
MEK/ERK inhibition might decrease protein expression of KIM-1 and NGAL at later 




We next focused on potential mechanisms responsible for the protective effects 
GSK1120212 on proximal tubule injury following CLP. Given that this drug restored 
microvascular perfusion, we anticipated that MEK/ERK inhibition would attenuate CLP-
induced ROS/RNS generation and oxidative stress in the proximal tubule.  Previous 
studies demonstrated that multiple pharmacological approaches that improve peritubular 
capillary blood flow prevent oxidative injury to the proximal tubule (134, 406). CLP 
robustly increased oxidation of dihydrorhodamine-123 to rhodamine in the proximal 
tubule, indicating that renal oxidative stress was elevated in this model.   However, 
contrary to our expectations, GSK1120212 had no effect on CLP-mediated ROS/RNS 
production.  These findings suggest that the sepsis-induced increase in proximal tubular 
oxidative stress may occur independently of deficits in microvascular function and 
perfusion.  It should be noted that this phenomenon has been previously described (132).  
Since MEK/ERK inhibition had negligible effects on oxidant generation in the 
proximal tubule following CLP, we explored other potential mechanisms underlying 
GSK1120212-mediated protection of the proximal tubule.  In our previous study, pre-
treatment with GSK1120212 partially attenuated local increases in inflammatory 
cytokine (TNF-α, IL-1β) production in the renal cortex at early time points (3 h) after 
systemic endotoxin exposure in mice (142).  Given the well-characterized roles of pro-
inflammatory cytokines in sepsis-induced tubular insult, we hypothesized that the 
protective effects of MEK/ERK inhibition might be associated with reduced production 
of these mediators in the kidney.  GSK1120212 post-treatment fully attenuated CLP-
induced up-regulation of TNF-α in the renal cortex.  Similar effects, though less 




these data suggest that MEK/ERK inhibition prevents local, organ-specific inflammatory 
responses in the setting of sepsis.  In support of this, previous reports have observed a 
reduction in tissue levels of TNF-α, IL-1β, and IL-6 in the lung and liver in CLP mice 
following treatment with the MEK1 inhibitor PD98059 (414).  It is likely that attenuation 
of both systemic and local cytokine production contributes to GSK1120212-mediated 
protection of the proximal tubule after sepsis-induced AKI.  Indeed, treatments aimed at 
reducing renal inflammation have proven beneficial in multiple experimental models of 
AKI (415, 416).  
The MEK/ERK signaling pathway has been identified as a potential negative 
regulator of mitochondrial biogenesis in multiple cell types (244, 245).  In addition, early 
(< 3 h) improvement in renal function following endotoxin-induced AKI in mice treated 
with GSK1120212 was closely associated with restoration of PGC-1α and subsequent 
mitochondrial biogenesis in the renal cortex (142).  Interestingly, MEK/ERK inhibition in 
the CLP model did not promote renal cortical expression of PGC-1α or its downstream 
targets involved in regulation of mitochondrial biogenesis and electron transport chain 
function.  This result is not entirely unexpected given that GSK1120212 had only modest 
effects on PGC-1α and mitochondrial biogenesis at later time points (18 h) after systemic 
LPS exposure in our earlier work (142).  Further studies are necessary to determine 
whether ERK activation plays a similar role in acute suppression of renal mitochondrial 
biogenesis after CLP induction.  However, the data presented here do allow us to rule out 
stimulation of mitochondrial biogenesis as a contributor to GSK1120212-mediated 




In summary, we have demonstrated here that a potent, specific allosteric inhibitor 
of MEK1/2, GSK1120212, reduces the systemic inflammatory response and prevents 
AKI and other organ injury in a clinically relevant model of sepsis induced by CLP in 
mice.  Given the favorable pharmacological properties of GSK1120212 and its recent 
FDA approval, we believe that MEK/ERK inhibition by GSK1120212 may represent a 




             




Chapter 5:  
Summary, Contributions, and Future Directions  
SUMMARY OF CURRENT LITERATURE  
Disruption of Mitochondrial Biogenesis in AKI 
 AKI arises from a variety of insults including sepsis, ischemia/reperfusion injury, 
and nephrotoxicant exposure.  Mitochondrial dysfunction is now recognized as a critical 
contributor to the development of renal and proximal tubular dysfunction after multiple 
forms of AKI.  Thus, restoration of normal mitochondrial function may represent a novel 
therapeutic approach to prevent renal injury and facilitate repair after AKI.  
Unfortunately, relatively little is known about the mechanisms responsible for inducing 
mitochondrial dysfunction in the setting of AKI.   
 Our laboratory and others have focused on disruption of mitochondrial 
homeostasis and dynamics in the proximal tubule as a potential contributor to renal 
dysfunction.  In particular, we have demonstrated that mitochondrial biogenesis, the 
process by which a cell generates new, functional mitochondria, is suppressed in multiple 
experimental models of AKI.  Funk et al. demonstrated that expression of PGC-1α, the 
so-called “master regulator of mitochondrial biogenesis,” is decreased in the renal cortex 
following I/R injury in mice (274).  Reduced PGC-1α levels in I/R animals were closely 
associated with persistent down-regulation of electron transport chain proteins including 
nuclear-encoded NDUFB8 and ATP synthase β (ATPSβ) and mitochondrial-encoded 
cytochrome c oxidase subunit I (COXI) in the renal cortex up to 144 hours, indicating 
that mitochondrial biogenesis is persistently disrupted after AKI (274).  Further studies 




leads to a significant decrease in ADP-stimulated respiration in isolated renal 
mitochondria, further revealing an important role for disruption of biogenesis in 
mitochondrial dysfunction (278).  We have also observed similar changes in renal 
mitochondrial biogenesis in mouse models of glycerol-induced rhabdomyolysis and folic 
acid-induced AKI (274, 279).  These data suggest that disruption of mitochondrial 
biogenesis and function is common to multiple forms of AKI.   
 Based on the findings described above, our group has identified a number of 
pharmacological compounds that stimulate mitochondrial biogenesis in the kidney and 
promote recovery of renal function in experimental models of AKI.  For example, we 
found that administration of formoterol, a long-acting β2-adrenoreceptor agonist, after I/R 
injury in mice restores ETC protein expression, mitochondrial respiration, and renal 
function (278). The cGMP-specific phosphodiesterase 5 (PDE5) inhibitor sildenafil also 
increased mitochondrial biogenesis and mtDNA content and reduced tubular injury as 
measured by KIM-1 protein expression following folic acid-induced AKI in mice (291).  
In addition, we have previously shown that overexpression of PGC-1α in primary renal 
proximal tubule cells (RPTCs) following oxidative insult with tert-Butyl hydroperoxide 
(TBHP) promotes recovery of mitochondrial function and active Na+ transport (289).   
 Taken together, these findings suggest that pharmacological targeting of 
mitochondrial biogenesis represents a feasible approach to prevent both mitochondrial 
dysfunction and renal insult following AKI.  However, very little is known about the 
molecular mechanisms underlying suppression of PGC-1α and subsequent mitochondrial 
biogenesis in the setting of AKI.  Thus, one goal of the work presented here was to 




sepsis-induced AKI.  We propose that a better understanding of these mechanisms may 
lead to development of novel therapeutic approaches to limit mitochondrial dysfunction 
following renal injury. 
Changes in Glycolytic Metabolism in the Renal Cortex Following AKI     
 Renal function depends heavily on oxidative phosphorylation in the proximal 
tubule to facilitate active reabsorption of solutes from the glomerular filtrate.  Disruption 
of normal mitochondrial function may thus contribute to renal dysfunction by reducing 
energy production that drives active transport in the tubule.  Early work by Guder and 
Ross demonstrated that renal proximal tubule cells have the lowest glycolytic capacity 
along the entire nephron segment (258).  However, it is possible that the proximal tubule 
responds to disruption of mitochondrial function and biogenesis by increasing glycolytic 
metabolism to provide ATP in support of normal cellular function.  In isolated rabbit 
proximal tubules in vitro, previous studies demonstrated that inhibition of ETC function 
by hypoxia (1% O2), rotenone (a complex I inhibitor), or FCCP (an ETC uncoupler), 
resulted in a significant increase in lactate production via anaerobic glycolysis (293).  
Induction of anaerobic glycolysis was closely associated with preservation of cellular 
ATP content and Na+/K+-ATPase function.  In addition, 2-deoxyglucose, an inhibitor of 
glycolysis, increased injury in proximal tubules exposed to rotenone as indicated by 
increased cellular release of lactate dehydrogenase (LDH) (293).  These findings support 
the notion that induction of glycolytic metabolism may serve a protective role in the face 
of mitochondrial dysfunction in the proximal tubule by facilitating energy generation.   
 Despite the in vitro evidence described above, there have been relatively few 




AKI in vivo.  A recent study by Zager et al. demonstrated that increases in renal cortical 
lactate content occur with as little as 15 minutes of ischemia in mice, indicating a shift 
toward anaerobic glycolysis in the ischemic kidney (294).  However, lactate production 
rapidly returned to baseline levels after restoration of vascular flow (294). The authors 
therefore suggested that physiologically meaningful induction of glycolytic metabolism 
in the proximal tubule only occurs during overt renal ischemia.  In contrast, earlier work 
by Ash and Cuppage demonstrated that renal glucose uptake and lactate production are 
increased following administration of the nephrotoxicant mercuric chloride in rats despite 
an absence of changes in renal blood flow (296).  However, these data should be 
interpreted with caution because the increase in renal glycolytic metabolism occurs at a 
much later time point (5 – 10 days) after mercuric chloride-induced AKI and glycolytic 
parameters were measured for the whole kidney rather than more specifically in the renal 
cortex or proximal tubule. 
 Evidence for induction of glycolysis in the septic kidney is lacking.  Given that 
sepsis-induced AKI is associated with substantial mitochondrial dysfunction in the 
proximal tubule, we wondered if glucose utilization through the glycolytic pathway might 
be increased to support cellular and renal function.  Thus, another goal of the work 
presented here was to better characterize time-dependent changes in glycolytic 
metabolism following LPS-induced AKI in mice.               
MEK/ERK Signaling as a Therapeutic Target in Sepsis and Sepsis-induced AKI 
 The MEK/ERK signaling pathway is an important downstream target of pattern 
recognition receptors (PPRs) expressed on a variety of cell types including immune cells 




endothelial cells and epithelial cells (including proximal tubular epithelial cells).  
Activation of PRRs including the Toll-like receptors (TLRs) by bacterial products known 
as pathogen associated molecular patterns (PAMPs) is responsible for the massive 
inflammatory response observed in sepsis and subsequent sepsis-induced organ 
dysfunction.  Previous studies demonstrated that MEK/ERK signaling is involved in both 
transcriptional and post-transcriptional regulation of pro-inflammatory cytokines 
including TNF-α and IL-1β following cellular exposure to TLR agonists (309, 310, 318, 
378, 379, 382, 398).   
There has been surprisingly little interest in targeting MEK/ERK in animal 
models of sepsis, probably due in part to the lack of potent, specific, and safe 
pharmacological inhibitors of this pathway.  However, a new generation of allosteric 
inhibitors of MEK with more favorable pharmacological properties has been developed 
for use in chemotherapy regimens for cancer.  In particular, GSK1120212 (also known as 
trametinib) is a potent allosteric inhibitor of MEK1 (IC50 = 0.92 nM) and MEK2 (IC50 = 
1.8 nM) that showed no inhibitory activity on a panel of over 100 off-target kinases 
(304).  GSK1120212 has been safely and successfully used in a number of clinical trials 
and gained FDA approval for use in unresectable metastatic melanoma with specific 
BRAFV600E or BRAFV600K mutations in 2013 (417-419).  In our earlier work, we 
demonstrated that GSK1120212 pre-treatment prevents acute LPS-induced renal 
dysfunction and tubular injury in mice, suggesting that this drug may be efficacious in the 
treatment of sepsis-induced AKI.  However, the clinical relevance of these findings was 
limited due to the model and pre-treatment protocol used.  Thus, the final aim of this 




relevant model of sepsis and septic AKI induced by cecal ligation and puncture (CLP) in 
mice.   
CONTRIBUTIONS TO THE FIELD 
Mechanisms Underlying Suppression of Mitochondrial Biogenesis in Septic AKI 
Although our lab and others have reported suppression of renal mitochondrial 
biogenesis in the setting of AKI, there have been very few studies aimed at determining 
the molecular mechanisms mediating this effect.  I decided to address this unanswered 
question in a mouse model of sepsis-induced AKI.  I hypothesized that renal 
mitochondrial biogenesis is disrupted following LPS-induced AKI through suppression 
of PGC-1α expression by TLR4-dependent activation of MAP kinase and/or NFκB 
signaling pathways and this disruption contributes to loss of mitochondrial homeostasis.  
PGC-1α expression was rapidly decreased at both the mRNA (3 h) and protein (18 h) 
level the renal cortex following systemic exposure to LPS in mice.  Loss of renal cortical 
PGC-1α was closely associated with increased BUN and up-regulation of KIM-1 and 
NGAL, proteins that served as markers of injury to the proximal tubule.  Taken together, 
these findings suggested that development of AKI occurs simultaneously with 
suppression of PGC-1α following endotoxin administration.   
Since a significant reduction in renal cortical PGC-1α content was observed in the 
LPS model, I next sought to determine whether this resulted in disruption of normal 
mitochondrial biogenesis in the septic kidney.  LPS-induced PGC-1α suppression was 
associated with reduced transcript (at 18 h) and protein (at 42 h) expression of essential 
regulators of mitochondrial biogenesis (TFAM), nuclear-encoded ETC components 




In addition, I observed significant reductions in renal cortical mtDNA, an indicator of 
cellular mitochondrial content, at both 18 and 42 h post-LPS.  The results generated from 
these experiments provide strong evidence that suppression of PGC-1α is closely 
associated with loss of normal mitochondrial biogenesis following LPS-induced AKI.   
Once I established that disruption of PGC-1α and subsequent mitochondrial 
biogenesis in the LPS model is consistent with other experimental models of AKI, I 
began to focus on the molecular mechanisms underlying the observed changes.  LPS 
primarily signals through TLR4-mediated activation of NFκB and MAPK pathways (86, 
87, 347).  However, TLR4-independent effects of LPS have also been described in some 
models of septic shock (94, 95).  Using TLR4-deficient mice, I asked whether TLR4 was 
required for disruption of mitochondrial biogenesis in endotoxin-induced AKI.  TLR4KO 
mice were completely protected from LPS-induced disruption of PGC-1α and its 
downstream targets. In addition, TLR4 deficiency blocked development of renal 
dysfunction in endotoxin-treated mice.  Although the requirement for TLR4 in sepsis-
induced AKI has been previously reported, this is the first study to demonstrate that 
TLR4 is also essential for suppression of renal cortical PGC-1α and mitochondrial 
biogenesis in LPS-induced AKI (150).   
I next focused on downstream targets of TLR4 that might mediate mitochondrial 
dysfunction in sepsis-induced AKI.  There is some evidence suggesting that cytokine-
induced NFκB signaling may down-regulate PGC-1α and mitochondrial biogenesis in 
skeletal muscle cells in vitro (241, 242).  Despite testing multiple pharmacological 
inhibitors of the NFκB pathway including TPCA-1, BAY11-7085, and PPM-18, I was 




the LPS model (see Figure 5-2 in the following section).  Given these results, I turned my 
attention to MAPK signaling pathways downstream of TLR4.  I noted rapid 
phosphorylation (and thus activation) of ERK1/2 and TPL-2, a MAP3K responsible for 
TLR4-mediated stimulation of the MEK/ERK signaling, in the renal cortex within 1 h of 
systemic LPS exposure.   
Pre-treatment with the MEK1/2 inhibitor GSK1120212 renal cortical blocked 
ERK1/2 activation and attenuated early (3 h) LPS-induced renal dysfunction and tubular 
injury in mice.   Most interestingly, the protective effects of this compound were 
associated with restoration of renal cortical PGC-1α expression at the 3 h time point.  
These findings indicate an important role for MEK/ERK signaling in LPS-induced renal 
injury and disruption of PGC-1α and mitochondrial biogenesis.  However, it should be 
noted that blockade of MEK/ERK had only modest effects on renal cortical expression of 
PGC-1α and downstream targets at later time points (18 h).   This likely indicates that the 
TPL-2/MEK/ERK pathway mediates acute suppression of PGC-1α in the renal cortex 
after endotoxic AKI, but other signaling mechanisms contribute to late-phase disruption 
of mitochondrial biogenesis.  Despite the modest effects of GSK1120212 on 
mitochondrial homeostasis at 18 h post-LPS, this drug maintained significant protective 
effects on late-phase elevation of BUN and renal cortical KIM-1 expression in this 
model, indicating further therapeutic potential for pharmacological inhibition of 
MEK/ERK in sepsis-induced AKI.  To our knowledge, this is the first study to reveal an 
important role for MEK/ERK in regulation of mitochondrial biogenesis in response to 




After determining that MEK/ERK signaling was critical for LPS-induced 
suppression of PGC-1α, I focused on downstream effectors of this pathway.  In 
particular, I noted that GSK1120212 pre-treatment significantly reduced transcriptional 
up-regulation of the pro-inflammatory cytokines TNF-α and IL-1β in the renal cortex 
after systemic LPS administration in mice.  Based on previous studies and our own 
preliminary data indicating that TNF-α is a negative regulator of mitochondrial 
biogenesis in renal proximal tubule cells in vitro, I hypothesized that a reduction in TNF-
α production might be responsible for the effects of MEK/ERK inhibition.  Indeed, mice 
receiving an anti-TNF-α neutralizing antibody prior to systemic LPS exhibited partial 
restoration of renal cortical PGC-1α mRNA and mtDNA content.  The incomplete return 
of PGC-1α after TNF-α neutralization suggests that multiple pro-inflammatory cytokines 
(TNF-α, IL-1β, IL-6) signal through similar mechanisms to suppress PGC-1α in sepsis-
induced AKI.  In an additional set of experiments, I also demonstrated that in vivo 
administration of high dose (50 µg/kg) recombinant murine TNF-α is sufficient to disrupt 
mitochondrial homeostasis and renal function in mice.  Taken together, the studies 
describe above have identified a novel role for the TLR4/TPL-2/MEK/ERK/TNF-α 
signaling axis in mediating early renal injury and suppression of mitochondrial 
biogenesis in a mouse model of sepsis-induced AKI.  These findings may be useful in 
developing new therapeutic approaches to reverse mitochondrial and renal dysfunction in 
AKI.   
Changes in Glucose Utilization in the Renal Cortex Following AKI    
As described above, mitochondrial homeostasis and function is significantly 




known regarding how glucose metabolism through glycolysis changes in response to this 
mitochondrial dysfunction.  I hypothesized that glycolytic metabolism is activated to 
provide ATP, support cellular function, and limit renal dysfunction in the septic kidney. 
In order to assess changes in glucose flux through glycolysis, I first measured 
time-dependent changes in the activities of the 3 major regulatory enzymes of this 
pathway (hexokinase [HK], phosphofructokinase [PFK], and pyruvate kinase [PK]) in the 
renal cortex after systemic LPS administration in mice. I observed a rapid increase in 
renal cortical HK activity as early as 3 h after LPS exposure in mice that was maintained 
for at least 18 h without changes in PFK or PK activity at any of the time points 
examined.  Analysis of mRNA and protein expression of other glycolytic enzymes 
further confirmed that the effects of LPS were specific to HK.  Since I observed a 
sustained increase in HK activity, I next questioned whether this change led to an overall 
increase glycolytic metabolism.  Using standard biochemical assays, I measured pyruvate 
and lactate content in the renal cortex of mice subjected to endotoxin.  Contrary to our 
original hypothesis, I was unable to detect increases in renal cortical pyruvate, lactate, or 
the lactate:pyruvate ratio, an index of anaerobic glycolysis.  Together, these findings 
indicated that LPS-mediated HK activation in the renal cortex was not sufficient to 
increase glucose utilization through glycolysis.   
Because glycolytic metabolism was not increased in the septic kidney, I next 
sought to determine the physiological relevance of HK activation in the LPS model by 
assessing alternative fates of glucose-6-phosphate produced by this enzyme including 
gluconeogenesis, glycogen synthesis, and the pentose phosphate pathway (PPP).  




in the renal cortex after I/R injury (294).  In contrast to changes observed in the I/R 
model, I observed a decrease in both glucose and glycogen content in response to 
systemic endotoxin exposure.  Instead, activity of glucose-6-phosphate dehydrogenase 
(G6PDH), the rate-limiting step of the PPP was significantly increased in the renal cortex 
of mice exposed to LPS. To our knowledge, this is the first study to demonstrate 
increases in both HK and G6PDH in the setting of sepsis-induced AKI.  These findings 
provide evidence that increased glucose phosphorylation by activated HK may be 
necessary to supply substrates for the PPP.  These findings are consistent with earlier 
reports of increased renal cortical glucose phosphorylation and PPP activity following 
mercuric chloride-induced injury in rats (296).  The physiological relevance of PPP 
induction in this setting remains unclear.  However, it should be noted that this pathway 
is essential for generation of NADPH and thus replenishment of cellular glutathione and 
antioxidant defense.  Since oxidative stress is an important contributor to tubular insult 
following systemic LPS exposure, these findings suggest an alternate view that HK and 
G6PDH activation may be an adaptive response to limit cellular injury (339).  
Interestingly, reduced NADPH levels in G6PDH-deficient mice are associated with 
increased renal oxidative stress, inflammation, and dysfunction, indicating an important 
role for NADPH in antioxidant defense in the kidney (367).  Further studies are 
warranted to confirm the physiological significance of increased PPP activity following 
LPS-induced AKI in mice.   
I also investigated the mechanisms responsible for HK activation in this model.  
LPS-induced increases in renal cortical HK activity occurred independently of changes in 




activity might be regulated by post-translational modifications after endotoxin-induced 
AKI.  In particular, Akt is known to modulate both HK activity and subcellular 
localization via phosphorylation (363, 369).  Using a series of pharmacological inhibitors, 
I demonstrated that LPS-induced HK activation in the renal cortex occurs via an 
EGFR/PI3K/Akt-dependent mechanism.  These findings are consistent with previous 
reports from our laboratory and others demonstrating induction of HK and/or PPP 
activity in response to EGFR stimulation in a variety of renal cell types in vitro (335, 340, 
343).  In addition, TLR4 agonism by LPS has been shown to rapidly transactivate EGFR 
via protease-mediated EGFR ligand shedding in epithelial cells (347, 348).   
MEK/ERK Inhibition in a Clinically Relevant CLP Model of Sepsis 
 As discussed previously, the potent and specific MEK1/2 inhibitor GSK1120212 
prevented early renal dysfunction following systemic LPS exposure in mice.  Given the 
well-characterized limitations of endotoxin models in rodent, I decided to test the 
efficacy of this drug in the “gold standard” model of sepsis induced by CLP in mice.  The 
specific model used in these studies also implemented supportive measures commonly 
used in clinical management of sepsis including a broad-spectrum β-lactam antibiotic 
(imipenem/cilastatin) and aggressive fluid resuscitation with saline.  In contrast to our 
earlier studies conducted in the LPS model that utilized a pre-treatment protocol, 
GSK1120212 administration was also delayed to 6 h post-CLP, a time point when renal 
injury is already established.  I anticipated that MEK/ERK inhibition by GSK1120212 
would prevent CLP-induced systemic inflammation as well as development of AKI.   
 In order to assess the systemic response to sepsis induction, I first measured 




and GM-CSF.  All of the cytokines measured increased markedly at 18 h after CLP in 
mice.  In agreement with our hypothesis, GSK1120212 treatment significantly attenuated 
CLP-induced increases in these pro-inflammatory molecules.  I also evaluated the 
development of hypothermia as a secondary measure of physiologic dysfunction.  
Delayed drug administration completely reversed the decrease in core body temperature 
following CLP in mice.  These findings provided encouraging evidence that MEK/ERK 
signaling is an important mediator of the systemic inflammatory response.  To our 
knowledge, this is the first study to demonstrate that inhibition of MEK1/2 may represent 
a novel therapeutic approach to limit deleterious inflammation in the CLP model.   
 Once I established the effects of GSK1120212 on systemic parameters, I turned 
my focus to CLP-mediated AKI.  Microvascular dysfunction is a well-characterized 
mediator of renal injury, resulting in sluggish capillary blood flow and development of 
local regions of hypoxia and hypoperfusion in the septic kidney.  We utilized intravital 
microscopy to assess changes in microvascular perfusion after CLP.  MEK/ERK 
inhibition completely restored peritubular capillary flow to sham levels at the 18 h time 
point.  However, I noted only modest effects of GSK1120212 on cellular adhesion 
markers expressed by the vascular endothelium including ICAM-1 and E-selectin that 
facilitate immune cell infiltration, indicating that this drug does not fully prevent 
microvascular dysfunction in the septic kidney.   
 Since pharmacological blockade of MEK/ERK reversed peritubular capillary 
perfusion deficits after CLP, I expected to see a reduction in injury to the renal proximal 
tubule.  At 18 h post-CLP, markers of tubular including KIM-1, NGAL, and HO-1 were 




partially attenuated the observed transcriptional up-regulation of all three markers.  When 
examining potential mechanisms for GSK1120212-mediated tubular protection, I noted 
that renal cortical pro-inflammatory cytokine (TNF-α, IL-1β, IL-6) expression was 
decreased in CLP mice treated with this drug.  These findings are consistent with our 
earlier studies in LPS-induced AKI (142).  However, delayed MEK/ERK inhibition had 
no effect on either oxidative stress or renal cortical PGC-1α/mitochondrial biogenesis.  It 
is not entirely surprising that mitochondrial biogenesis remained unaltered after 
GSK1120212 administration, because we previously noted that MEK/ERK signaling was 
only necessary for acute (< 3) suppression of PGC-1α in LPS-induced AKI.  Together, 
these findings suggest that GSK1120212 exerts protective effects against renal injury 
primarily through modulation of circulating cytokine production, microvascular 
dysfunction, and local, organ-specific inflammatory responses in the septic kidney at later 
time points.  
 Given the beneficial effects of MEK/ERK inhibition described above, I was 
optimistic that this therapeutic approach would reverse CLP-mediated renal dysfunction.  
However, to my surprise, I was unable to detect differences in BUN when comparing the 
CLP + vehicle and CLP + GSK1120212 groups.  There are a number of potential 
explanations for this finding.  BUN is affected by changes in intravascular fluid status 
and nutrition, both of which may be significantly altered in the setting of sepsis (420-
422).  It is therefore likely that the observed change in BUN reflects more than simply 
renal dysfunction in the CLP model.  A more direct assessment of renal function (e.g. 
glomerular filtration rate) would be useful to address this issue.  However, it is also 




sufficient to reverse CLP-mediated renal dysfunction.  Although this may suggest limited 
utility of MEK/ERK inhibition in sepsis-induced AKI, it is important to note that we did 
see a number of beneficial effects of this intervention including reduced systemic 
inflammation, improved renal microvascular perfusion, and decreased proximal tubule 
injury.  Given that GSK1120212 has already been FDA approved, we believe we have 
provided sufficient evidence to suggest that this drug may represent a rapidly translatable 
and targeted approach to improve outcomes associated with sepsis and sepsis-induced 
organ injury.   
FUTURE DIRECTIONS  
Mechanisms Underlying Suppression of Mitochondrial Biogenesis in AKI 
  The findings presented above raise a number of new and exciting questions that 
warrant further attention.  In an endotoxin model of sepsis-induced AKI, I identified 
TLR4-dependent activation of MEK/ERK as an essential component of acute suppression 
of PGC-1α and mitochondrial biogenesis in the renal cortex.  A question I have been 
particularly interested in is whether this pathway might be a common mediator of 
mitochondrial dysfunction in multiple forms of AKI.  Interestingly, a number of 
endogenous agonists of TLR4, referred to as danger-associated molecular patterns 
(DAMPs), are elevated after renal I/R including hyaluronan, high-mobility group box 1 
(HMGB1), and bigylcan (423, 424).  TLR4 deficiency in mice protects against 
development of AKI in the I/R model and this appears to be dependent on local TLR4 
signaling in the kidney, further indicating that TLR4 activation may be a common 
mediator of renal injury in multiple experimental models (423).  Given these results, I 




mitochondrial homeostasis after I/R injury.  To address this hypothesis, we subjected 
both wild-type and TLR4KO to bilateral renal pedicle clamping for 15 min before 
reperfusion as previously described (425).  In our hands, TLR4 deficiency had no effect 
on acute (< 3 hr) development of renal dysfunction as measured by BUN.  Suppression of 
renal cortical PGC-1α and its downstream targets (TFAM, NDUFS1, and COX1) at 3 h 
post-I/R was similar in both wild-type and TLR4KO mice, suggesting that TLR4 does not 
mediate acute disruption of mitochondrial biogenesis in this model (Figure 5-1).  This 
does not rule out the possibility that TLR4 activation contributes to the persistent loss of 
mitochondrial homeostasis that we have previously demonstrated following renal I/R 
injury (274).  However, it should be noted that pre-treatment with the MEK/ERK 
inhibitor GSK1120212 (1 mg/kg, i.p.) does restore renal cortical PGC-1α mRNA levels at 
3 h, but not 24 h, after I/R AKI (data not shown).  Taken together, these findings suggest 
that MEK/ERK signaling is a common contributor to acute down-regulation of 
mitochondrial biogenesis in multiple forms of AKI, although the upstream signals for 
activation may differ.  Further work using both genetic and pharmacological approaches 
is warranted to determine whether these effects can be attributed solely to MEK/ERK-





Figure 5-1: TLR4 deficiency does not alter suppression of mitochondrial biogenesis 
following I/R-induced AKI in mice.  Wild-type and TLR4 knockout (TLR4KO) mice 
on a C57BL/6 background were subjected to bilateral renal ischemia for 15 min prior to 
reperfusion.  Kidneys were collected for biochemical analysis at 3 h post-I/R and total 
RNA was isolated from the renal cortex.  mRNA expression of mitochondrial biogenesis 
markers including PGC-1α (A), TFAM (B), NDUFS1 (C), and COX1 (D) were 
determined by RT-qPCR.  Disruption of mitochondrial homeostasis was not different 
when comparing wild-type and TLR4KO animals subjected to I/R injury.  Data are 
presented as fold change relative to wild-type sham (mean ± S.E.M.; n = 3 animals per 
group).  Different superscripts above bars indicate statistically significant differences (p < 




 Studies conducted in both the LPS and I/R models now indicate that MEK/ERK 
inhibition is only sufficient to reverse suppression of PGC-1α in the early time period (< 
3 h) after development of AKI.  An issue of particular interest to our laboratory is 
defining the molecular mechanisms that maintain disruption of mitochondrial biogenesis 
at later time points.  We were particularly interested in the NFκB proteins given recent 
evidence suggesting that this family of transcription factors acts as a negative regulator of 
PGC-1α transcription in skeletal muscle cells and identification of a putative NFκB 
binding site in the PGC-1α promoter (241, 242).  I was unable to show any significant 
effects of pharmacological inhibition of NFκB signaling on PGC-1α at 3 h after LPS-
induced AKI using a diverse set of compounds including TPCA-1, BAY11-7085, and 
PPM-18 (Figure 5-2).   However, it should be noted that immunoblot analysis of 
phosphorylated p65 NFκB and IκBα in the renal cortex as an indicator of NFκB 
activation did not conclusively demonstrate efficacy of any of the drugs tested.  This 
suggests alternative approaches may be necessary to probe the role of NFκB in late-phase 
dysregulation of PGC-1α following AKI.  Although global knockout of most components 
of the NFκB signaling pathway is embryonic lethal in mice, recent studies have employed 
cell-type specific ablation of the NFκB essential modulator (NEMO, required for IKK-
mediated phosphorylation and degradation of IκB) or expression of a degradation-
resistant, dominant negative IκBα to genetically target NFκB (426).  It would be 
interesting to generate mice expressing these alleles under the control of proximal tubule-
specific promoters (e.g. γ-glutamyl transferase) to further elucidate the role of NFκB 




other well-characterized negative regulators of mitochondrial biogenesis such as RIP140 





Figure 5-2: Pharmacological blockade of NFκB by diverse chemical inhibitors does 
not restore acute loss of PGC-1α following systemic LPS exposure in mice.  Wild-
type, male C57BL/6 mice were treated with inhibitors of the NFκB signaling pathway 
including TPCA-1 (20 mg/kg, i.p.), BAY11-7085 (20 mg/kg, i.p.), or PPM18 (5 mg/kg or 
15 mg/kg, i.p.) 1 h prior to administration of LPS (10 mg/kg, i.p.)  Kidneys were 
collected for biochemical analysis at 3 h post-LPS and total RNA was isolated from the 
renal cortex. RT-qPCR analysis revealed no changes in transcript levels of PGC-1α 
following pre-treatment with TPCA-1 (A), BAY11-7085 (B), or PPM18 (C).  Data are 
presented as fold change relative to control mice (mean ± S.E.M.; n ≥ 5 animals per 
group).  Different superscripts above bars indicate statistically significant differences (p < 
0.05).  Note: TPCA-1 and BAY11-7085 were used in the same experiment, so control 





Hexokinase and PPP Activation in Sepsis-induced AKI  
 I was surprised to observe increased activity of glucose-6-phosphate 
dehydrogenase in association with HK activation in the renal cortex after systemic LPS 
exposure in mice.  Since this was not in agreement with our original hypothesis that 
induction of HK would facilitate increased glucose flux through the glycolytic pathway, I 
did not further pursue the physiological relevance of PPP activation.  However, it is 
possible that this shift in glucose metabolism in the renal cortex provides NADPH for 
glutathione regeneration and thus cellular antioxidant defense in the septic kidney. 
G6PDH knockout mice were previously generated and are viable to adulthood (367).  It 
would be interesting to expose these mice to LPS and determine whether renal oxidative 
stress (and thus renal injury) increases.  In addition, we could employ transgenic 
overexpression of G6PDH in the renal proximal tubule to further elucidate the role of this 
pathway in antioxidant defense.  These studies could potentially identify a novel 
metabolic adaptation to protect renal cells after AKI and lead to interest in developing 
compounds that stimulate G6PDH/PPP activity for treatment of this disease.     
MEK/ERK Inhibition in the CLP Model  
 My studies using GSK1120212 in the CLP model were largely focused on renal 
injury and dysfunction.  Since this project was intended to address the therapeutic 
potential of MEK/ERK blockade in sepsis, it would be beneficial to further evaluate the 
effects of GSK1120212 on CLP-induced dysfunction of other organ systems.  In 
particular, there is evidence of injury to the liver, lungs, pancreas, and skeletal muscle in 
the same CLP model used for our studies (159).  Many of these parameters are easily 
assessed by serum markers commonly used in the clinic including aspartate transaminase 




creatine kinase (CK) for skeletal muscle.  Unfortunately, there was not sufficient serum 
from the mice used in these experiments to measure all of these endpoints.  It would also 
be interesting to conduct an additional study determining the effects of GSK1120212 on 
mortality in the CLP model.  Together, these results could provide even stronger support 
for MEK/ERK inhibition as a viable therapeutic option for treatment of sepsis and 
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